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Abstract
Polymer encapsulation is now an accepted route into cellular therapies via implantation 
of therapeutically active allogeneic and xenogeneic cells. Although many methods are 
currently used for encapsulation of cells, no single method is capable of producing large 
volumes of mono-disperse beads, containing cells completely covered by the polymer of 
choice. The overall aim of this project was to develop a microfluidic method to 
encapsulate dopamine releasing cells in an alginate matrix, determine their viability in 
vitro and investigate implantation into a rodent model of Parkinson’s disease.
During the course of this study a novel microfluidic method was developed. Two cell 
types were encapsulated; a human test line and a therapeutic cell line derived from rat 
brain tumour cells (PC 12). Cell viability, measured using an adapted trypan blue 
exclusion method, was observed to be minimally affected by the encapsulation process. 
Confocal images of cells encapsulated within alginate beads were collected in addition to 
long term viability data, up to 90 days post-encapsulation. Dopamine was still detected 
after PC 12 cell encapsulation through use of an ELISA.
Modifications to the developed microfluidic method allowed beads of an appropriate size 
(<250pm in diameter) to be implantated into a rodent brain via a cannula. Upon 
implantation of alginate beads into rats’ brains there was no evidence of beads after 7 
days. Attempts were made to stabilise alginate beads further by addition of barium as a 
cross-linking agent and polycation secondary coating. Beads were observed to be more 
stable and remained visible within brain tissue for 14 days. Imaging of fluorescent 
alginate beads revealed that beads produced using the developed microfluidic method 
were homogeneous in nature.
The work presented here represents the first microfluidic method to be developed which 
is capable of encapsulating viable cells. Moreover, the viability measurements carried out 
were the first such experiments to be performed on cells encapsulated using microfluidic 
methods. Although the structure of alginate beads produced using more commonplace 
methods has been shown, this has not previously been reported for beads produced using 
a microfluidic technique.
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Chapter 1. Introduction
1.1 E n c a p s u l a t io n  o f  c e l l s
Classical Mendelian disorders are curable by administration of a missing gene
product, for example factor VIII or IX in patients with haemophilia (Liu et al., 1993), 
or erythropoietin in sufferers of anaemia (Murua et al., 2007). An ideal way to 
achieve this would be to introduce cells which express the missing gene product and 
integrate with the patient. Another class of disorders which could be cured by 
replacement of secretory cells are autoimmune diseases, such as Type I diabetes. In 
these cases, the immune system destroys a patients own cells, leading to loss of vital 
biochemical functions. Autoimmune disorders could be cured by replacement of 
destroyed cells. However, as with whole organ transplantation, immune reaction to 
cell transplantation is inevitable. A typical solution to immune rejection is treatment 
with immunosuppressive drugs. However, even with immunosuppression, many 
transplants are unsuccessful. For example, of the 267 patients receiving transplanted 
pancreatic islet cells between 1990 and 1999, only 12.4% (33 patients) experienced 
insulin independence for periods of more than one week, and only 8.2% (22 patients) 
for more than one year (Brendel et al., 1999).
Transplantation of human or animals cells into a human patient requires 
immunosuppression to prevent rejection of the transplant. Rejection occurs when the 
body recognizes the cells as non-self and attempts to destroy them (Section 1.4). 
Immunosuppression has intolerable side-effect profiles and limited efficacy (Rang et 
al., 2007). Skin cancer is a serious problem in immunosuppressed patients, this may 
be due to a general decrease in cancer surveillance due to immunosuppression, 
although specific drugs have been shown to sensitise DNA to ultraviolet A radiation 
(O'Donovan et al., 2005). Some immunosuppressants, for example prednisone (Zeng 
et al., 1993), induce diabetes, damage beta cells or induce peripheral insulin 
resistance. In these cases, the side effects exacerbate, or are worse than, the condition 
being treated.
Cell encapsulation was proposed as a means to immunoisolate transplanted 
cells (Chang, 1964). Through use of a semi-permeable membrane, the immune system 
is prevented from detecting or responding to foreign cells present within the device. 
The membrane is permeable to oxygen, nutrients and the therapeutic molecule(s).
1
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Chang proposed using haemoglobin cross-linked with a diacid to form the cell- 
enclosing membrane. Whilst Chang has successfully developed red-blood-cell 
substitutes using cross-linked haemoglobin, cells were not effectively encapsulated 
until 1980. Lim and Sun pioneered the use of alginate and poly-l-lysine (PLL) in so 
called APA (alginate-PLL-alginate triple layer -  Section 1.8.1) capsules to 
encapsulate cells (Lim and Sun, 1980). This is still the most widely used technique in 
research into cell encapsulation.
Three different sources of cells are available for cellular therapy; patients own 
cells (autologous), cells from another human (allogeneic) or cells from another 
species (xenogeneic). Autologous and allogeneic cells have limited availability and 
xenogeneic cells, although widely available, may transmit viruses to human hosts 
(Blusch et a l , 2002). Cell types from all three sources can be genetically modified to 
produce virtually any desired factor in vivo. A patient’s cells can be removed, 
genetically engineered to produce the required factor and then re-implanted. 
Encapsulation is not necessary in this scenario as a patient will not attack their own 
(autologous) cells. However, as each treatment is patient-specific, costs would be high 
and scale up to treat multiple patients would be impossible (Gansbacher, 2002). A 
better solution might be to produce large batches of engineered human cells for use in 
any patient with the disease. Although banking of many different histocompatibility 
types has been postulated (Taylor et a l , 2005), a better approach may be cell 
encapsulation to overcome immune-mediated rejection of the allogenic graft.
1.2 P r e v io u s  u se  o f  e n c a p s u l a t e d  c e l l s  f o r  t r e a t m e n t  o f  d ia b e t e s
The most widely studied disease within the field of cell encapsulation is Type
I diabetes. The World Health Organization (WHO) estimates that more than 170 
million people worldwide suffer from diabetes, and this number is predicted to more 
than double by 2030 (Wild et a l , 2004). The National Diabetes Information 
Clearinghouse estimates that diabetes costs the United States $132 billion every year. 
The prospect of replacement of insulin-producing pancreatic islet beta cells has been 
described as “the ultimate treatment for Type I diabetes” (Shi and Cheng, 2004). The 
use of a bioartificial pancreas (providing immediate regulation of glucose levels via 
natural feedback mechanisms) is a seemingly simple way to cure Type I diabetes.
2
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In spite of the proposed potential and massive research effort surrounding this 
area, researchers are apparently only slightly closer to the “ultimate cure” than in 
1980 when Lim and Sun reversed diabetes in rats. Allotransplantation, in conjunction 
with encapsulation, is now routinely shown to be successful in treating diabetic 
rodents and canines (Soon-Shiong et a l , 1992; Calafiore et al., 2004). Encapsulated 
allografts have been shown, in a Phase I clinical trial, to be successful in humans 
(Calafiore et a l , 2006). Encapsulated human pancreatic islets were transplanted into 
two patients, without immunosuppression, and decreased the need for exogenous 
insulin, although it was not completely withdrawn.
Encapsulated xenografts have been used to reverse diabetes in rodents 
(Duvivier-Kali et al., 2004) and non-human primates (Sun et al., 1996). There has 
been limited success with human patients. As part of a Phase I/II clinical trial in 1996, 
on an undisclosed number of patients, a diabetic patient received microencapsulated 
porcine islets. When followed-up in 2005, the xenotransplantation appeared to have 
had no deleterious effects on general health and dependence on insulin was reduced 
(Elliott et a l , 2007). Another clinical trial, consisting of 12 patients, reported 6 
patients required a significantly reduced amount of insulin and two patients who were 
insulin-independent for several months (Valdes-Gonzalez et al., 2005). Encapsulated 
islet cells, of human or porcine origin, have limited success when implanted, as shown 
by the low patient numbers “treated”.
Although diabetes is most commonly investigated to model encapsulated cell 
systems, it will not be used within this study. Treatment of diabetes requires 
pancreatic islet cells, and although initial work has been carried out to immortalise 
pancreatic islet cells (Sinden et a l , 2007), these were not available for this study and 
so use of primary cells would have been necessary. As pancreatic islet cells and an 
animal model for diabetes were not available for use in this study an alternative model 
for investigation was required.
1.3 N e u r o d e g e n e r a t iv e  d ise a s e s  a n d  Pa r k in s o n ’s  d ise a se
Neurodegenerative diseases are caused by the degeneration of neurons within
the brain. Cells within the brain are not readily regenerated (Cajal, 1928) and so these 
diseases worsen over time and commonly affect older people (Mayeux, 2003). Some 
of the more common neurodegenerative diseases include Alzheimer’s disease,
3
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Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, spinal cord 
injury, cerebrovascular disease (associated with stroke) and epilepsy. In 2004, more 
than 15 million people in Europe were estimated to be affected by neurodegenerative 
disease, costing more than €60 billion (Andlin-Sobocki et al., 2005).
Therapeutic strategies to treat neurodegenerative diseases are problematic as, 
although it is often known which molecules are required, neuroactive compounds are 
difficult to provide systemically. The difficulties arise as neuroactive molecules either 
have a short half life or the liver degrades them before they reach the brain. In 
addition, the blood-brain barrier (BBB), due to its low passive permeability (Rubin 
and Staddon, 1999), does not allow molecules to pass into the brain from the blood 
stream. Various delivery methods have been investigated (for example osmotic pumps 
(Olson et a l , 1991), sustained release polymer systems (McRae et al., 1990) and 
direct gene therapy (Barsoum et al., 2003)), but all have drawbacks limiting their use 
in patients.
Cellular therapy, as a treatment for neurodegeneration, allows cells to be used 
to deliver the therapeutic factor into the target area of the brain. Cellular therapy relies 
on de novo synthesis and release of missing molecule(s) by the introduced cells. This 
can be addressed in two ways; cell replacement by transplantation or polymer- 
encapsulated cell implantation. Functional reinnervation via cell-to-cell contact can be 
established through use of cell transplantation, whereas this is not possible with 
encapsulated cells. Although the primary purpose of cell encapsulation is 
immunoisolation of implanted cells from the host immune system, a secondary benefit 
might be to protect the host from any potential tumour formation by the implanted 
cells. Several beneficial cell lines for neurodegeneration are known to form tumours 
upon implantation (for example; PC 12 cells (Jaeger, 1985)).
Through use of different cell types, various therapeutic molecules can be 
delivered to the brain for treatment of neurodegenerative diseases (Table 1.1). 
Parkinson’s disease (PD) was chosen as a model to investigate cellular therapy 
through use of polymer encapsulated cells in this study. Simple animal models of 
Parkinsonism are available and well validated allowing in vivo testing to be carried 
out. The use of PD as a model was also advantageous as immortalised cell lines 
producing various neurotrophic factors are available. The various neurotrophic factors 
expressed are of different molecular weights and so allowed more flexibility in choice 
of molecule.
4
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Cell type Therapeutic expressed MW(kDa) Applicable disease
PC12 Dopamine 0.153 PD
Choroid plexus Various neurotrophic factors HD, stroke, spinal injuries
Neurosphere Various neurotrophic factors Stroke, spinal injuries
Engineered
fibroblasts BDNF 13.6 HD, PD, spinal injuries
Engineered 
Baby Hamster 
Kidney
CNTF
GDNF
22
30
HD, PD 
PD
PD: Parkinson’s disease; HD: Huntington’s disease; BDNF: Brain derived neurotrophic factor;
CNTF: Ciliary neurotrophic factor; GDNF: Glial cell line-derived neurotrophic factor.
Table 1.1: Alternative therapeutic factors and cell types for encapsulation and treatment of a 
limited number of neurodegenerative diseases
PD is a disease of aging; typically age of onset is after 60. In order to be 
clinically diagnosed a patient must present with 3 out of 4 cardinal symptoms; tremor, 
slowness of movement (bradykinesia), rigidity (akinesia) and postural instability. The 
cause of symptoms is loss of dopaminergic neurons in the nigrostriatal pathway, 
which is responsible for the regulation of the forebrain centres controlling motor 
function. Up to 70% of dopaminergic neurons can be lost before symptoms become 
apparent; up to this point compensation within the system occurs (Bemheimer et al., 
1973). The cause of PD is unknown; some cases are caused by genetic factors, 
although this is not at all common (Polymeropoulos et al., 1997). Prevalence of PD in 
the UK is 140 per 100,000, and 69% of these patients develop the disease after 65 
years of age (Wickremaratchi et al., 2009). Men are almost twice as likely to develop 
PD as women (Van Den Eeden et al., 2003), although it is not clear why this is, it is 
possibly due to gender differences in exposure to chemicals, attitudes to smoking and 
employment history.
Cell transplantation has previously been used to treat PD in humans with 
variable success (for example, see Winkler et al., 2005). Not only are there ethical and 
sourcing issues surrounding the use of the most promising cell type - midbrain foetal 
dopaminergic neurons - but the treatment is not an effective solution. In particular it 
remains unreliable even in the best centres, and results have not been entirely
5
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consistent either between patients or research groups carrying out the surgery (Freed 
et a l, 2001; Olanow et a l, 2003; Piccini et a l, 2005; Mendez et a l, 2008). Use of 
polymer encapsulation allows many more cell sources to be exploited, as chemical 
immunosuppression is not required to protect allogeneic or xenogeneic cell types (as 
previously discussed regarding diabetes (Section 1.2)). Although various groups have 
attempted to use encapsulated cells to reverse Parkinsonism in animal models, there 
have been no studies carried out in humans.
1.4 H o st  r e a c t io n s  t o  t r a n s p l a n t e d  c e l l s
The immune system functions via three mechanisms: humoral immunity,
cellular immunity and secretion of lymphokines. Humoral immunity relies on 
molecules in solution; these molecules are immunoglobulins, more commonly known 
as antibodies, which act by recognising non-self material. In cellular immunity, 
antibodies are attached to immune cells, known as T cells. The secretion of 
lymphokines stimulates humoral and cellular immunity as well as producing 
phagocytes; cells that kill, ingest and digest pathogens and any cell debris (Murphy et 
a l, 2007).
All cells in the body display a marker based on the major histocompatibility 
complex (MHC). Non-self material introduced into the body does not express the 
same MHC antigens as the host. T cells are produced which recognize non-self 
material, by direct contact with antigens on a foreign cell; CD8 T cells target peptides 
bound to MHC class I and CD4 T cells target MHC class II (Remes and Williams, 
1992). When these T cells attach to foreign cells, many more T cells are clonally 
produced that are able to kill the foreign cells (Lombardi and Lechler, 1991).
Encapsulation of non-autologous cells prevents T cells from coming into 
direct contact with non-self antigens. However, any cells not entirely protected by the 
matrix can be attacked by T cells. Incomplete encapsulation is a major problem with 
current encapsulation techniques, as described below (Section 1.6.4). Cells fully 
encapsulated within a polymeric capsule must also be protected from antibodies in 
solution. The capsule material must have sufficiently low porosity such that 
immunoglobulin (Ig) antibody molecules cannot permeate. Immunoglobulin 
molecules range in size from IgG at around 150 kDa to IgM at around 950 kDa;
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therefore any polymers used for encapsulation must have pore sizes below 17nm to 
prevent IgG entry (Saphire et al., 2001).
The immune system also uses the complement system to detect pathogenic 
material. This is a biochemical cascade consisting of over 35 different proteins. The 
most important protein with regard to cell encapsulation is C3, as its activation does 
not rely upon pathogen-binding antibodies (Gotze et al., 1976). Therefore, 
encapsulated cells can still be attacked even if antibodies have not bound to and 
recognized them. C3 is cleaved into C3a and C3b by enzymes in the blood. C3b will 
bind to any pathogenic material within its vicinity. This binding starts a cascade of 
hydrolysis and cleavage, ultimately resulting in rapid pathogenic cell lysis (Liszewski 
et al., 1996). Part of the function of this cascade is to initiate a positive-feedback 
mechanism that produces even more C3b (Sim and Tsiftsoglou, 2004). C3b is an 
example of an opsonin, in that it acts as a binding enhancer for the process of 
phagocytosis (Hart et al., 1986). In vivo, exposed antigens on a foreign cell are bound 
by antibodies and complement proteins. This enhances phagocyte binding to the 
foreign cell as phagocytic cells express receptors which bind opsonin molecules 
(Ezekowitz et a l , 1984). Without opsonin binding, most phagocytic binding would 
not occur. As C3b is a small (181 kDa) protein, it is likely to be able to diffuse 
through the capsule membrane, thus allowing complement system activation.
The mammalian brain does not have any true lymphatic vessels and the 
presence of the BBB isolates it from the circulatory system. For these reasons the 
brain was historically thought of as an “immuno-privileged” site (Barker and 
Billingham, 1977). However, this assumption has recently been dispelled. Lymphatic 
drainage from the brain is thought to occur (Knopf et a l , 1995), thus allowing naive T 
cells to be activated in the cervical lymph nodes through indirect antigen presentation. 
Microglia within the brain can act as antigen presenting cells and interact with 
activated T cells, which can cross the BBB (Aloisi, 2001). In addition, the BBB is 
necessarily disrupted by surgery required for grafting; the immune response thus 
generated keeps the BBB open. In conclusion, the seemingly simple task of 
preventing immune rejection of foreign cells is actually exceedingly complex.
Although there are reports of allogeneic (Borlongan et al., 2008) and 
xenogeneic (Kordower et al., 1995; Veng et a l, 2002) transplantation into rodent 
models for human neurodegenerative diseases, it is important to remember that 
rodents react less aggressively to transplantation than humans. For instance, in
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rodents, invaders such as parasites can be separated from the host systems via 
production of dense fibrous tissue, which is not observed in humans (Veng et a l, 
2002).
1.5 IMMUNOISOLATION DEVICES
Immunoisolation devices are typically divided into two categories;
macrocapsules and microcapsules. Each of these approaches makes use of different 
geometries, imparting distinct advantages and disadvantages. The characterizing 
differences are size of device and number of cells encapsulated.
Macroencapsulation employs large macroscopic devices (0.5-6mm in 
diameter, 0.5-10cm in length (Gentile et al., 1995)), originally derived from 
microdialysis tubing, filled with thousands, often millions, of cells. The membrane is 
usually prepared prior to filling with cells and so synthetic polymers (Section 1.7.1) 
can be employed more easily than when manufacturing microcapsules, without 
harming encapsulated cells. Use of synthetic polymers and manufacture prior to 
filling with cells allows for the permeability, together with various other advantageous 
properties of the device, to be easily tuned. Macroencapsulated cells are easily 
retrievable and devices are often mechanically strong. However, implantation of these 
devices can be invasive, and, due to their small surface area to volume ratio, problems 
with oxygen transfer are common. For this reason macroencapsulated cells often have 
lower viability than microencapsulated cells, and so, many more cells are required 
(Kordower et al., 1995).
Microencapsulation allows small numbers of cells to be immobilized in 
spherical beads <lmm (but more commonly <450pm) in diameter. 
Microencapsulation offers many advantages over macroencapsulation. Due to higher 
surface area to volume ratio and hence enhanced oxygen transfer, microencapsulated 
cells often have higher viability. As microcapsules are smaller then macrocapsules, a 
greater number of suitable implantation sites are available. The smaller size is also 
advantageous as it allows simple and precise stereotaxic positioning within the brain, 
which removes the need for major invasive surgery. Moreover, in contrast to 
macrocapsules, if one microcapsule breaks the whole graft is not lost. However, 
microcapsules are more difficult to retrieve after implantation than macrocapsules.
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The major limitations of microencapsulation are fibrotic overgrowth of beads and low 
stability (de Vos et a l, 2006).
1.6 R e q u ir e m e n t s  o f  e n c a p su l a t e d  c e l l  s y st e m s
Depending on the function of the cell line encapsulated, for cell encapsulation to
be successful there are several essential capsule and cell requirements. These are:
• Diffusion of materials to and from cells
• Stability -  both mechanical and chemical
• Small size (<350pm in diameter) and narrow size distribution
• Complete coverage of cells
• Capsule production needs to harness simple and non-toxic procedures
• Biocompatible encapsulation material -  non-toxic to both cells and host
1.6.1 Diffusion
Cells need a constant supply of oxygen and nutrients to survive. The 
encapsulation material in use must allow efficient diffusion of oxygen and nutrients 
into capsules and allow noxious materials and therapuetic products out again. The 
permeability of a molecule through a polymer matrix is dependant upon the molecular 
weight cut off of the polymer and the rate of diffusion of the molecule. The rate of 
diffusion is determined by the size, shape and charge of the molecule; the charge of 
the polymer is also important. Changing porosity affects diffusion rates of molecules 
into and out of capsules. Hence, the porosity of the capsule matrix must be tailored to 
fit the requirements of the system. To prevent immune rejection of encapsulated cells, 
the porosity must be low enough to exclude antibodies and other immune molecules 
(Section 1.4).
Due to ineffective diffusion of oxygen, nutrients and waste products, cell 
necrosis frequently occurs at the centre of large capsules (>500pm), when implanted 
(De Vos et a l, 1999). Ogbonna et a l  (1991) calculated that capsules, in a stirred 
bioreactor, should be no more than 300pm in diameter to ensure effective diffusion 
and hence cell survival. Many polymer-encapsulation techniques fail to produce 
capsules of sufficiently small diameter (to be discussed in Section 1.10.4).
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1.6.2 Stability
Mechanical stability is important in the production and handling of capsules. 
Capsules must remain intact throughout surgical procedures and be able to withstand 
any pressure or stress at the site of implantation. In cases where the implanted cells 
are intended to serve as long-term replacements for endogenous cells, it is clear that 
the capsules must stay intact after implantation. Degradation of capsules due to 
chemical changes is undesirable, as again, capsules will lose integrity and the graft 
will be lost. However, for other applications, slow predictable solubility of the capsule 
may allow timed delivery of compounds over periods of weeks or months prior to cell 
exposure and shut down. In vitro testing of beads is often carried out minus 
encapsulated cells, however, the addition of cells has been shown to decrease the 
mechanical strength of alginate beads (Rokstad et a l , 2003). It is therefore important 
that complete encapsulated cell systems are measured for mechanical strength, not 
merely polymeric capsules.
The mechanical strength required of capsules is dependant upon the site of 
implantation. The most commonly used site for encapsulated cell implantation is the 
peritoneal cavity. It has been shown that alginate capsules break down faster in the 
peritoneal cavity than in the striatum or subcutaneous space (Thanos et a l , 2007). 
Distributions of capsules within each of these implantation sites are different, as are 
forces exerted upon the capsules. For example, capsules are implanted into the brain 
in a cylindrical tract arrangement. Although some surfaces of some capsules are not 
exposed to the surrounding tissues, the forces exerted by the neighbouring tissue has 
been posited to be able to cause physical damage (Thanos et a l , 2007).
In humans, intracranial pressure has been measured to be 7-15mmHg when 
lying down, which falls to -lOmmHg when standing (Steiner and Andrews, 2006). As 
the brain is incompressible and the volume within the skull is fixed, blood, 
cerebrospinal fluid and brain tissue are in a state of volume equilibrium (Monro, 
1783; Kelly, 1824). Hence, intracranial pressure can be extrapolated to pressure 
exerted within the brain tissue. Converting to kPa, the pressure exerted within brain 
tissue is -1.3kPa to 1.9kPa. Alginate gels (2%, M:G = 1.67) have been shown to 
withstand compression forces of up to lOkPa (LeRoux et a l, 1999). Hence, the 
pressure exerted by surrounding brain tissue should not be enough to cause damage to 
implanted beads.
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1.6.3 Small size and narrow size distribution
According to Robitaille et al (1999), small capsules (<35Opm) show
increased biocompatibility when compared to capsules with a diameter of 1250pm. It 
is not clear why this should be the case, though it has also been observed in another 
study (Omer et al., 2005). Ross and Chang (2002) showed that smaller APA (Section 
1.8.1) capsules have higher mechanical strength than larger ones. As discussed 
previously (Section 1.6.1), smaller size capsules allow enhanced oxygen transfer 
(Ogbonna et a l, 1991). Many properties of capsules are dependant upon size, 
therefore a narrow size distribution is important to ensure a homologous population of 
beads which will all respond in the same manner (Strand et a l, 2002).
1.6.4 Complete covering of cells
Cells protruding from the bead matrix through incomplete covering are
susceptible to attack by the immune system. This not only compromises the individual 
bead concerned, but also exposes the whole graft to immune attack (King et a l, 
2001b). Through exposure to a few cells which are not encapsulated, the immune 
system becomes sensitised to the encapsulated cells and increased levels of antibody 
are produced, causing the entire graft to be destroyed. Several studies by de Vos et al 
into encapsulated islets have found that physical irregularities such as tails, craters 
and protruding islets decrease the stability of beads, leading to bead breakage as well 
as fibrotic overgrowth (de Vos et a l, 1994). Decreasing bead diameter from 800pm to 
500pm increased the likelihood fourfold of islets protruding (De Vos et a l, 1996). An 
increased fibrotic reaction was observed with islets encapsulated in beads 500pm in 
diameter compared with beads 800pm in diameter (De Vos et a l, 1996).
1.6.5 Non-harmful procedures
It is clear that the encapsulation procedure should not adversely affect the
viability of the cells to be encapsulated, i.e. ensuring maximum cell viability at the 
end of an encapsulation procedure is of paramount importance. Current procedures 
have limitations in this regard. For example, the encapsulation method (such as 
interfacial polymerisation) may involve organic solvents (Sefton et a l, 1987; 
Desmangles et a l, 2001) or expose the cells to high shear forces, (i.e. any production 
method which forces cells in solution through a narrow aperture at high velocities or 
involves an impeller (Section 1.9)), both of which may be harmful.
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1.6.6 Biocompatible encapsulation material
Biocompatibility has many definitions, not all of them useful. The Williams
definition of biocompatibility is “the ability of a material to perform with an 
appropriate host response in a specific application” (Williams, 1987). This definition 
allows interaction between the host and the implant to be taken into account. In the 
context of encapsulated cells, the encapsulation material should not irritate the tissues 
surrounding the implant, provoke an inflammatory response nor incite allergic 
reactions. It is preferable that the polymeric material should not be cytotoxic or 
mutagenic, either to the encapsulated cells or to the host. The immune system should 
not attack the material and no changes in the material’s properties should occur when 
in a biological environment.
1.7 E n c a p s u l a t io n  m a t r ic e s
Most cell encapsulation is “polymeric”, i.e. it makes use of polymers.
Polymers are molecules made up of repeating units (monomers), which can be 
naturally occurring or synthetically produced. Monomers are connected together by 
covalent chemical bonds into repeating chains by the process of polymerisation. The 
term homopolymer describes a polymer chain where all the monomers are identical; 
in contrast, a copolymer consists of a mixture of monomers. Polymer chains can be 
linear or branched and are joined together by various cross-linking mechanisms. 
Cross-linked polymers often have very different properties from their pre-cross-linked 
counterparts. Take for example polyacrylamide; used in gel electrophoresis. This 
homopolymer is made up of acrylamide monomers (Fig 1.1).
Figure 1.1: Chemical structure of acrylamide
Many hundreds of thousands of monomers are polymerized to form long 
chains of polyacrylamide. These chains are not attached to each other and can move 
freely. Upon addition of a cross-linking agent (for example, bisacrylamide in the case 
of gel electrophoresis), the chains become linked to each other. The resulting cross­
o
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linked polymer is a gel capable of absorbing many times its own mass in water (Fig 
1.2).
— CH=— CH*
C -O
I
NH„
n
Figure 1.2: Cross-linking of polyacrylamide
1.7.1 Synthetic encapsulation matrices
Use of synthetic polymers for cell encapsulation is advantageous as they can,
in principle, be designed to meet specific requirements and reproducibly 
manufactured. Many synthetic polymers do not permit cell adhesion (Folkman and 
Moscona, 1978), but can be made more suitable for cell attachment (Chinn et al., 
1989). For example, cell adhesion has been enhanced within beads by manufacturing 
polymers incorporating arginine-glycine-aspartic acid (RGD) peptides (reviewed in 
Hersel et al., 2003). Other disadvantages to the use of synthetic polymers are issues 
with toxicity. Polymerisation often requires the use of conditions that affect 
encapsulated cell viability, for instance, organic solvents or high temperatures. In 
addition, low molecular weight components of the polymer, such as unreacted 
monomers, plasticizers or catalysts, are able to leach from the device upon 
implantation and cause harm (Taylor et al., 1994).
Due to the detrimental effects of polymerisation, synthetic polymers have 
most often been used in conjunction with macroencapsulation devices (Section 1.5). 
As the device is manufactured prior to filling with cells, cells are not exposed to 
conditions required for device formation. Numerous synthetic polymers have been 
used for the microencapsulation of cells including; an amphiphilic poly(ethylene 
glycol)-conjugated phospholid derivative (Teramura and Iwata, 2009), poly(ethylene 
glycol)-co-poly(glycolic acid) (Bencherif et al., 2009) and Poly(ethylene glycol)- 
poly(propylene glycol) block copolymers (Cellesi and Tirelli, 2005). However, due to 
the concerns of long-term safety, naturally occurring polymers are used in preference 
to synthetic polymers.
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1.7.2 Alginate
The most commonly used polymer in cell encapsulation is alginate (salt of 
alginic acid), a naturally occurring hydrogel. Hydrogels are hydrophilic polymers 
which can consist of up to 99% water. Their high water content and hydrophilic 
nature prevents damage through friction to tissues when implanted. The aqueous 
environment can also protect encapsulated cells and allow transport of nutrients to 
cells. Alginic acid has properties which make it ideal for cell encapsulation. For 
example, alginate forms a gel under very mild, physiological conditions (Smidsrod 
and Skjakbraek, 1990), very rapidly, and it is both biocompatible and biodegradable 
(Orive et al., 2004).
1.7.2.1 Structure
Alginate is obtained relatively easily from seaweed, although extraction and 
purification techniques must be extensive to prevent an immune response upon 
implantation (Zimmermann et al., 2005). This naturally occurring polysaccharide is a 
block copolymer comprised of (3-D-mannuronic (M) acid and a-L-guluronic (G) acid 
residues (Figure 1.3).
OH
Figure 1.3: Chemical structure of alginate. Ring conformation of (3-D-mannuronic acid (M) and a - L -  
guluronic acid (G)
The residues can form into four types of diad: MM, GG, MG and GM. These 
diads can then form into three types of block: homopolymeric M- and G-blocks and 
alternating MG-blocks (Gaserod et al., 1998). The percentage and sequence of the 
block is unique to each algal species it is extracted from. Alginic acid extracted from 
Laminaria hyperborea has a high percentage of G residues, whereas alginic acids 
extracted from Durvillea antartica, Ascophyllum nodosum, Laminaria digitata and 
Macrocystis pyrifera have a high percentage of M residues (Smidsrod and
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Skjakbraek, 1990). Gels formed from these different alginic acids have varying pore 
sizes, degradation rates, mechanical stability and diffusion kinetics (Smidsrod, 1974; 
Martinsen et a l , 1989; Stokke et a l , 1991).
The carboxyl groups on alginate residues have a strong affinity for divalent 
and trivalent cations such as Ca2+, Sr2*, Al3+ or Ba2+. The affinity of alginate chains 
for alkaline earth metals decreases thus; Ba2+ > Sr2+ > Ca2+ »  Mg2+ (Smidsrod and 
Skjakbraek, 1990). The selective binding of divalent and trivalent cations leads to 
ionotropic gel formation. Ca2+ is the most widely used ion to form alginate gels for 
cell encapsulation, as it is non-toxic at the low concentrations used and selectively 
binds G-blocks. Two alginate chains are thought to form helical structures around
^ I
Ca ions (Figure 1.4), this is often referred to as the “egg-box model” (Braccini and 
Perez, 2001).
Figure 1.4: Representations of cross-linked alginate 3D structure. A) Ball and stick representation 
of poly-L-guluronate sequences of alginate cross-linked by calcium ions. B) Conversion of random 
coils to buckled ribbon-like structures which contain arrays of Ca2+ ions. C) Schematic of the proposed 
stereochemistry of Ca2+ ion complexation. The oxygen atoms involved in the coordination sphere are 
shown as filled circles. From Wee and Gombotz (1998)
• 94*Anions with the ability to chelate Ca , such as citrate, phosphate or EDTA 
will destabilise ionically cross-linked alginate gels, causing the 3D matrix to dissolve 
(Smidsrod and Skjakbraek, 1990). Ca2+ ions can also be displaced by other cations
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such as sodium and magnesium, so high concentrations of these cations can also 
dissolve alginate gels. This example of ion-exchange occurs via diffusion of ions into 
the cross-linked structure. LeRoux et al. (1999) found that 60% of the mechanical 
strength of an alginate bead is lost within 15 hours of exposure to biological buffers. 
Destabilisation is bought about by a combination of ion-exchange of Ca with 
sodium, and calcium chelation by phosphate.
1.7.2,2 Internal and External cross-linking
The most common method for producing alginate beads is droplet formation
with subsequent ionic cross-linking occurring in a setting bath containing a calcium
94-(II) ion solution (Section 1.9). This is termed “external gelation”, as Ca ions are 
external to the droplets of dissolved alginate. Alginate chains within the fluid droplet
94-diffuse to the interface of the droplet where the Ca concentration is highest, thus 
forming an alginate gradient within the cross-linked alginate beads. Beads formed via 
external cross-linking are termed “non-homogeneous” as there is a higher 
concentration of alginate and Ca2+ at the surface than the core (Quong et al., 1998).
9  i
Internal cross-linking occurs when Ca ions are liberated, within an alginate 
droplet, from an insoluble or inactive form. The only cells to be encapsulated thus far 
using internal cross-linking were Lactococcus lactis, an acid-loving bacterial species 
(Larisch et al., 1994), based on a method described by Lencki et al. (1989). Calcium 
citrate was used as the insoluble calcium source. This was dispersed in a solution of 
alginate, which was emulsified in vegetable oil. Acetic acid in vegetable oil was 
subsequently added to the emulsion. Liberation of Ca2+ occurs upon reaction of 
calcium citrate with H+, from the dilute solution of acetic acid. Thus, Ca2+ ions were 
released within the dispersed phase of the emulsion, thereby initiating ionic cross- 
linking of alginate chains.
In 1995, Poncelet et al. replaced calcium citrate with calcium carbonate (see 
Figure 1.5). As calcium carbonate releases Ca2+ at a higher pH than calcium citrate, 
the cross-linking reaction is almost instantaneous. Equation 1.1 shows the reaction 
that occurs; the by-products from this reaction are water and carbon dioxide. With 
modifications, such as the addition of chitosan, this method has subsequently been 
widely used to encapsulate biological macromolecules, such as haemoglobin (Ribeiro 
et al., 2005) and DNA (Quong et al., 1998). Internal cross-linking of alginate is most 
commonly used in conjunction with an emulsion formation method (Section 1.9.3).
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Alginate beads formed using internal cross-linking methods typically have a 
homogeneous concentration of alginate and calcium throughout. As the calcium 
source is homogeneously dispersed throughout the fluid alginate droplets, a gradient 
of alginate chains is prevented from forming.
CaC03  + 2H+ —► Ca2+ + CO2 + H2O Equation 1.1
A lg in ate  c h a in s
+ 2ET
C ross-lin k ed  a lg in a te
Figure 1.5: Schematic diagram illustrating internal gelation. Ca2+ is released from calcium 
carbonate upon addition of acid, inside a liquid alginate droplet. Chains of alginate become cross- 
linked by free Ca2+ (red circles)
Although the cross-linking reaction of alginate by calcium is often thought of 
as “mild” and occurs under physiological conditions, both external and internal cross- 
linking methods can be toxic to cells. Calcium at high concentrations is known to be 
toxic to cells (Choi, 1992; Barros et al., 2002; Burek et al., 2003). There is a danger 
with both methods that excess calcium which is not used in the cross-linking reaction 
may harm encapsulated cells. The acidic conditions required by the internal cross- 
linking method, coupled with the extended (20 minute) exposure required when using 
emulsion formation techniques (Section 1.9.3) to fully cross-link the alginate, are also 
extremely toxic to cells. Indeed, this may explain why only acid-loving bacterial 
species have previously been encapsulated using internal cross-linking.
1.7.2.3 Porosity
Pore sizes range widely from 50 -  200nm in calcium cross-linked alginate gels 
(Smidsrod and Skjakbraek, 1990). Increasing alginate concentration has the effect of 
decreasing the matrix porosity (Martinsen et al., 1992). Gels formed from alginates 
high in M-residues have a more flexible structure and a lower porosity than alginate 
high in G-residues (Martinsen et al., 1989). This is due to G-blocks forming more
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rigid tertiary structures than M-blocks upon cross-linking, as Ca preferentially binds 
G-residues. Homogeneous beads have a higher porosity than non-homogeneous beads 
(Section 1.7.2.2) as the increased concentration of alginate at the surface of non- 
homogeneous beads reduces diffusion of molecules (Martinsen et al., 1992).
As the primary function of an immobilisation matrix is to prevent 
encapsulated cells being attacked by the immune system, it should be impermeable to 
antibodies and complement species (Section 1.4). Calcium cross-linked alginate beads 
have been shown to be permeable to IgG (Strand et a l , 2002) and C3 (Section 1.4, 
Lanza et a l , 1995). Barium cross-linked alginate beads have also been shown to be 
permeable to IgG (Morch et a l, 2006). Coating alginate beads with a secondary layer 
of PLL was shown to prevent diffusion of IgG and tumour necrosis factor (Kulseng et 
al., 1997). Such a molecular weight cut-off (tumour necrosis factor has a MW of 
51kDa) was not observed to detrimentally affect viability of encapsulated islets of 
Langerhans. It is conceivable, however, that other cell types may be affected by 
encapsulation within such a membrane.
1.7.2.4 Mechanical strength
Encapsulated cells should have sufficient mechanical strength to be able to
withstand forces exerted during administration and in vivo (Section 1.6.2). The 
rigidity of alginate gels increases with the affinity for the cross-linking ion, thus; Ba2+ 
> Sr2* > Ca2+ »  Mg2+ (Smidsrod, 1974). So, barium cross-linked alginate gels are 
mechanically stronger than calcium cross-linked alginate gels due to the stronger 
affinity of alginate residues for Ba2+ than Ca2+.
As stated in Section 1.7.2.1, exposure of calcium cross-linked alginate to 
biological buffers leads to significant loss of mechanical strength. As Ba2+ has a 
stronger affinity for alginate, barium cross-linked alginate is expected not to undergo 
ion-exchange with monovalent ions, or smaller divalent ions. Addition of small 
amounts of barium (ImM) during cross-linking was shown to reduce the swelling of 
alginate beads, as well as increase gel strength (Morch et a l , 2006). Another method 
of stabilising alginate beads is to apply a secondary polycation layer; this will be 
discussed in Section 1.8.
Rokstad et al (2006) have pioneered an alternative approach to producing 
stronger gels. By introducing photo-cross-linkable methacrylate groups onto M- 
residues of alginate chains, beads could be produced using ionic and covalent cross­
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linking. Hence, beads were produced using conventional cross-linking methods 
(Section 1.9), and subsequently photo-cross-linked by methacrylates, initiated by 
Eosin Y and white light. The resultant beads were found to be more mechanically 
stable than barium cross-linked alginate beads. HEK (Human Embryonic Kidney), 
C2C12 (mouse myoblasts) and pancreatic islet cells were successfully encapsulated 
and showed excellent initial viability. However, only slow growing C2C12 cells and 
islet cells continued to be viable for longer than 13 days. HEK cells did not proliferate 
in the photo-cross-linked beads. Increased cross-linking density was thought to make 
the beads more solid, hence preventing the fast growing HEK cells from expanding.
1.7.3 Alternative, naturally occurring encapsulation polymers
Temperature sensitive gels, such as agarose (Sakai et al., 2005), have also
been utilised for cell encapsulation. Agarose is soluble in hot water and forms a 
reversible hydrogel upon cooling. Due to its inherent hysteresis (the difference 
between its melting and gelling temperatures) it melts at a very high temperature (80- 
95°C) and gels at 32-45°C. Other examples of this kind of temperature sensitive gel 
are agar and K-carrageenan (Prakash and Bhathena, 2008). Agarose gels are highly 
porous and have previously been used as extracellular matrices. Lahooti and Sefton 
(2000) incorporated agarose cores into poly(hydroxyethyl methacrylate-co-methyl 
methacrylate) (poly(HEMA-MMA)) capsules in order to promote cell growth. They 
observed that HEK cells suspended within agarose cores surrounded by poly(HEMA- 
MMA) capsules showed decreased cellular aggregation, and increased viability over 
time. An overproliferation of cells was also reported, with subsequent capsule rupture.
1.8 Coating
An additional coating layer can be used to improve the characteristics of 
encapsulated cell systems. For instance, additional coating may improve mechanical 
stability (Section 1.7.2.4), as well as reducing matrix porosity (Section 1.7.2.3). By 
reducing matrix porosity, it is less likely that elements of the immune system will be 
able to enter the encapsulated system by diffusion. Also, if any cells protrude from the 
polymeric matrix, an additional coating layer may prevent them from coming into 
contact with immune cells and antibodies (Section 1.6.4).
Commonly, coating is performed using a two-step process. Polymeric beads 
are formed using an entrapment technique, as described below (Section 1.9), and then
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treated with a solution of the appropriate coating species. Coated beads are removed 
from the solution after an empirically determined time and washed to remove 
unbound coating material. The original bead material may also be re-dissolved, to 
leave cells in a liquid centred capsule surrounded by a polymer shell (Lim and Sun, 
1980; Kampf, 2002).
Coating materials must be similar in characteristics to the encapsulation matrix 
materials, namely; non-toxic to cells, appropriate porosity, mechanical stability and 
biocompatibility. Alginates are negatively charged polymers, and as such form strong 
complexes with polycations (positively charged polymers). Several forms of 
polycation have been used to stabilise alginate beads and reduce their porosity. The 
following sections discuss the most commonly used polycations for coating alginate 
beads.
1.8.1 Poly-L-lysine
Poly-L-lysine (PLL, Figure 1.6) is the most commonly employed coating 
material used in conjunction with alginate. The use of this polycation and the method 
for producing PLL-coated alginate beads was pioneered by Lim and Sun (1980).
NH
NH
Figure 1.6: Chemical structure of poly-L-lysine
Although there was initial enthusiasm for PLL coating, it has since been 
shown that PLL attracts inflammatory cells, and fibrotic overgrowth often occurs in 
implanted capsules of this type (Vandenbossche et a l , 1993). Fibrotic overgrowth is 
undesirable as it leads to a decrease in transfer of oxygen, nutrients and metabolites 
and ultimately cell death. To prevent fibrotic overgrowth, PLL capsules are 
additionally treated with an external second coat of alginate. The resulting capsules 
are known as alginate-PLL-alginate (APA) capsules. It was thought that the additional
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alginate layer prevented the PLL from coming into contact with cells at the 
implantation site, thus reducing the immune response. However, it has recently come 
to light that there is no distinct outer alginate layer in APA beads. Tam et al (2005) 
have shown, using high performance techniques (such as attenuated total reflectance 
Fourier transform infrared spectroscopy, X-ray photoelectron spectroscopy, and time- 
of-flight secondary ion mass spectrometry) that APA beads consist of an alginate core 
surrounded by a single layer of alginate and poly-L-lysine complexes. This could 
explain observations that immune responses are still evoked by these beads (King et 
a l , 2001a).
Calcium cross-linked alginate beads swell when placed in solutions which do 
not contain calcium, but do contain Na+ (Morch et a l, 2006); this is due to ion 
exchange of Na for Ca , which destabilises the gel. In an attempt to prevent 
destabilisation and swelling, a semi-permeable membrane of PLL has been used. 
Ideally the PLL membrane would be elastic and flexible enough to counteract the 
increased osmotic pressure caused by influx of water. If the osmotic pressure becomes 
too high or the elasticity of the membrane is too low the capsule will burst. To test the 
ability of beads or capsules to withstand osmotic pressure they are exposed to 
solutions of different osmolarities, the most extreme being distilled water. The so- 
called osmotic pressure test (Van Raamsdonk and Chang, 2001) and explosion assay 
(distilled water only, Thu et a l, 1996a) have allowed investigations to be carried out 
to improve the mechanical stability of APA capsules.
It has been shown that APA capsules with a membrane more resistant to 
osmotic pressure can be produced by increasing the exposure time of alginate beads to 
PLL, and also by increasing the concentration and decreasing the MW of PLL (Thu et 
a l, 1996a). The same study also found that PLL binding is proportional to the content 
of M residues present within the alginate, and that this is irrespective of alginate 
gradient.
1.8.2 Poly-L-ornithine
Poly-L-omithine (PLO, Figure 1.7) has been used as an alternative coating
material to PLL. As PLO is similar to PLL, i.e. a positively charged polypeptide, 
additional coating with alginate is required to prevent a strong immune reaction and 
fibrotic overgrowth. PLO has been shown to reduce swelling observed with PLL 
coated alginate beads, resulting in increased stability as well as reduced permeability
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(Darrabie et a l, 2005). It was postulated that the improved performance of PLO- 
coated alginate beads were due to more efficient binding of PLO to alginate than PLL, 
brought about by its more compact structure (Darrabie et a l, 2005). As can be seen by 
comparing Figure 1.6 to Figure 1.7, PLO is shorter in structure than PLL by one 
methylene group.
NH,
NH
Figurel.7: Chemical structure of poly-L-ornithine
Despite improved in vitro properties, PLO-coated alginate beads were 
observed to elicit an even larger immune response in vivo than PLL-coated alginate 
beads (Ponce et a l, 2006). Although some enhanced properties have been observed, 
the improvements are minor and do not represent significant advantages over PLL.
1.8.3 Chitosan
Chitosan (Figure 1.8) is a naturally occurring polymer, prepared by N- 
deacetylation of chitin occurring in crustacean exoskeletons. It is biocompatible and 
has a low toxicity. Chitosan is soluble in acidic conditions, but insoluble at neutral 
pH.
Riberio et a l (2005) compared chitosan-coated alginate beads, made using 
two different methods, to non-coated alginate beads. In all methods, alginate beads 
were formed using emulsification (Section 1.9.3) and internal gelation (Section
1.7.2.2). In the one-step coating method, chitosan was added to the oil phase in an 
acidified state. In the two-step method, beads were isolated, washed, and then 
transferred to an aqueous solution of chitosan. Beads coated via the two-step method 
showed decreased porosity compared to both uncoated beads and coated beads 
produced via the one-step method. These beads were also found to be more 
mechanically stable than beads coated using the one-step method (Gaserod et a l, 
1999).
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Figure 1.8: Chemical structure of chitosan
Gaserod et al (1998) carried out a comprehensive investigation of the 
interaction between alginate and chitosan. By changing various factors related to the 
alginate bead composition, method of production and the chitosan coating it was 
found that binding of chitosan to alginate could be increased. Increased binding of 
chitosan to alginate decreased the permeability of the bead and increased stability 
(Gaserod et a l , 1999).
Hepatocytes have been successfully encapsulated, using the two-step method, 
in alginate-chitosan capsules (Haque et a l, 2005). However, viability was reduced 
when compared to APA capsules. Reduced viability was thought to be due to the 
longer coating time (30 minutes compared to 10 minutes for PLL) required for 
chitosan, although it is more likely to have been caused by the acidic pH (pH 5.2) 
required to dissolve chitosan.
1.9 Current encapsulation  methods
Numerous methods for encapsulating cells in alginate are described in the
literature, which are outlined below. All methods employ a two step process; 
production of fluid alginate droplets containing cells, followed by Ca2+ cross-linking 
to form solid beads. Beads can be maintained in a solid state, or, with the application 
of additional coating layer/s, be converted into capsules (Section 1.8). Beads are solid
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throughout their cross-section, whereas capsules have a liquid centre with a layer of 
polymer forming a peripheral shell (Kampf, 2002).
The main difference between the current encapsulation methods is one of 
droplet generation. Once droplets are formed, cross-linking is always achieved by 
dropping into a collection bath. The collection bath contains CaC^, which allows 
diffusion of Ca into droplets to form beads. This mode of forming alginate beads is 
termed external gelation, as the Ca source is outside the alginate droplet (Section
1.7.2.2). The most commonly used techniques are discussed briefly below. A more 
detailed discussion of the advantages and disadvantages of the methods, with 
emphasis on key requirements, will follow in Section 1.10
1.9.1 Extrusion through a needle
A narrow stream of polymer (containing cells) is pumped through a small
needle/nozzle, whereupon it breaks up into droplets, due to the phenomenon known as 
Rayleigh break-up (Rayleigh, 1879). The described break-up only occurs if there is 
sufficient distance between the nozzle and the collecting bath. Extrusion is the 
simplest of all the described methods and uses readily available equipment. Very 
large beads are produced using this method and users have little control over the 
diameter and size distribution of beads produced (For example, see Fundueanu et al., 
1999, mean diameter 1.2mm, CV = 16%). For this reason many groups utilize one of 
the modifications discussed below (Sections 1.9.1.1 -  1.9.1.3).
1.9.1.1 Coaxial air or liquidflow
The needle extrusion method is most commonly modified by allowing a fluid
(for example, air (Tagalakis et al., 2005) or hexadecane (Sefton et al., 1987)) to flow 
around the polymer stream. The liquid stream break-up is thus enhanced and smaller 
beads can be produced. Once the flows of fluid and distance of the nozzle from the 
collecting bath have been empirically determined, this procedure is straightforward.
1.9.1.2 Electrostatic
Another modification of the needle extrusion method establishes an
electrostatic potential of l-20kV between the needle and the collection bath, thus 
enhancing droplet formation by drawing the droplet towards the collection bath. 
Another consequence of an electrostatic potential is to disperse droplets as they fall 
into the collection bath (Serp et al., 2000; Koch et al., 2003). Thus, beads do not
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coalesce upon falling into the collection bath and the polydispersity of the beads is 
reduced. By altering the needle diameter and alginate flow rate, varying bead 
diameters can be achieved.
1.9.1.3 Vibrating je t break-up
In this adaptation of the needle extrusion method, harmonic vibrations are
applied to the needle thus aiding droplet formation (Seifert and Phillips, 1997). This 
method is difficult to reproduce in a laboratory-made device and is more commonly 
employed in commercial encapsulation devices, such as those manufactured by Nisco 
(Zurich, Switzerland). An electrostatic potential can be additionally applied to further 
enhance bead formation (Serp et al., 2000).
1.9.2 Rotating jet break-up
Polymer solutions containing cells are forced out of nozzles to form fluid jets.
Droplets are generated by cutting the continuous jet of fluid with rotating wires, 
which are angled to prevent “spraying loss” (PruPe et a l , 1998). The cylinders of 
fluid produced form into droplets due to surface tension. As this technique does not 
rely upon Rayleigh break-up to produce droplets, it is uniquely compatible with 
highly viscous fluids.
1.9.3 Emulsion formation
An aqueous polymer solution containing cells is rapidly stirred with an
immiscible phase to form small, spherical droplets of one phase within the other. The 
polymer is referred to as the dispersed phase; the immiscible fluid is referred to as the 
continuous phase. Surfactants are often used to enhance emulsion formation. Both 
internal and external gelation approaches (Section 1.7.2.2) can be used in conjunction 
with emulsion formation. If external gelation is employed, an appropriate cross- 
linking agent is added to the continuous phase and polymer cross-linking occurs in the 
dispersed polymer phase. Alternatively, an immobilised or inactivated cross-linking 
agent can be added to the dispersed polymer phase and then activated by addition of a 
chemical or photochemical trigger. Although all of the above methods (Section 1.9) 
can also be used in combination with internal gelation, oil-in-water emulsion 
formation is most suitable and frequently used with internal gelation (Poncelet et al., 
1992).
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1.10 R e q u ir e m e n ts  o f  a  c e l l  e n c a p s u la t io n  m e t h o d
Based upon a review of current cell encapsulation devices and platforms, the
following points have been identified as being critical to further development in this 
field.
• Sterile
• Not harmful to cells
• Able to produce many beads -  requiring scale-up
• Small diameter of beads with a narrow size distribution
• Short production time
The methods outlined in Section 1.9 have various advantages and disadvantages; 
each method has one or more major disadvantage which makes its use for cell 
encapsulation problematic. Each requirement will be discussed, highlighting any 
disadvantages of the described methods.
1.10.1 Sterile production method
Sterility is defined as the complete absence of all viable microorganisms
(Akers et al., 2002). Sterility is paramount when beads are prepared for clinical use 
and this can often be problematic with many of the discussed methods. All parts of the 
device which come into contact with alginate solutions, cells and beads should be 
capable of being autoclaved, to ensure sterility of product. Many non-commercial 
encapsulation devices are small enough to be operated within a sterile hood, thus 
bypassing the need for further modifications to ensure sterility.
All of the methods discussed above (Section 1.9) utilise devices which are 
constructed from components which can be autoclaved. Devices which operate on the 
basis of electrostatic and vibrating jet break-up comprise a sealed collection unit, 
which removes the need to operate the devices within a sterile flow hood. The only 
method which cannot be operated within a sterile environment is the rotating jet cutter 
(Section 1.9.2). The fluid containing the material to be encapsulated has to be 
accelerated to maintain a jet. The droplets thus produced travel at high velocity. Upon 
entering the collection bath droplets travelling at these high velocities deform and do 
not produce spherical beads. To avoid droplet deformation, droplets are pre-gelled by 
spraying with CaCh whilst travelling down a 5m long spraying tunnel (Nedovic and 
Willaert, 2004). The spraying tunnel used is not sterile; despite this cells have been 
encapsulated and shown good viability (Schwinger et a l , 2002).
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1.10.2 Non-toxic encapsulation process
Cytotoxic process steps reduce cell viability and therefore therapeutic
productivity. The process of cross-linking alginate is considered to be “gentle” as it is 
carried out at neutral pH and does not require the use of organic solvents. As has
9 4 -previously been discussed (Section 1.7.2.2) high concentrations of Ca can be toxic 
to cells and therefore must be limited. It is important that droplet generation methods 
do not involve high shear forces as these are harmful to cells. Although a high shear 
stress is inflicted upon cells suspended in droplets produced using rotating jet break­
up (Section 1.9.2), murine fibroblasts were successfully encapsulated and shown to be 
viable and able to proliferate up to 6 weeks post-encapsulation (Schwinger et a l, 
2002). All other “dropping” techniques have been used to successfully encapsulate 
viable cells (coaxial fluid flow (Fiszman et al., 2002), electrostatic (Zhou et a l, 
2005), and vibrating jet break-up (Coward et a l, 2005)). Emulsion formation (Section 
1.9.3) is not regularly used with mammalian cells due to issues of cell viability. The 
use of an oil phase is essential for emulsion formation, but many cell types cannot be 
exposed to oil for prolonged periods of time (Kim et a l , 2009).
1.10.3 Production of large volumes of encapsulated cells in a short time period
Production of large quantities (50ml per patient (Calafiore et a l, 2006)) of
mono-disperse beads required for clinical applications is problematic with many of 
the methods discussed above (Section 1.9). Whilst the majority of the methods are 
easy to establish within a laboratory setting, few can be used to produce batches larger 
than 20ml, which may be insufficient for treatment of even a single patient. The 
exception to this is rotating jet technology, which is capable of producing 2L/hour of 
600 pm diameter beads (Priipe et al., 2000). The solution to producing larger batches 
is to produce devices consisting of multiple parallel nozzles. For example, a device 
using the principles of laminar jet break-up (Section 1.9.1.1) was designed with 13 
nozzles, which were supplied from a common reservoir (Brandenberger and Widmer, 
1998). The 13 nozzle device was used to produce 1L of beads 560pm in diameter in 
12 minutes. In contrast, a device based upon electrostatic principles with 20 needles, 
took much longer (1.5 hours) to produce an equivalent volume of 400pm diameter 
beads (Poncelet et a l, 1994).
Although scaled-up devices can produce large beads at high production rates, 
this is more problematic for small beads. Not only is the production of narrow
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aperture nozzles problematic, blockage is more likely to occur than with larger 
nozzles and operating pressures become high. The number of needles required to 
maintain flow rate for production of small diameter beads is inversely proportional to 
the bead volume. Reduction of bead diameters to 100pm, or even 500pm, requires 
several hundreds or thousands of needles working in parallel to maintain required 
flow rates (Poncelet et al., 1992). Seifert and Phillips (1997) calculated that 250pm 
diameter beads took nearly four times as long to manufacture using a vibrating jet 
method as an equivalent amount of beads 500pm in diameter. The increased 
production time is due to an inability to maintain high frequencies required for droplet 
formation. With rotating jet technology, reduction of bead diameters to 200pm 
reduces production time to 80ml/h (PriiPe et al., 2000).
1.10.4 Small diameter beads with a narrow size distribution
More implantation sites are available through the use of beads with small
diameters (Robitaille et al., 1999), and bead samples with a narrow size distribution 
are required for reproducibility between experiments and groups (Strand et al., 2002). 
However, many of the methods discussed above have only recently been optimised to 
allow beads with a diameter less than 400pm to be produced and size distributions 
remain large and uncontrollable. This is typically exacerbated by attempts to scale-up 
production. Issues with variability in nozzle manufacture and other physical 
parameters involved mean that multiple devices (nozzles) run in parallel each produce 
a slightly different bead diameter and size distribution (Brandenberger and Widmer, 
1998). Size distribution is often described using the coefficient of variation (CV), 
which is defined as the ratio of the standard deviation to the mean and expressed as a 
percentage.
The major limitation of all non-commercial devices based upon needle 
extrusion (Section 1.9.1) is the nozzle size, which is restricted by the size of needles 
available commercially. As the narrowest needle available has an outer diameter of 
250pm it is not possible to reproducibly manufacture beads smaller than this. Another 
problem is that of size distribution. Satellite droplets much smaller than the parent 
droplets are commonly produced with any method utilising nozzles (Figure 1.9). It is 
reported that satellite droplets produced using coaxial air flow droplet break-up 
(Section 1.9.1.1) are roughly 1% of the volume of the parent droplets (Zhang, 1999). 
Thus a bi-, or even, poly-modal size distribution are often obtained.
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Satellite droplets
Figure 1.9: Satellite droplet formation from a needle. A) Fluid extruded from a needle begins to 
form a droplet. B) A parent droplet is formed as well as satellite droplets from the neck o f the droplet
Needle extrusion (Fundueanu et a l, 1999), coaxial fluid flow (Fiszman et al., 
2002; Koch et al., 2003) and electrostatic jet break-up (Strand et al., 2002; Zhou et 
a l , 2005) are not suitable methods for producing small beads with a size distribution 
of less than 5% CV. Vibrating (Seifert and Phillips, 1997; Serp et al., 2000) and 
rotating (Schwinger et al., 2002) jet break-up methods are capable of consistently 
producing small beads with a CV of less than 5%. Large quantities of small beads are 
easily produced using emulsion formation; however, product size distribution is the 
largest of all the techniques discussed here. For example, Silva et al report the 
smallest diameter beads generated using this method as 25 pm with a CV of 47% 
(2005). Poncelet (2001) posited that a size dispersion of less than 30% of the mean 
bead size was not achievable using present emulsion techniques.
The information discussed above is summarised in Table 1.2.
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Technique Product bead diameter CV
Possibility 
of scale-up?
Length of time to 
produce 1L of beads
Maximum 
batch size
No. of batches to 
make 1L of beads Sterility Toxicity
Needle
extrusion
Very large 
(l-5mm) >5% 30 nozzles Slow Small Hood None
Coaxial Small (200pm) >5% 4 nozzles 100 hours (500pm 50ml 20 Hood Nonefluid flow Large (700pm) <5% beads, 4 nozzles)
Electrostatic
Small (160pm) >5%
20 needles
31 hours (160pm, 
single needle) 20ml 50 Sealed None
Large (700pm) <5% 1.5 hours (400pm, 20 needles) 1L 1
unit
Vibrating Small (300pm) <5% 13 nozzles
4 hours (200pm, single 
nozzle) 20ml 50 Sealed Nonejet break up Large (700pm) <5% 12 minutes (560pm, 13 nozzles) 1L 1
unit
Rotating jet
Small (<300pm) <5% 48 wires, 4
6 hours (200pm, 48 
wires, 1 jet) 1L 1 No None
Large (3mm) <5% jets 1.5 hours (200pm, 48 wires, 4 jets)
Emulsion Any Large Yes 20 minutes, any size >10L 1 Hood Possibly
Table 1.2: A summary of methods used for encapsulating cells discussed in Section 1.9. CV is calculated as standard deviation divided by mean diameter and 
expressed as a percentage. Parameters which fall outside optimal conditions are highlighted with red lettering, parameters which are ideal are highlighted with green 
lettering and sub-optimal parameters are highlighted with orange lettering
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1.11 L im it a t io n s  o f  c u r r e n t  c e l l  e n c a p s u la t io n  s y s t e m s
Although extensive research has been carried out over the last 25 years on
encapsulated cell systems, a “perfect” capsule is only slightly closer to being realised 
(Lacik, 2006). Several reasons for this failure have been suggested, including those 
discussed in Sections 1.6 and 1.10. Some progress has been made with issues such as 
biocompatibility of polymers, where use of highly purified alginate has reduced 
immune reactions to implanted beads (see Section 1.7.2.1 and De Vos et a l , 1997; 
Zimmermann et a l , 2005). Even if problems with encapsulation systems were solved, 
a major issue yet to be overcome is that of cell availability. For instance, 8 donors 
were required to provide the 678,000 encapsulated islet equivalents implanted into 
one patient, at half the optimal therapeutic dose (Soon-Shiong et a l , 1994).
The major limitation to progress in the field of cell encapsulation appears to be 
one of reproducibility. Currently results cannot be replicated between different labs, 
using differing protocols or even between batches of encapsulated cells. Much of the 
published data is conflicting, with little agreement between research groups; this is 
thought to be due to a lack of workable definitions and incomplete reporting of 
encapsulation protocols concealing differences between groups (Orive et a l, 2003). 
Any new encapsulation procedure must (at least) address the issue of reproducibility 
to prevent these problems arising.
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1.12 M i c r o f l u i d i c  t e c h n o l o g y
Microfluidics is the study and use of fluid flows in micrometer scale channels
(i.e. less than 1mm, Stone et a l , 2004; Atencia and Beebe, 2005). At this scale, 
viscosity, surface tension and diffusion have a larger effect on fluid flow than the 
forces of gravity and inertia, which influence the macro-world. At macro-scale, 
liquids flowing through pipes do so in a turbulent fashion, i.e. flow is chaotic and 
unpredictable (the position, within a fluid stream, of a particle cannot be predicted as 
a function of time, Beebe et a l , 2002). In micrometer scale channels, fluids flow in a 
laminar fashion due to a low Reynolds number (Re), which is defined as:
L v pRe = ---- — Equation 1.2
Where L = most relevant length scale,
H = viscosity,
p  = fluid density,
vs = average velocity of the flow.
For circular microchannels, L = 4A/P, where A = cross sectional area o f channel and P = wetted 
perimeter of channel. For rectangular microchannels, L = 2 a b/ (a + b), where a = height of channel 
and b = width o f channel.
As the cross-sectional area is small, the Reynolds number is decreased, usually 
to below 100. Therefore, viscous forces (denominator in Equation 1.2) dominate in 
this scenario, resulting in smooth, constant fluid flow. As a result, mixing between 
fluids in microchannels occurs via interfacial diffusion not turbulent agitation (Brody 
et a l , 1996). The transition from laminar to turbulent flow generally occurs in the 
range of Re = 2000. A corollary of the above equation is that only one dimension of 
the channel needs to be micro-scale (<lmm) to harness these properties.
The science of microfluidics has expanded rapidly in the past two decades. 
Part of the reason for this is advancement in microfabrication techniques, allowing 
microfluidic structures to be manufactured more easily. Since its inception in the mid 
1990’s, many different fields have used this science in a multitude of ways, for 
example; electrophoresis in biology (Yu et a l, 2007), chemical transformations 
(Palmieri et a l, 2009) and miniature fuel cells in electrical engineering (Brushett et
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al., 2009). Not only do the uses of microfluidic science cross many different fields, it 
is itself also a multi-disciplinary field, linking engineering and physics with chemistry 
and biotechnology.
1.12.1 Use of microfluidic principles to form linear emulsions
Fluid flow in microfluidic channels is typically laminar (Re < 2000), this
means that two fluid streams brought into contact in a microchannel will flow side- 
by-side, with mixing occurring via interfacial diffusion (see Figure 1.10A). Miscible 
fluids will always flow in this fashion, independent of microchannel geometry. 
Immiscible fluids will only flow in a laminar manner in a straight channel, due to low 
Reynolds number. However, this is only true for short periods of time, after which 
droplets of one liquid spontaneously form within the other. Certain channel 
geometries, i.e. cross-junctions (see Figure 1.10B) or T-junctions (see Figure 1.10C) 
enhance this effect, which is termed segmentation. Thorsen et al (2001) were the first 
group to report incorporating segmented flow into a microfluidic chip.
Fluid y Fluid p
Figure 1.10: Schematic representations of laminar and segmented flow within microchannels. A)
Schematic showing laminar flow between two miscible fluids. B ) Schematic showing segmented flow 
of two immiscible fluids in a microfluidic cross-junction. C) Schematic showing segmented flow in a 
microfluidic T-junction
In conventional emulsion formation, the fluid which forms droplets is termed 
the dispersed phase, with the immiscible fluid being termed the continuous phase 
(Section 1.9.3). This is also true in microfluidic circuits. The fluid which forms 
droplets (Fluid a  in Figure 1.10) is also called the functional fluid, and the 
immiscible fluid (Fluid P in Figure 1.10) is called the carrier fluid. Channel 
properties, such as surface energy, contact angle and hydrophobicity, influence which 
fluid forms droplets. Hydrophobic channels repel aqueous flows; hence aqueous 
droplets are formed within an organic continuous phase. Conversely, hydrophilic
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surfaces attract aqueous flows, thereby coating (termed wetting) the channel walls and 
forcing the immiscible (organic) phase to form droplets. In both cases, segmented 
flow occurs and linear emulsions are formed. In the latter scenario a reverse emulsion 
is produced i.e. oil droplets in a continuous water phase (Shinohara et al., 2008).
1.12.2 Use of microfluidic devices for alginate bead production
Several attempts have been made since the beginning of this project, by other
groups, to produce alginate beads using microfluidic systems. The work presented 
within this thesis was carried out prior to or concurrently with the work discussed in 
the next sections. Both internal and external cross-linking methods have been 
employed, as have ionic cross-linking occurring on- and off-chip. Huang et al. (2006) 
first demonstrated that liquid alginate solutions could be segmented using a cross­
junction microchannel to generate droplets of liquid alginate. These droplets were 
transported, with the oil used for segmentation, into a beaker containing a calcium (II) 
ion solution. Beads were produced with a diameter of 200±5pm and a CV of 2.5%. 
These beads were ionically cross-linked off-chip via external gelation. Yeh et al. have 
recently used a microfluidic T-junction to produce alginate droplets, which were also 
subsequently ionically cross-linked off-chip via external gelation (2009).
Two groups have attempted to make alginate beads ionically cross-linked on- 
chip using external gelation and collision of droplets, with varying degrees of success. 
Both groups produced separate droplets of CaCl2 solution and alginate solution using 
oil. These two sets of droplets were then collided, within the system, to produce solid 
alginate beads. Neither of these methods produced spherical beads; Liu et al. (2006) 
produced disk-like and thread-like structures and Shintaku et al. (2007) produced 
tooth-shaped structures. As the kinetics of alginate gel formation are extremely fast, 
the reaction was complete before the two droplets had fully merged to form a 
spherical droplet.
Various other attempts have been made to use external gelation to ionically 
cross-link alginate on-chip. The most successful of these produced beads with a 
diameter of 70pm and a CV of 1.1% (Choi et al., 2007). This is by far the best size 
distribution achieved to date; however, this method was unsuitable for use with cells, 
as hexadecane was used to segment the alginate solution. Kim et al. (2009) produced 
externally cross-linked alginate beads on-chip by using a flow focussing device
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(Section 3.2). The oil used for segmentation contained a small amount of CaCI2 thus 
allowing cross-linking of alginate chains.
Several groups have adapted internal gelation methods pioneered by Poncelet 
et al. (1992) and Ribeiro et al. (2005) for use in microfluidic systems. Huang et al. 
(2007) segmented liquid alginate solutions containing CaC03  using oil in a cross­
junction microchannel. The emulsion generated was dripped into a beaker containing 
oil, Tween80 and acetic acid. Alginate chains became ionically cross-linked when 
droplets containing CaCC>3 came into contact with acetic acid. Zhang et al. (2007) 
proposed adding acetic acid to the fluid used for segmentation, in a similar system to 
the one described above. They were unable to collect any solid beads from this 
endeavour, although partially gelled beads were produced. Tan and Takeuchi (2007) 
used a T-junction to produce droplets of fluid alginate solutions containing CaCC>3 
nanoparticles. Downstream of the junction used to produce droplets, com oil 
containing acetic acid was introduced. Solid alginate beads were produced and 
collected. The work presented in this thesis was carried out and published 
concurrently with these studies.
The use of microfluidic techniques to produce alginate beads is summarised in 
the following table (Table 1.3).
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Study Carrier
fluid
Cross-linking method Channel dimensions Size of product 
bead
CV
Huang et al. (2006) Sunflower
oil
External -  dripped into bath 400pm cross-junction 200±5pm 2.5%
Liu et al. (2006) Soybean oil External -  collision of droplets 60pm cross-junction Threads and discs
Zhang et al. (2006) Undecanol External 100pm flow focussing 
device
30-320pm 2.2%
Shintaku et al. (2007) Food oil External -  collision of droplets 105 pm flow focussing 
device
129pm (not 
spherical)
6.4%
Choi et al. (2007) Hexadecane External -  mixing prior to 
segmentation
90pm modified T- 
junction
~70pm 1.1%
Huang et al. (2007) Sunflower
oil
Internal -  dripped into bath 200pm cross-junction 180±10pm 5.5%
Zhang et al. (2007) Soybean oil Internal 100pm flow focussing 
device
60-110pm 1.5-
2%
Tan and Takeuchi 
(2007)
Com oil Internal 50pm T-junction 94-150pm 2 .8%-
3.6%
Yeh etal. (2009) Sunflower
oil
External -  dripped into bath 200pm T-junction 70-220pm <10%
Kim et al. (2009) Oleic acid External Unreported flow 
focussing device
96-195 pm 11-
13%
Table 1.3: Summary of attempts to use microfluidic devices to produce alginate beads
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1.12.3 Advantages of microfluidic technology for cell encapsulation
The requirements of a production method for encapsulating cells were
discussed previously (Section 1.10). The use of microfluidic techniques to encapsulate 
cells will be considered as compared to these requirements.
1.12.3.1 Small diameter beads with a narrow size distribution
Most importantly for the present application, linear emulsions of droplets with
diameters ranging from 60-320pm have been reported with size distributions of <3% 
CV formed using microfluidic devices (Table 1.3). Production of bead samples with 
size distributions less than 3% are the very best that non-microfluidic techniques can 
achieve (Section 1.10.4). As discussed previously (Section 1.10.4), beads produced 
via emulsification methods typically have a large size distribution (-30%). Within 
microfabricated devices, the size of produced droplets can be varied both by the 
dimension of the channels and by the speed of fluid flows. By decreasing channel 
sizes to below 50pm and increasing flow rates, droplets with diameters (10-30pm) 
approaching that of cells have been produced (Chabert and Viovy, 2008; Edd et a l , 
2008). Droplets of such a small diameter are useful for encapsulating single cells, 
which in this case were then sorted for down-stream applications. Encapsulated single 
cells may be useful for implantation as the diffusion barrier created by the matrix 
would be greatly reduced. Data summarised in Table 1.3 shows that all of the methods 
which can produce spherical beads can produce bead samples with size distributions 
<5.5% CV, typically <2.5% CV.
1.12.3.2 Production o f large volumes o f encapsulated cells in a short time period
In comparison to previously described nozzle-based methods (Section 1.9),
size distribution of produced beads does not increase when microfluidic systems are 
scaled up as circuits are identical, merely run in parallel. The ability of microfluidic 
devices to be run in parallel has been illustrated by Nisisako and Torii (2008); their 
128-circuit device was capable of producing acrylate beads with a diameter of 96pm 
and a CV of 1.3%. Beads were produced at a rate of 320 ml/h, proving that 
microfluidic devices are suitable for generating large batches of small, monodisperse 
beads. Using Nisisako and Torii’s device, 1L of beads would take 3 hours to produce. 
None of the methods discussed previously (Section 1.9) were seen to be capable of 
producing beads of this diameter. The smallest bead size produced was 160pm in
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diameter, using electrostatic jet break-up (Table 1.2, Section 1.10.4). It would take 31 
hours to produce 1L of beads this size.
1.12.3.3 Sterile production method
Devices incorporating microfluidic channels are necessarily sealed, therefore
they are easily kept sterile. Many materials used in the production of microfluidic 
devices can be sterilised, for example polydimethylsiloxane (PDMS) can be sonicated 
in ethanol and then exposed to UV (Gomez et a l , 2007). Most microfluidic devices 
are small; even the multichannel device (previously described) with 128 circuits 
running in parallel only measures 4cm3 (Nisisako and Torii, 2008). Devices of this 
scale can easily be operated inside a sterile hood, thus removing the need for 
additional modifications to ensure sterility. By incorporating filters into microfluidic 
devices, solutions can be sterilised on-chip (Mohamed et a l , 2004; Crowley and 
Pizziconi, 2005; VanDelinder and Groisman, 2006; VanDelinder and Groisman, 
2007).
1.12.3.4 Non-toxic encapsulation process
As most encapsulation polymers are aqueous in nature, a non-aqueous carrier
fluid is required to promote segmented flow and thus produce droplets. Oils and 
organic solvents are often used as carrier fluids. As previously stated (Section 1.10.2) 
many oils and organic solvents are toxic to mammalian cells. However, the use of 
microfluidic processes can help to overcome the deleterious effects of the carrier 
fluids chosen. As each droplet is produced individually and transported along the 
same circuit, each undergoes the same chemical treatment for the same length of time. 
These features can be exploited to ensure that droplets, and hence cells within them, 
are exposed to chemicals for equivalent, minimal periods. Nonetheless, successful 
encapsulation of viable cells through use of microfluidic techniques has been reported 
rarely. Those that have will be discussed in the following section (Section 1.12.4).
1.12.4 Use of microfluidic devices to encapsulate cells
Prior to this study, microfluidic devices had been used to encapsulate cells
within liquid droplets. He et a l (2005) encapsulated cells and single organelles into 
picolitre- and femtolitre-volume droplets using microfluidic circuits. However, these 
droplets were not hardened to make beads and maintaining cell viability was not their 
aim; rather they sought to carry out further analytical tests on the cells/organelles after
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lysing them within their droplet. Tan et al (2006a) also used microfluidic devices to 
encapsulate cells and proteins, this time within lipid vesicles. Viability of HeLa cells 
was shown for over two hours, but no further time points were reported. The produced 
lipid vesicles were reported to be stable for more than 26 days.
Of the methods discussed in the previous section (Section 1.12.2); very few 
groups have successfully encapsulated live cells. Shintaku et al. (2007) encapsulated 
mouse erythroleukemia (MEL) cells in alginate, but presented no viability data. Choi 
et al. (2007) successfully encapsulated GFP-expressing yeast cells in alginate, which 
were shown to still express GFP after encapsulation, but no long term viability study 
was carried out. GFP expression is not the most accurate or reliable way of 
demonstrating cell viability as GFP can still be observed in dead, fixed samples 
(Chalfie et al., 1994). Given its cytotoxicity, it is doubtful that cells encapsulated 
using hexadecane would survive. Tan and Takeuchi (2007) encapsulated viable Jurkat 
cells using internal gelation of alginate, but no long term viability data was reported. 
Kim et al. (2009) successfully encapsulated mouse stem cells (PI9 EC), HepG2, and 
human breast cancer cells (MCF-7) in alginate beads and reported viability 0, 3 and 7 
days after encapsulation. It should be noted that all of these reports were published 
after the start of this project.
1.12.5 Microfluidic experiments performed with a MicroPlant™
This project makes use of a unique platform allowing rapid evaluation of
microfluidic circuits and junctions. The microfluidic device used was developed by Q 
Chip (Cardiff, UK), based on a patent by Professor David Barrow (Barrow et a l, 
2002). In contrast to many other microfluidic systems, polytetrafluoroethylene 
(PTFE), a rigid and hydrophobic plastic, is utilised for microfluidic chip synthesis. 
PDMS is the substrate of choice for many groups fabricating microfluidic devices. 
This is due, in part, to its favourable hydrophobic properties, its relatively low cost 
and standardisation of the soft-lithography technique utilised to produce 
microchannels in this substrate. However, synthesis of such devices takes a minimum 
of eight hours (Zhao et a l, 2003). In addition, as the devices are permanently sealed, 
any blockage of channels (which can occur rapidly after commencement of an 
experiment) results in unusable devices.
Through use of PTFE as a material for microfabrication of devices, the multi- 
step lithography process can thus be avoided, and substituted by a single, automated
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micro-machining operation. This method allows microfluidic features composed of 
microchannels with square or rectangular cross-sections. Microchannels with 
dimensions of 100pm or greater can be produced. Typically, a microfluidic device of 
this kind, containing multiple parallel circuits can be produced within sixty minutes. 
In addition, by avoiding a permanently sealed cover, a compression-sealed PTFE 
device may be dismantled, cleaned and reassembled as required. This is particularly 
useful in cases of accidental experimental failure (e.g., channel blockage due to 
unwanted polymer cross-linking), allowing rapid recovery during testing and 
optimisation of conditions, which would be impossible in PDMS/PMMA/glass 
devices.
In 2005, the microfluidic evaluation platform used in this project had 
previously been used for the generation of cross-linked hydrogel beads, composed of 
PVA (polyvinyl alcohol), PEGDM (poly(ethylene glycol) dimethacrylate) or HEMA 
(hydroxyethyl methacrylate). All these hydrogel beads were formed via a 
photochemical cross-linking method. A photo-initiator is added to the polymer 
solution, which is then segemented to produce droplets. When the droplets are 
illuminated with UV light (~350nm), the photoinitiator undergoes homolytic 
cleavage, which produces two radical-bearing intermediates, these go on to initiate the 
cross-linking reaction and crosslink the polymer within the droplet. Exposure of cells 
to UV light is inappropriate and so the developed methods were not applicable to 
encapsulation of cells. A purpose-made microfluidic device for ionotropic gelation, or 
manipulation of polysaccharides or cells was not available and thus, this project was 
established to develop a microfluidic method for cell encapsulation.
1.13 AIMS
Currently there is much interest surrounding encapsulated cells. Alginate has 
emerged.as the polymer of choice, for several reasons; alginate is biocompatible and 
biodegradable, as well as requiring an innocuous cross-linking reaction. However, 
challenges remain to be solved before a satisfactory production method is found. For 
example; cells must be completely covered by the polymeric matrix, the capsules 
produced must be consistently small and in large volumes. Although there are 
currently many production techniques for encapsulating cells, no single method can 
solve these challenges.
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The overall aim of this project was to develop a microfluidic method to 
encapsulate dopamine releasing cells in an alginate matrix, determine their viability in 
vitro and investigate implantation into a rodent model of Parkinson’s disease. This 
process took part in several stages:
AIM 1: to develop a microfluidic process to generate alginate beads encapsulating 
cells and to evaluate the short and long term impact of this process on cell viability. 
Prior to this study alginate solutions were segmented using microfabricated arrays 
within a macro-scale device (Sugiura et a l , 2001) but there were no methods using 
microfluidic devices to encapsulate cells. Several viability methods were investigated 
to determine their suitability for use with encapsulated cell systems. The acute and 
long term effects of the developed microfluidic encapsulation process on cells were 
examined.
AIM 2: to validate the encapsulation process with therapeutically relevant cells 
(PC 12) and determine dopamine release.
Initial encapsulation experiments were carried out with a rapidly dividing epithelial 
cell line; Human Embryonic Kidney 293 (HEK293). Upon successful development of 
a microfluidic encapsulation protocol using HEK293 cells, a therapeutic cell line, 
PC 12, was encapsulated. Measurement of the levels of the therapeutic molecule 
dopamine, produced by PC 12 cells, ensured that the developed microfluidic 
encapsulation method did not adversely affect cells.
AIM 3: to modify the microfluidic method developed in the previous steps to produce 
smaller beads suitable for cannula implantation and determine their in vivo stability. 
Use of encapsulated PC 12 cells in a rodent model of Parkinson’s disease required that 
beads were small enough to be implanted through a cannula with a 300pm inner 
diameter. To manufacture beads <200pm in diameter, modifications were made to the 
developed microfluidic system and cell processing. Stabilisation of the resultant beads 
was investigated to ensure beads would persist in the brain for more than 6 weeks. 
Stabilisation was carried out by i) barium cross-linking and ii) secondary coating with 
polycations. The resultant beads were implanted into rats to investigate in vivo 
stability. The internal structure of alginate beads produced using the developed 
microfluidic method was also elucidated.
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Chapter 2. Materials and Methods
2.1 M a te r ia ls
2.1.1 Alginate
Pronova UltraPure alginate was purchased from NovaMatrix™ (Drammen, 
Norway). This medical grade alginate is ultrapure with low endotoxin levels and low 
protein contamination. Viscosity can be controlled by changing the molecular weight 
of the alginate used. Pronova UltraPure medium viscosity, high mannuronate (UP 
MVM) alginate has a molecular weight of 200,000 -  300,000 g/mol and was 
composed of 57% mannuronate units with a viscosity of 254 mPa-s at 20°C. Pronova 
UltraPure medium viscosity, high guluronate (UP MVG) alginate has a molecular 
weight of 200,000 -  300,000 g/mol and was composed of 31% mannuronate units 
with a viscosity of 318 mPa-s at 20°C.
2.1.2 Carrier fluid
High oleic acid sunflower oil was used in all experiments as it is inexpensive 
to obtain in large quantities, from a batch traceable source (Statfold, Staffordshire, 
UK). Sunflower oil can also be sterilised using heat.
2.1.3 Cross-linker
Microcrystalline precipitated calcium carbonate (a gift from Specialty 
Minerals, Birmingham, UK); with an average particle size of 0.07pm (Figure 2.1) was 
used in all experiments.
mI »
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Figure 2.1: Particle size distribution of microcrystalline precipitated calcium carbonate. Supplied 
by Specialty Minerals, Birmingham, UK
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Supplier Reagent
Autogen Bioclear, Foetal bovine serum
Wiltshire, UK
Greiner, Stonehouse, UK Culture flasks/dishes and disposable plastics
Biotech-IgG, Winslow, UK Dopamine research EIA (ELISA kit)
Invitrogen, Paisley, UK LIVE/DEAD viability assay
RPMI medium
D-MEM/F12
0.05% Trypsin/EDTA
Donor Horse serum (Heat inactivated)
10,000U/ml Penicillin & 10,000pg/ml Streptomycin in 
85% saline
alamarBlue™
Sigma Chemicals, Dorset, 0.4% Trypan blue
UK MTT assay
Flouresceinamine (C20H 13NO3, mixed isomers)
Poly-L-omithine hydobromide (MW 5-15 kDa)
Poly-l-lysine hydrobromide (MW 4-15 kDa)
FITC-labelled Poly-l-lysine (MW 30-70 kDa (high 
MW) or 15-30 kDa (low MW))
Procion Blue 4
Rhodamine B
All other chemicals
AbCellute, Cardiff, UK Hepatocytes
Lonza, Cambridge, UK Phosphate Buffered Saline
Partec, Kent, UK CellTrics® (30 and 150pm)
BD Biosciences, Oxford, Cell Strainers (100 pm)
UK
Medicell, London, UK Dialysis membranes (12-14 kDa)
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2.1.4 Solutions
2,1,4,1 Artificial cerebrospinal fluid (CSF)
Solution A Compound g/L
NaCl 17.32
KC1 0.448
CaCl2 • 2H20 0.412
 MgCl2 • 6H20_________________ 0.326
Solution B Compound g/L
Na2HP04 • 7H20 0.214
NaH2PQ4 •H20________________ 0.027
Solutions were autoclaved separately and then combined in 1:1 ratio. 
Electrolyte concentrations of the resultant solution are shown in Table 2.1.
Ion/Compound Cerebrospinal fluid (mM)* Artificial CSF (mM)
Na 154 150
K 3.0 3.0
Ca 1.4 1.4
Mg 0.9 0.8
P 0.4 1.0
Cl 136 155
h c o 3 24.1 N/A
* Concentrations are an average of values for human, dog, cat and rabbit taken from an average of 
data listed in Davson (1967) and Altman and Dittmer (1974)
Table 2.1: Comparison of real and artificial CSF electrolyte concentrations
2.1.4.2 TRIS-buffered saline
Compound g/L
Trizma base 48
NaCl 36
pH was adjusted to 7.4 using hydrochloric acid.
2.1.4.3 Cresyl violet
Compound
Cresyl violet 5g in 600ml distilled water
1M sodium acetate 600ml
Glacial acetic acid 340ml
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2.2 B ea d -b a sed  m e t h o d s
2.2.1 Microfluidic experiments
The microfluidic device used in all experiments (MicroPlant™) consists of a
316 stainless steel manifold into which HPLC fluid connectors (Anachem, 
Bedfordshire, UK) are introduced equatorially. Vertical through holes were sealed 
with nitrile rubber O-rings (Sealmasters, Cardiff, UK), allowing fluid to flow to the 
top surface of a virgin PTFE disc (50mm diameter x 3mm thickness) located on the 
manifold. A circular PFA gasket (250pm thickness; Polyflon, Staffordshire, UK) was 
placed in between the PTFE chip (Polyflon, Staffordshire, UK) and a borosilicate 
glass disc cover (50mm diameter x 5mm thickness; H Baumbach, Suffolk, UK). A 
316 stainless steel clamping piece was bolted to the fluidic manifold, allowing the 
entire laminated assembly to be compression sealed. Fluids were introduced into the 
microfluidic circuit via sterile 1/16th inch inner diameter Teflon-FEP tubing 
(Anachem, Bedfordshire, UK) using syringe drivers (KD Scientific - Linton 
Instrumentation, Norfolk, UK).
The development of a microfluidic method for production of alginate beads is 
described and discussed in detail in Chapter 3. As the main aim of this thesis was the 
development of the microfluidic process it was felt that this was a more appropriate 
location than this chapter. Specific details for encapsulation of cells using the chosen 
microfluidic method can be found in Section 3.3.3.
In all cell encapsulation experiments, the stainless steel manifold, glass, 
gasket, fittings and PTFE chip were autoclaved and then air dried in an oven at 50°C. 
Syringe drivers were cleaned with bactericidal wipes before being placed in a Class II 
hood to maintain sterility. All cell encapsulation experiments were carried out in a 
Class II hood.
2.2.2 Manufacturing microfluidic chips
Microchannels were machined into virgin PTFE discs using a Computer
Numerical Controlled milling machine (Roland, Swansea, UK). An example of a 
milled chip is shown in Figure 2.2A. Microfluidic circuit diagrams (an example is 
shown in Figure 2.2B) used to mill each chip are presented in Appendix 1 along with 
details of channel geometry.
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Figure 2.2: A PTFE chip with a milled microfluidic circuit. A) Photograph of an example 
microfluidic chip. Scale bar represents 1 cm. B) Circuit diagram of the microfluidic chip shown in A
2.2.3 Measuring bead diameter
Beads were measured from a representative sample of each bead type. Beads
from all experiments were not measured so there is no indication of batch to batch 
variability. A small volume of beads were placed on a microscope slide with 
sufficient buffer to form a single layer. Photographs of beads were taken using a light 
microscope equipped with a camera (Motic, Microscopes Plus Limited, London, UK). 
Sphere diameters were measured using calibrated Motic software tools. The 
coefficient of variation (CV) was calculated as shown in Equation 2.1.
_ standard deviation , _ _
CV = -----------------   xlOO Equation 2.1
mean diameter
2.2.4 Viscosity measurement
Viscosity was measured using a vibrational viscometer (SV-10, Patterson
Scientific, Cambridge, UK). The device has two gold plated paddle-shaped sensors 
which were immersed into the sample to be measured (3 5-45ml depending upon 
viscosity). The paddles vibrate at a constant frequency when stimulated by an 
electromagnetic drive. Constant amplitude is maintained by the electromagnetic drive 
in response to the amplitude of vibration. The vibration is dampened by the viscosity 
of the sample. The current required to maintain the vibration amplitude is monitored 
and converted to viscosity at a given temperature.
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2.2.5 Atomic absorption spectroscopy
Bead samples (n=450) were transferred to 100ml Kjedahl digestion tubes. In a
fume cupboard, concentrated AnalaR-grade HNO3 (3.5ml) was added to the beads. A 
glass marble was placed on the top of each tube, to prevent evaporation. Tubes were 
then placed into a digestion block. The temperature was gradually increased to 140°C 
and the samples left for 2-2.5 hours until all the liquid had evaporated. The tubes were 
removed from the block and allowed to cool. KC1 (3ml) was added to each tube at a 
final concentration of 2000pg/cm . Standard solutions of barium and calcium as well 
as samples and control samples were analysed using a Varian AA100 atomic 
absoiption spectrophotometer by Mr M. O’Reilly (Cardiff University, UK).
2.2.6 Secondary coating of alginate beads with polycations
Calcium cross-linked alginate beads were produced using the microfluidic
internal gelation method (Section 3.3.3). Poly-L-lysine (PLL) and poly-L-omithine 
(PLO) solutions (0.05% w/v) were prepared in PBS; alginate solutions (0.15% w/v) 
were prepared with D-MEM/F12 medium. PLL or PLO solution (twice bead volume) 
was added to beads for 10 minutes with agitation. Beads were added to 100pm filters; 
Phosphate Buffered Saline (PBS, 10ml) was added four times to wash off excess 
coating solution. A secondary coat of alginate was added by placing beads into 
alginate solution (twice bead volume) for 5 minutes. Washes were again carried out 
four times by washing PBS (10ml) over beads placed on 100pm filters.
2.2.7 Determination of pH of carrier phase
Carrier phase (2ml sunflower oil, Section 2.1.2) was mixed with an equal
volume of HBSS (Hank’s Buffered Saline Solution). An approximate pH of the 
medium was gained using narrow-range pH paper (pH 3-7).
2.2.8 Fluorescently labelled alginate
Alginate was labelled with the fluorochrome fluoresceinamine using a method
adapted from Strand et al. (2003). Briefly, sodium alginate was dissolved in PBS (pH
7.2 -  7.4) to give ~90mM carboxylic groups. 1-Ethyl-3-(3-imethylaminopropyl) 
carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide sodium salt 
(Sulfo-NHS) were then added to give 9mM of each. The solution was stirred for 2 
hours at room temperature. Fluoresceinamine was added to give a final concentration 
of 0.6mM and the solution was stirred, protected from light, at room temperature for 
18 hours. To remove fluoresceinamine which had not reacted, the solution was
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transferred to dialysis membranes (MWCO 12,000-14,000) and dialyzed against ion- 
free water overnight at 4°C (1 shift). The solution was then dialyzed against 1M NaCl 
for 24 hours (3 shifts) and finally against ion-free water until the water was no longer 
yellow (~5 shifts). The solution was adjusted to pH 7.4 before being freeze-dried. 
Fluorescence labelled alginate was kept at 4°C, protected from light until use.
2.2.9 Confocal microscopy
A Leica DM6000B upright confocal microscope was used for all confocal
microscopy experiments.
2.2.9.1 Analysis o f fluorescent beads with confocal microscopy
An argon 488nm laser was used for excitation of the fluorescein-labelled 
alginate and FITC-labelled PLL, and emission light between 505 and 530nm was 
detected. Beads were scanned through the equator. The images were taken at constant 
laser power, and were optimised to the dynamic range of the detectors used.
2.2.10 Production of alginate beads with air-assisted droplet break-up
A method for the production of alginate beads cross-linked using external
gelation was adapted from Fiszman et al. (2002). Briefly, a 21 gauge needle was 
adapted by making the end blunt and removing the plastic hub. A T-shaped fluid 
connector was used to hold the adapted 21 gauge needle in place. A liquid alginate 
solution (2% w/v) was pumped through the needle using a syringe driver (20ml/h). 
Air was forced through the remaining arm of the T-shaped fluid connector and past 
the needle (Figure 2.3). The airflow was empirically determined as it could not be 
measured with the equipment used. A beaker containing CaCh (50mM) collecting 
solution was placed 6cm below the tip of the needle.
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Figure 2.3: Schematic of homemade device for producing alginate beads via air-assisted droplet 
break-up. A cross-section through the homemade device, showing the needle position. Alginate 
solution (2% w/v) was pumped through the needle and air was forced to flow around it
2.3 In  v i tr o  m e t h o d s
2.3.1 Cell culture methods
2.3.1.1 Maintenance o f cell lines in culture
Routine cell culture work was carried out under laminar flow in a Class II 
hood (MDH, Andover, Hampshire, UK). Cells were maintained at 37°C in a hydrated 
atmosphere of 5% CO2 and air in appropriate medium. Human Embryonic Kidney 
(HEK293) cells (American Type Culture Collection, CRL-1573) were maintained in 
Dulbecco’s modified Eagle medium: Nutrient Mixture F12 (D-MEM/F12) 
supplemented with 10% foetal bovine serum (FBS). PC 12 (ATCC, CRL-1721, a gift 
from Dr Jack Ham at the Centre for Endocrine and Diabetes Sciences, Cardiff 
University, UK) were grown in D-MEM/F12 supplemented with 5% foetal calf serum 
and 10% heat-inactivated horse serum. Serum was supplied heat inactivated (to 
inactivate complement) and was of foetal origin so that levels of antibodies (which 
may bind to human cells) would be low. Penicillin (10,000 units per ml) and 
streptomycin (10,000 pg per ml) were also added to all medium. All medium was 
stored at 4°C until use, when it was warmed to 37°C to prevent temperature shock of 
cells.
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2.3.1.2 Sub-culturing o f cells
The cell line HEK293 was routinely passaged weekly when growth had 
achieved confluence using 0.02% trypsin/0.05% EDTA in PBS. Culture medium was 
removed and cells rinsed with pre-warmed (37°C) trypsin/EDTA (0.5ml). This was 
removed and further enzyme (1ml) added to the flask. Cells were incubated for 2-3 
minutes at 37°C to allow detachment of cells into a single-cell suspension. After 
incubation, enzymatic action was terminated through the addition of serum-containing 
medium (3ml). Gentle pipetting was used to disperse any clumps of cells and cells 
were then divided at a ratio of approximately 1:8 into new T-75 flasks before media 
was replenished (final volume 25ml).
The PC 12 cell line was routinely passaged when growth had achieved 
confluence by scraping cells from the flask surface with a cell scraper. Approximately 
1/3 to 1/2 of the cell suspension was removed and discarded. New medium was added 
to a final volume of 25ml.
2.3.L3 Freezing and thawing ceUs
To preserve stocks of cells, samples were harvested (see Section 2.3.1.2), 
pelleted by centrifugation at 100 x g, washed and resuspended in foetal bovine serum 
with 10% sterile DMSO at a concentration of 106 cells/ml (calculated as described in 
Section 2.3.1.4). The DMSO added interacts with plasma membranes and reduces 
cell lysis upon freezing. Cell suspensions (1ml) were pipetted into a cryovial (Fisher, 
Leicestershire, UK) and then frozen to -70°C in a container filled with isopropanol, 
which is specially designed to cool at a rate of less than 1°C per minute (Fisher, 
Leicestershire, UK). Once frozen (overnight) cell vials were placed into liquid 
nitrogen and stored until required.
Recovery of cells was achieved by removing a vial of cells stored in liquid 
nitrogen, which were then warmed rapidly by placing in a 37°C water bath. Cells 
were then diluted into culture medium prewarmed to 37°C, doubling the volume 
every 4 minutes until the volume was increased to 20ml. Cells were pelleted by 
centrifugation at 100 x g, resuspended into medium (2ml), placed into a 25cm2 flask 
and cultured for at least 24 hours at 37°C in a hydrated atmosphere of 5% CO2 and 
air.
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2.3.1.4 Counting o f total cell numbers and number o f viable cells
After enzyme disaggregation, cell suspensions were counted using a 
haemocytometer. Haemocytometer counting allowed not only the counting of cells in 
suspension under phase contrast microscopy, but the percentage of viable (intact) cells 
to be determined using the dye exclusion method (described below).
A haemocytometer is a modified microscope slide comprising two polished 
surfaces, each of which displays a precisely ruled, sub-divided grid (Figure 2.4). The 
grid consists of nine primary squares, each measuring 1mm on each side (area 1mm2) 
and limited by three closely spaced lines (2.5pm apart). Each of the primary squares 
is further divided into secondary squares, each measuring 0.2mm on each side (area 
0.04mm2). The plane of the grid rests 0.1mm below two ridges that support a sturdy 
coverslip. There are bevelled edges at both sides of each polished surface where cell 
suspension is added which is subsequently drawn across the grid by capillary action.
Primary s q u a r e  
= 1 m m 2
s q u a r e
Figure 2.4: Grid patterns of Neubauer ruled haemocytometer. The figure shows the size of primary 
and secondary squares, with the inset showing an enlargement of the secondary squares. The number 
of cells in 5 secondary squares is counted
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To carry out a total cell count, cells were trypsinsed as described in Section 
2.3.1.2. Cells were pelleted by centrifugation at 100 x g for 5 minutes at room 
temperature and resuspended in an appropriate volume of medium ensuring a 
unicellular suspension. The haemocytometer and cover slip were then cleaned using 
70% ethanol and the coverslip placed squarely on top of the haemocytometer, lightly 
moistening the polished surface of the slide before pressing the coverslip into 
position. Cells were gently redistributed throughout the medium as before and a small 
sample of cells taken up into the pipette. The haemocytometer was loaded so that the 
fluid entirely covered the polished surface of each chamber. Care was taken not to 
overload the counting chambers. Any accidental overloading was rectified by 
carefully removing any excess fluid from the groove using filter paper. Using the 20X 
objective of the microscope, the upper left primary square of each grid was located. 
The number of cells in 5 secondary squares were counted using the following 
conventions:
a) The middle of the triple lines separating each primary square is the 
boundary. Cells that touched the upper or left boundaries were included, 
those that touched the bottom or right boundaries were excluded.
b) If greater than 10% of particles were cell clusters, the original cell 
suspension was dispersed further and the process was started again. 
Alternatively, clusters containing more than five cells were assigned a 
value of five.
c) If there were too many cells present to realistically count, a dilution was 
carried out using a buffer or dye (if a viable count was being performed). 
Any diluent was isotonic.
d) For accuracy and reproducibility, counts were carried out in the same 
manner each time.
e) The volume of cell suspension occupying one primary square in a 
correctly loaded haemocytometer is 0 .1mm3 (1mm2 x 0 .1mm) or 1 x 10* 
4ml.
f) In practice, cell counts of 5 secondary squares give the number of cells 
within 0.02mm3 (5 x 0.004 mm3) or 2 x 10*5ml. Total cell concentration in 
the original suspension (in cells/ml) is then:
Cells/ml = total count x 50,000 x dilution factor
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To determine the approximate number of viable cells by dye exclusion, an 
aliquot of cells was mixed with a volume of buffer or balanced saline containing a 
water-soluble (membrane lipid-insoluble) dye (e.g. trypan blue) which is visible when 
it leaks into cells that have damaged plasma membranes.
An aliquot (5pi) of cell suspension was mixed with trypan blue solution (5pi). 
The haemocytometer was prepared and loaded as previously described in this section. 
Unstained (viable) cells and stained (non-viable) cells were counted using the 
conventions listed above and the following equation:
„ . . .  .. number of unstained cells countedPercentage viable cells = ------------------------------------------- x 100 Equation 2.2
total cell count
2.3.2 Reactivating hepatocytes
Hepatocytes and all solutions were supplied in 100mm Petri dishes by
AbCellute (Cardiff, UK). Reactivation medium (3ml) was added to each Petri dish, 
which was then incubated for 20 minutes in a humidified 37°C incubator without CO2. 
When cells were freely in suspension, they were transferred into sterile 50ml 
centrifuge tubes. Wash medium (2ml) was added to each Petri dish, which was then 
manually rocked from side to side to release any residual cells. This wash solution 
was added to cells in the centrifuge tubes. The suspension was centrifuged at 100 x g 
for 4 minutes. The supernatant was removed without touching the cell pellets. Cells 
were washed using wash medium and resuspended by gentle pipetting through a 5ml 
pipette tip. The cells were re-pelleted and resuspended in hepatocyte medium ready 
for use.
2.3.3 Cytotoxicity testing
Cells were harvested, washed and counted as described in Sections 2.3.1.2 and
2.3.1.4. Cells were pipetted into an appropriate number of tubes and pelleted by 
centrifugation at 100 x g. Medium was removed and replaced with the substance to be 
tested, into which cells were gently resuspended. At timed intervals as stated in the 
relevant sections, aliquots (2 0 pl) were removed from tubes and mixed with trypan 
blue (20|il), then counted as described in Section 2.3.1.4. If oil was the substance 
being tested, trypan blue (2 0pl), medium (2 0 pl) and oil plus cells (2 0 pl) were added 
to a separate eppendorf and mixed. The cells moved into the aqueous phase, which 
was then added to the haemocytometer and counted.
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2.3.4 Viability methods
2.3.4.1 Use o f MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide) 
fo r viability testing
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide) assay was 
purchased from Sigma and used according to the manufacturers’ instructions. Briefly, 
each vial of MTT (15mg) was resuspended in culture medium (3ml). Reconstituted 
MTT (10% of culture volume) was added to cells or beads and incubated for 2 hours 
at 37°C, 5% CO2. Formazan crystals were dissolved by adding MTT Solubilization 
Solution (at a 1:1 ratio with original culture volume). Absorbance was subsequently 
measured at a wavelength of 570 nm. Absorbance was used to compare rates of cell 
growth.
2.3.4.2 Use o f lactate dehydrogenase (LDH) fo r viability testing
A lactate dehydrogenase (LDH) based in vitro toxicology assay kit (Sigma) 
was used to estimate LDH released by dead cells. Briefly, cells were harvested, 
washed and counted as described in Sections 2.3.1.2. and 2.3.1.4. A standard curve of 
cells was prepared by 2-fold dilution between 1 x 106 cells/ml and 7.81 x 104 cells/ml 
in 100pi of medium in a 96-well plate. LDH Assay Lysis Solution (lOpl) was added 
to each well in the prepared standard curve and the plate returned to the incubator for 
45 minutes. Cells were pelleted by centrifugation at 100 x g for 4 minutes. Medium 
(50pl) was removed from each well containing the standard curve and transferred to a 
fresh 96-well plate. An equal amount of LDH assay substrate, cofactor and dye 
solutions were mixed together and added to each well of the plate (final volume of 
150pl). The plate was left at room temperature, protected from the light for 30 
minutes. Absorbance was measured at a wavelength of 490nm, with background at 
690nm subtracted.
2.3.4.3 Use o f alamarBlue™for viability testing
The assay was purchased from Invitrogen and carried out according to 
manufacturers’ instructions. Briefly, varying numbers of beads were counted into 
separate wells of a 96-well plate in lOOpl of medium. Each well received lOpl of 
alamarBlue™. The plate containing beads and alamarBlue™ was incubated for 24 
hours at 37°C, 5% CO2. Samples were taken from the plate at 0, 2, 4, 6 , 8 , 16 and 24 
hours, added to a separate plate from which spectrophotometric readings (at 540nm
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and reference at 620nm) were taken. A correction factor (Ro) was calculated, as 
shown in Equation 2.3, as the filters used were slightly different to those suggested 
(570nm and reference at 600nm). However, as this is a common issue, the 
manufacturers recommend a correction factor to calculate the percentage of reduced 
alamarBlue™ present (Equation 2.4).
Ro = AO540 / AC>620 Equation 2.3
AR540 = A540 — (A$20 X Ro) X 100 Equation 2.4
Where Ro = correction factor, AO540 = absorbance of oxidised alamarBlue™ at 540nm, AO620 = 
absorbance of oxidised alamarBlue™ at 620nm, AR540 = percentage of reduced alamarBlue™, A540 = 
absorbance at 540 nm, and A^o= absorbance at 620nm.
2.3.4.4 LIVE/DEAD® viability/cytotoxicity kit
Cells were detached from culture flasks using trypsin, washed and counted as 
described in Sections 2.3.1.2. and 2.3.1.4. Cells were passed through a 30pm 
CellTrics strainer to remove any clumps of cells or large debris and resuspended at a 
cell count of between 0.1 to 5 x 106 cells/ml in D-MEM/F12 (1ml). Beads were 
removed from medium by passing through a 30pm CellTrics strainer. As serum 
contains esterases, which can interfere with this analytical method; any remaining 
serum was removed by washing, and replaced with medium. Calcein AM stock 
solution (supplied at 4mM in DMSO by Invitrogen) was diluted to 50pM in DMSO. 
Diluted calcein AM (2pl, final concentration 2pM) and ethidium homodimer-1 stock 
solution (4pl, supplied at 2mM in DMSO by Invitrogen, final concentration 4pM) 
were added to cells (1ml) or bead samples and mixed by gentle inversion. Cells or 
bead samples were incubated for 20 minutes at room temperature, then analysed. 
Calcein fluoresces green (479nm excitation and 517nm emission) and ethidium 
homodimer-1 fluoresces bright red (528nm excitation and 617nm emission, Figure 
2.5).
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530/30 610/20
Figure 2.5: Absorption and fluorescence emission spectra of dyes used in LIVE/DEAD® staining.
Green lines show absorption and fluorescence emission spectra of calcein in pH 9.0 buffer and dark 
blue lines show absorption and fluorescence emission spectra of ethidium homodimer-1 bound to 
DNA. The light blue line marked 488 represents the excitation wavelength of the laser (488nm). Green 
shading represents the 530nm bandpass filter used to collect fluorescence from calcein and the light 
orange shading represents the 610/20nm longpass filter used to collect fluorescence from ethidium 
homodimer-1
2.3.4.5 Flow cytometry to detect and quantify cell numbers
Cell samples were analysed using a FACSCanto flow cytometer (Beckton 
Dickinson, Oxford, UK); where they were focussed into a fluid stream one cell wide. 
Cells then passed through a laser one at a time. Voltage fluctuations caused by cells 
passing through the laser beam were converted to digital form and analysed 
automatically via computer to generate dot-plot displays indicating the fluorescent 
characteristics of the cell sample being analysed. Output data from the flow 
cytometer was analysed using Win MDI software which presents data as dot plots and 
histograms and permits calculation of the mean fluorescent intensity of the cells.
To analyse the stained cells, 30,000 events were captured for each sample 
using a FACSCanto flow cytometer. Constant machine settings were maintained 
during each experiment. An argon 488nm laser was used for excitation. Green 
fluorescence emission for calcein (530/30nm bandpass filter) and red fluorescence 
emission for ethidium homodimer-1 (610/20nm longpass filter) was measured. The 
data was transferred to a computer with the Win MDI software.
2.3.4.6 Analysis o f LIVE/DEAD stained cells with confocal microscopy
An argon 488nm laser was used for excitation of calcein and emission light 
between 505 and 530nm was detected. A HeNe 543nm laser was used for excitation 
of Ethidium homodimer-1 and emission light over 650nm detected. Due to limited 
passage of fluorescent light through the alginate beads, optical sections were taken
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through the upper half of the bead. Three-dimensional images were constructed using 
Leica Confocal Software (Leica Microsystems, version 2.61).
2.3.5 ELISA to detect dopamine
Dopamine release was quantified using an ELISA kit developed by LDN
(Nordhom, Germany, purchased from Biotech-IgG, Winslow, UK). To extract 
dopamine from samples, a cis-diol specific affinity gel present within wells of a 
microtitre plate was used. All buffers and solutions were proprietary and provided 
with the kit. Sample (lOOpl), standards (lOpl) and controls (lOpl) were added to wells 
containing cis-diol specific affinity gel. All wells were made up to a final volume of 
lOOpl with distilled water. Assay (25pi) and extraction buffers (25 pi) were added to 
the wells. The microtitre plate was covered and incubated whilst shaking (600rpm) for 
30 minutes at room temperature. The wells were washed twice with wash buffer 
(300pl). Acylation of dopamine to N-acyldopamine was carried out by adding 
acylation buffer (150pl) and reagent (lOpl) to the wells. The acylation reaction was 
allowed to proceed for 15 minutes with shaking (600rpm) at room temperature. The 
wells were washed twice with wash buffer (300pl). Dopamine was eluted from the 
wells using hydrochloric acid (0.025M, 50pl). Eluate (40pl) was removed from the 
wells after 10 minutes incubation at room temperature with shaking (600rpm) and 
used in the dopamine enzyme immunoassay.
Dopamine was bound to the solid phase of the provided microtitre plate. 
Enzyme solution (containing the enzyme catechol-O-methyltransferase and coenzyme 
S-adenosyl-methionine, 25 pi) and extracted samples, controls and standards (40pl 
each) were added to the microtitre plate. During a 30 minute incubation, with shaking 
(600rpm), at room temperature the N-acyldopamine was converted to N-acyl-3- 
methoxytyramine. Acylated dopamine from the sample and solid phase bound 
dopamine competed for a fixed number of antiserum binding sites introduced by 
adding dopamine antiserum (50pl) and antiserum buffer (50pl). After incubating the 
microtitre plate for 2 hours at room temperature with shaking (600rpm), any free 
antigen and free antigen-antiserum complexes were removed by washing three times 
with wash buffer (300pl). The antibody bound to the solid phase dopamine was 
detected using an anti-rabbit IgG-peroxidase conjugate (lOOpl) using TMB 
(tetramethyl benzidine, lOOpl) as a substrate. After 1 hour incubation at room 
temperature with shaking (600rpm), stop solution (lOOpl) was added. Absorbance of
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the solutions in the wells was read using a microplate reader set to 450nm with a 
reference wavelength of 630nm. The amount of antibody bound to the solid phase 
dopamine was inversely proportional to the amount of dopamine present in the 
sample. The amount of dopamine was calibrated from a standard curve based on 
standards provided in the kit.
2.4 I n  v iv o  m e th o d s
2.4.1 Animal care
All animal experiments were performed in full compliance with local ethical 
guidelines and approved animal care according to the UK animals (Scientific 
Precodures) Act 1986 and its subsequent amendments. Adult, female Sprague-Dawley 
rats, typically weighing 200-250g at the start of experiments, were used. They were 
housed in cages of 4, in a natural light-dark cycle, with access to food and water ad 
libitum.
All surgery was performed under isoflurane anaesthesia. Anaesthesia was 
induced in an induction box with isoflurane and oxygen, and maintained by passive 
inhalation of isoflurane and a mixture of oxygen and nitrous oxide. Animals were 
allowed to recover in a warmed recovery chamber and received analgesia through 
paracetamol dissolved in drinking water (2mg/ml) for 3 days subsequent to surgery.
2.4.2 Bead injections into rat brain
Unilateral striatal injections of empty alginate beads without cells were carried
out by Dr E. Torres using a standard protocol (Torres et al., 2005). Briefly, beads 
were suspended in 0.9% sterile saline and injected into striatum using a 30-gauge 
cannula connected to a 10 pi Hamilton syringe in a micropump driver set to deliver 
lpl/minute. The stereotaxic coordinates for injection were: A=+0.6 from bregma, 
L=±3.0 from midline, V=-4.5 below dura. Beads were suspended in 3pi of saline and 
so injections therefore took three minutes. The micropump driver was stopped after 
three minutes, a further three minutes passed to allow diffusion of saline, before the 
cannula was slowly withdrawn from the brain. Control injections of 3pi artificial 
cerebrospinal fluid (Section 2.1.4.1) were carried out over three minutes, with a 
further three minutes to allow diffusion. Cleaning, closure and suturing of the wound 
was then carried out.
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2.4.3 Histopathology
Animals were terminally anaesthetised using a standard protocol (Torres et a l,
2005). Briefly, sodium pentobarbitone (200mg/kg) was injected intraperitoneally, 
followed by transcardial perfusion with PBS at pH 7.4 (100ml) and then 4% 
paraformaldehyde in PBS (250ml) over a 5 minute period. After brains were removed, 
they were post-fixed by immersion in the same fixative solution for 4 hours, and then 
transferred to 25% sucrose in PBS for equilibration. Coronal sections of 40pm 
thickness were cut on a freezing stage sledge microtome into 0.1M TRIS-buffered 
saline pH 7.4 (TBS, Section 2.1.4.2) and stored at +4°C prior to staining. 
Alternatively, coronal sections were cut on a cryostat and collected onto microscope 
slides coated with 1% gelatin.
The nissl stain, cresyl fast violet (Section 2.1.4.3) was used to stain neuronal 
cells using a standard protocol (Torres et a l, 2006) as follows. Sections were mounted 
onto gelatine coated microscope slides and dried at room temperature overnight. 
Dehydration was carried out in an ascending series of alcohol solutions (70%, 95% 
and 100% ethanol), and slides were immersed in 50/50 (v/v) chloroform/ethanol mix 
for 30 minutes. Slides were immersed (with agitation) in 95%, 70% ethanol and then 
distilled water for 5 minutes each to re-equilibrate. Slides were immersed in cresyl 
fast violet solution (5% in 0.1 M sodium acetate buffer, pH 3.5) for 5 minutes. Again 
slides were dehydrated in ascending alcohol solutions (see above), cleared in xylene, 
and a coverslip applied using DPX mounting medium (Thermo Scientific, 
Leicestershire, UK).
2.4.4 Magnetic Resonance Imaging (MRI)
Rats were imaged using a Bruker Biospec Avance 9.4T (400 mHz) MRI system, 
equipped with an SI 16 gradient set (EMRIC, Cardiff University). Each rat was 
operated upon (Section 2.4.2) and whilst still anaesthetised, positioned inside a 72- 
mm ID linear polarised birdcage volume coil coupled with a quaderature combined rat 
head surface coil. Anaesthesia was maintained with ~2% isoflurane and body 
temperature and breathing were monitored. Gradient-echo pilot scans were performed 
at the beginning of each imaging session for accurate positioning of the animal inside 
the magnet bore. For each animal a series of FLASH images (flip angle a =30°, 15 
slices, 0.5-mm thickness) were acquired in axial orientation. T2*-weighted data sets 
were acquired using gradient-echo sequence with the following acquisition
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parameters: repetition time=300 ms, echo time=8.5 ms, field of view= 1.92x1.92 cm2 
and image matrix=192xl92.
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Chapter 3. Development of a microfluidic system to generate 
ionically cross-linked alginate beads
3.1 In t r o d u c t io n
Although several methods for the production of alginate beads containing cells
already exist, there was no precedent for the use of microfluidics-based devices in 
continuous alginate bead production at the initiation of this project. Continuous 
microfluidic synthesis of alginate microbeads can be described as emulsification 
followed by on-chip cross-linking of alginate. Of these processes, the latter step is the 
most problematic to achieve in a microfluidic system. Polymer cross-linking on-chip 
is challenging as it must be prevented from occurring at the fluidic junction. 
Premature ionic cross-linking at the junction results in uncontrolled gel formation 
within the channel, which prevents further emulsion formation (i.e. a blockage). 
Therefore, although microfabricated devices had previously been employed to 
generate droplets of various liquids, some of which contained cells (He et al., 2005; 
Sakai et al., 2005; Sugiura et al., 2005), in situ cross-linking of alginate droplets was 
not reported prior to 2005. Continuous microfluidic synthesis is desirable as the need 
for further processing steps after bead collection can be eliminated.
In this study, continuous microfluidic synthesis was achieved through custom 
design of microfabricated circuits consisting of milled microchannels to form 
microemulsions of aqueous alginate solutions via segmented flow. Subsequently, 
various approaches to promote polymer cross-linking were investigated, and both 
internal and external gelation approaches were tested. Product beads were examined 
to ensure stable, spherical morphology; size and dispersity were measured. The target 
size of product beads produced by this prototype system was <500pm in diameter.
3.2 E m u l sio n  f o r m a t io n  in  m ic r o fl u id ic  d e v ic e s
Microfabricated devices consist of microchannels arranged in specific, user-
defined geometries to exploit specific microfluidic phenomena. Such arrangements 
are termed fluidic circuits. Originally, fluidic circuits were manufactured from silicon, 
although soft lithography of polydimethylsiloxane (PDMS) is now the most 
commonly used microfabrication method as it is easier, cheaper, quicker, requires less
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specialised knowledge and reduces the number of steps used in the manufacturing 
process. Typically devices are permanently sealed, with external connections through 
which fluids are introduced.
For this study a novel microfluidics-based device, termed a MicroPlant™ 
(described in Section 2.2.1), was used. The system, developed by Q Chip (Cardiff, 
UK), was designed to enable rapid evaluation of fluidic circuits. In comparison with 
traditionally fabricated microfabricated devices, MicroPlants™ are not permanently 
sealed and so can be assembled and disassembled rapidly. In addition, instead of the 
laborious processes used to produce circuits in PDMS (taking a minimum of 8 hours 
(Zhao et a l , 2003)), a single milling operation is employed, making the production of 
a circuit much quicker and easier. The use of a MicroPlant™ thus allowed ideas to be 
rapidly converted into testable circuits. Design iterations were also quick and easy to 
investigate.
Microfluidic circuits are machined into blank polytetrafluoroethylene (PTFE) 
chips, and as such are hydrophobic and rigid. The microfluidic circuits consist of 
microchannels, which are rectangular in cross-section. A Computer Numerical 
Controlled (CNC) milling machine is used to create the microchannels in the PTFE 
surface (Section 2.2.2). Microchannels, by definition, must be less than 1mm and can 
be made any size, to a minimum of 100pm, which represents the limit of the 
micromilling method.
The completed, milled PTFE chip is located onto a 316 stainless steel fluid 
distribution manifold, into which high performance liquid chromatography fluid 
connectors are introduced equatorially. Fluids can then be loaded into disposable 
syringes which are connected via narrow bore tubing to the device. Before fluids can 
flow through the channels a transparent borosilicate disc is placed over the chip, thus 
allowing observation of fluid flows in microchannels. As borosilicate is hydrophilic, a 
hydrophobic gasket (PFA film, 250pm thick) is inserted between it and the chip. 
Finally, a stainless steel clamping piece is bolted to the fluidic manifold, allowing the 
entire laminated assembly to be compression sealed. The device is illustrated 
schematically and pictorially in Figure 3.1.
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S ta in le s s  s te e l  
d e v ic e  a llow ing  
c o m p r e s s io n  
se a lin g
B
Figure 3.1: The microfluidic evaluation platform (MicroPlant™) used in all microfluidic 
experiments. A) Expanded schematic showing the components of the microfluidic evaluation rig. B) 
Photograph showing evaluation device sealed, with a microfluidic chip inserted and fluid connectors
Fluids enter the fluid distribution manifold and flow via vertical through holes 
(sealed with nitrile rubber O-rings) to the top of a chip located on it. Fluids are
C a p -h ea d  sc r e w s  
Spring w a s h e r s
Nitrile O-ring  
B orosilica te  d is c  
PFA  g a s k e t  
PT F E  chip
Fluid distribution m anifold
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pumped using syringe drivers, however any pulseless, pressure driven device may be 
substituted. Pressure in channels of square cross-section is described by the following 
equation:
32 LMv sPressure = Equation 3.1
w
Where L = length of channel, 
fi = viscosity, 
w  = width of channel, 
vs = average velocity of the flow.
Therefore, pressures exerted are dependant upon the flow rate and viscosity of 
fluids and size of channels. In a 1000 x 1000 micron channel, fluid flow rates of up to 
60ml/h for aqueous flows and 30ml/h for oil are at the limits of the MicroPlant™.
To form droplets in a microfluidic circuit, the inherent physical properties of 
immiscible liquids are exploited, namely that they may be emulsified. In a 
microfluidic circuit, a linear micro-emulsion can be formed when immiscible fluids 
flow together into a microfluidic junction. The simplest of these is the T-junction, 
illustrated in Figure 3.2A. Fluid flowing in one channel is sheared by a second 
immiscible phase, flowing in the cross-channel (Thorsen et a l , 2001). Co-flowing 
streams can also be used to generate emulsions, these can take the form of cross­
junctions (Figure 3.2B, Tan et al., 2008) or flow focusing devices (Figure 3.2C, Anna 
et al., 2003).
Fluid (3
Fluid a
B Fluid p
Fluid p
r
f Fluid p ------►
Fluid •  •  •  Fluid a --------►
• i Fluid p ------►
•
Figure 3.2: Schematic representations of microfluidic junctions. A) Emulsion formation in a T- 
junction, B) cross-junction, or C) flow focussing device. Orientation of flow is specified by arrows
In conventional emulsion formation, the fluid which forms droplets is termed 
the dispersed phase, and the immiscible fluid is termed the continuous phase. This is
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also true in microfluidic circuits, however the fluid which forms droplets (Fluid a  in 
Figure 3.2) is also called the functional fluid, and the immiscible fluid (Fluid p in 
Figure 3.2) is also called the carrier fluid.
Channel properties, such as contact angle, surface energy and hydrophobicity, 
influence which liquid forms droplets. Aqueous alginate solutions are repelled from 
the hydrophobic PTFE chip surface used in the MicroPlant™. A fluid which is 
immiscible with an aqueous alginate solution is required to form a linear emulsion. 
The nature of a linear emulsion is dependant on the surface tensions (and interfacial 
tension) of the component fluids, as well as the energies of the microchannel surfaces. 
The particular characteristics of a linear emulsion, e.g. droplet size, size variance, and 
droplet production frequency are strongly dependant upon fluid flow rate and 
microchannel architecture. As the interfacial surface tension is constant for a given 
pair of fluids at a given temperature, variations in relative flow rates are used to 
produce different flow patterns.
At slow fluid flow rates, plug formation occurs, rather than spherical droplet 
formation (Figure 3.3B). A plug is defined as a droplet large enough to fill the cross- 
section of a channel, with its length in the direction of fluid flow greater than its width 
(Christopher and Anna, 2007). Plugs are surrounded by a thin layer of continuous 
phase and so do not come into contact with the channel walls. Upon passing into a 
channel with a greater cross-sectional area, liquid plugs form spheres due to surface 
tension forces.
By increasing the continuous fluid flow rate, droplet formation is favoured 
(Figure 3.3A). The dispersed phase is forced to break into droplets by the increased 
pressure and viscous forces exerted by the continuous phase. However, if the 
continuous phase flow rate is increased further, the dispersed phase is pulled into a 
stable neck formation with droplets pinched off near the tip (Figure 3.3C). In this flow 
pattern, although droplets are very small, indeed much smaller than the channel 
diameter, satellite droplets (Section 1.10.4) are often also produced, leading to a large 
observed dispersity (Cramer et al., 2004). Flow rates were empirically determined in 
all experiments to bring about stable segmentation, as opposed to plug or unstable 
droplet formation.
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Fluid p B Fluid p Fluid p
Fluid a Fluid a Fluid a
Fluid p Fluid p Fluid p
Figure 3.3: Flow patterns produced in a microfluidic cross-junction. A) Droplet formation, B) plug 
formation and C) stable neck formation. Orientation of flow is specified by arrows
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3.3 Results
3.3.1 Use of 1-octanol as a carrier fluid
Production of alginate beads on-chip consists of two steps; emulsion formation
and ionic cross-linking of alginate chains within dispersed phase droplets. To 
emulsify aqueous alginate solutions an immiscible carrier fluid is required. Liquids 
which are immiscible with aqueous alginate solutions are necessarily non-polar, i.e. 
an organic solvent such as hexadecane or sunflower oil. Ionic cross-linking of alginate 
chains is bought about by divalent cations, the most commonly used being Ca2+. 
Calcium is described as a hard ion in the Lewis definition of acids and bases (Lewis, 
1923). As such, calcium (II) salts are easier to dissolve in polar solvents (high 
dielectric constant) such as water than in non-polar solvents (low dielectric constant).
The properties required for each step in alginate bead production are opposed. 
A non-polar solvent is required to form an emulsion of alginate droplets in a 
microfluidics-based circuit; however, the calcium ions required to cross-link alginate 
molecules have low solubility in such liquids. Either the calcium ions required for 
cross-linking must be supplied in the non-polar carrier fluid or in an additional 
aqueous flow. Both of these methods were investigated.
The solvent initially chosen as a carrier fluid was 1-octanol, which belongs to 
a class of chemicals known as fatty or aliphatic alcohols. These chemicals are 
amphiphatic in nature, meaning they are soluble in both water and organic solvents. 1- 
Octanol is immiscible with water, but still polar enough to dissolve calcium salts to a 
certain extent (dielectric constant = 10.34, compared with water = 80). Initially 1- 
octanol was saturated with CaCL by heating 1-octanol and excess CaCl2.
1-Octanol was demonstrated to be a suitable carrier fluid to produce a linear 
emulsion with alginate solution (1% w/v) as droplets of alginate were observed after 
segmentation by utilising a classical microfluidic cross-junction (as illustrated in 
Figure 3.4, circuit diagram shown in Appendix 1).
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1-octanol
A lginate solu tion
1-octanol
Chip num ber 1
Flow  rates:
Functional fluid = 1 .5m l/h  
Carrier fluid = 20m l/h
C hannel d im en sion s:  
B efore junction  = 500 |jm  
After junction  = 500pm
Figure 3.4: Schematic illustrating a classical microfluidic cross-junction. Functional fluid was 
composed of alginate solution (1% w/v) with carrier fluid composed of 1-octanol. Flow rates and 
channel dimensions are shown. Orientation of flow is specified by arrows
The experiment was repeated with 1-octanol saturated with CaCh; however, 
stable segmentation could not be achieved. Alginate chains are very rapidly cross- 
linked by Ca , and even the small amount of calcium present was enough to cause 
immediate gelation at the junction where the liquid interface is largest (Figure 3.5). 
Cross-linked alginate chains occluded the junction causing all flows to decelerate and 
eventually cease. Hence, direct exposure of the emerging alginate solution to free 
Ca2+ results in immediate gelation and channel blockage.
1-octanol + Ca2*
A lginate solution
Solid  hydrogel 
formation
Chip num ber 1
Flow  rates:
F unctional fluid = 1 .5m l/h  
Carrier fluid = 20m l/h
C hannel d im en sion s:  
Before junction  = 500p m  
After junction  = 500p m
1-octanol + C a 2+
Figure 3.5: Schematic showing immediate interfacial hydrogel formation in a classical 
microfluidic cross-junction. Functional fluid was composed of alginate solution (1% w/v) with carrier 
fluid composed of 1-octanol saturated with CaCl2. Alginate molecules react rapidly with Ca2+ dissolved 
in the carrier fluid. The cross-linked alginate chains form solid hydrogel at the junction. Flow rates and 
channel dimensions are shown. Orientation of flow is specified by arrows
A linear emulsion of alginate solution was generated at increased flow rates 
(60ml/h and 4ml/h for carrier fluid and functional fluid, respectively). However, 
alginate droplets did not become fully cross-linked and did not exit from the device as
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individual, separate particles in a solid form, rather as a large mass of partially cross- 
linked alginate gel. At increased flow rates, alginate droplets do not come into contact 
with sufficient Ca2+ to cross-link all alginate molecules. This could be for several 
reasons; Ca2+ diffusion to droplet surface is too slow, droplets do not reside in the 
device for enough time, or Ca2+ is depleted locally around the droplet. Two solutions 
to this were identified; increased residence time or increased Ca2+ concentration. The 
latter was chosen for further investigation.
As stated previously, calcium is a hard ion in the Lewis definition of acids and 
bases. Hard ions preferentially form complexes with hard ligands, such as chloride, 
and bind less favourably to soft ligands. It was postulated that the Ca2+ concentration 
could be increased by utilising a soft, organic anion as opposed to a hard counter-ion 
such a Cl*. In this way Ca is poorly bound to the ligand and more likely to dissolve 
in the solvent. A mixture of calcium cyclohexanebutyrate (Figure 3.6) and calcium 
nitrate allowed Ca2+ to be dissolved into 1-octanol at a concentration of 40mM. 
However, even at high flow rates (60ml/h and 4ml/h for carrier fluid and functional 
fluid respectively) stable segmentation was not possible due to the immediate reaction
^  j
between alginate moieties and Ca at the junction.
Figure 3.5: Chemical structure of calcium cyclohexanebutyrate
To remedy the problem of immediate gelation at the junction, it was 
postulated that a two-component laminar flow could be used as the carrier fluid. At 
the micron scale, turbulent fluid flow, which is responsible for fluid mixing, is 
constrained and replaced by laminar flow (Section 1.12.1). Under these conditions, 
fluids move in planes, and with the exception of slow interfacial diffusion, do not 
undergo mixing. Therefore, it is possible to create a laminar flow of two miscible 
liquids, and maintain separation of the two for some considerable time.
The microfluidic circuit was enhanced to include an additional fluid flow; into 
which pure 1-octanol was introduced. Hence, the carrier fluid can be thought of as a
Ca2+
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reactive stream of Ca2+ dissolved in 1 -octanol, containing a stripe of inert, unmodified 
1-octanol; hereafter referred to as the “shielding” flow (shown in red in Figure 3.7). 
The two-phase laminar flows were created at microfluidic T-junctions, and 
approached the aqueous alginate mixture from either side, at an angle of 90°. The 
fluid flows were oriented such that the non-reactive shielding flows contacted the 
aqueous alginate flow at the junction. However, the 1-octanol containing Ca did not 
come into contact with the emerging aqueous droplets at the junction.
R ea ctiv e  flow : 1-octanol + C a :
S h ie ld in g  flow :
1-octanol
F u n ction a l fluid:
alginate solution
S h ie ld in g  flow :
1-octario
Chip num ber 2
Flow  rates:
Functional fluid = 1ml/h  
R eactive fluid = 10m l/h  
Carrier fluid = 25m l/h
C hannel d im en sion s:  
B efore junction = 500pm  
After junction = 1000pm
R ea ctiv e  flow : 1-octanol + Ca
Figure 3.7: Schematic of novel shielding junction design incorporating additional fluid flows to 
provide a non-reactive shielding flow. Functional fluid (shown in blue) was composed of alginate 
solution (1% w/v), shielding flow (shown in red) was composed of 1-octanol and reactive flow (no 
shading) was composed of 1-octanol containing Ca2+ at a final concentration of 40mM, by dissolving 
calcium cyclohexanebutyrate and calcium nitrate into 1-octanol. Flow rates and channel dimensions are 
shown. Orientation of flow is specified by arrows
This modification allowed the problem of immediate gelation at the junction 
to be overcome. The emerging droplets were insulated from the fraction of the carrier 
phase containing Ca2+ by a layer of the shielding fluid. Spherical droplets of alginate 
solution were successfully generated at the junction, and these proceeded through the 
reactor channel. As the droplets were carried through the circuit, Ca2+ gradually 
diffused through the shielding layer surrounding them. The eventual reaction between 
calcium and alginate chains was seen to be more controllable; since the relative flow 
rates (and consequently the thicknesses) of the two components of the laminar flow 
could be entirely independently controlled. Hence, by varying the relative proportion 
of the shielding fluid within the carrier phase, the rate of alginate bead gelation could 
be adjusted. This novel method has been described in patent application number 
GB0525951.0 (Davies et a l, 2005).
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Solid calcium cross-linked alginate beads were successfully produced when 1 - 
octanol was used as a carrier fluid in conjunction with the novel shielding junction 
developed (Figure 3.7). For this experiment only, sodium alginate (1% w/v) from 
Sigma-Aldrich was used. Sodium alginate from this source is known to be of lower 
quality than the NovaMatrix sodium alginate used throughout the rest of this thesis. 
As the alginate solution was not filtered insoluble particles can be seen in the beads 
(Figure 3.8A). The average diameter of blank beads (n=50) made using this method 
was measured (Section 2.2.3) to be 277±5pm (Figure 3.8B). The coefficient of 
variation (CV) was 1.8%.
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Figure 3.8: Calcium cross-linked alginate beads produced using 1-octanol as a carrier fluid. A) A
representative calcium alginate bead population produced using 1-octanol as carrier fluid to segment 
alginate solution (1% w/v) using a shielded microfluidic junction (as shown in Figure 3.7). Insoluble 
particles are present due to use of low purity alginate. Scale bar represents 100pm, B) histogram of 
beads represented in A; grey bars show measured data, with black line representing normal 
distribution. Mean bead diameter was 277±5pm. Distribution was considered not normal (A2=1.37, p < 
0.005), with an outlier at 263 pm, represented by an asterisk (*)
3.3.2 Use of an aqueous shielding flow
As explained in the previous section, a liquid which is immiscible with
aqueous alginate solutions is required to enable segmentation. The method arrived at 
in the previous section (Section 3.3.1) utilised an organic solvent; however oils are 
also suitable for use as a carrier fluid to segment alginate, as they are non-polar. The 
dielectric constant (k; a measure of a solvent’s ability to decrease the force with which 
two oppositely charged ions attract each other) is even lower in oleic acid (k = 2.5) 
than in 1-octanol (k = 10.34), both of which are much lower than water (k = 80). 
Whereas a small amount of Ca2+ can be dissolved in organic solvents, such as 1-
/  % J* „• v
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octanol, virtually none can be dissolved in oils. As such, oils are not suitable for 
undertaking external gelation of alginate solutions.
A further attempt to use external gelation to cross-link alginate droplets was
0 4 -made. As Ca cannot be provided in the continuous oil phase, an additional aqueous 
flow containing Ca2+ was proposed as an alternative. As seen previously (Section 
3.3.1), allowing aqueous alginate solutions and Ca2+ ions to combine prior to 
segmentation causes cross-linking of alginate chains and subsequent occlusion of the 
junction. It was postulated that an aqueous shielding flow could be used as a barrier to 
prevent Ca2+ diffusing from an aqueous CaCb solution to an alginate solution.
To test this theory, a chip was designed and milled (Section 2.2.2, circuit 
diagram Appendix 1), and aqueous soluble dyes were used to visualise the laminar 
flow established. As can be seen in Figure 3.9, two aqueous dye-solutions (rhodamine 
B (1% w/v - Fluid a) and procion blue 4 (1% w/v - Fluid y)) and water (Fluid P) were 
pumped into this microfluidic chip and the expected laminar flow pattern was 
demonstrated.
C hip n u m b er 3
F low  rates: 
a  = 0 .2 5 m l/h  
P = 2m l/h  
y = 1 ml/h
C h a n n el d im en sio n s:  
All c h a n n e ls  =
5 0 0 p m
Figure 3.9: Laminar flow in a microfluidic circuit. Aqueous soluble dyes, rhodamine B (1% w/v - 
Fluid a ) and procion blue 4 (1% w/v - Fluid y), have been used to differentiate between the laminar 
fluid streams. Fluid P consisted of water. Flow rates and channel dimensions are shown. Orientation of 
flow is specified by arrows. Scale bar represents 500pm
Flow y in Figure 3.9 was replaced with sodium alginate solution (2% w/v), 
with no perturbation to the laminar flow regime. The aqueous rhodamine and alginate
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solutions were successfully segmented with oil (flow rate = 20ml/h, not shown on 
diagram). Mixing between the dyed water and alginate solution occurred inside the 
droplet after segmentation.
The replacement of Flow a  in Figure 3.9 with an aqueous solution of 0.1M 
CaCh containing rhodamine B (1% w/v) as shown schematically in Figure 3.10, 
caused turbulent flow between the shielding water and CaCl2 to occur. Upon 
segmentation, a chain of semi-hardened alginate beads linked by a thread of cross- 
linked alginate was produced. A possible explanation for this phenomenon is partial 
cross-linking of alginate chains via the disrupted shielding flow prior to segmentation, 
leading to an increase in viscosity which had an adverse effect upon segmentation.
A lginate  
W ater solution  Oil
Chip num ber 3
Flow  rates: 
C aC h = 1.5m l/h  
W ater = 20m l/h  
A lginate = 1ml/h  
Oil = 20m l/h
C aC h
solution
C hannel d im ensions: 
All ch a n n e ls  = 500 |jm
W ater A lginate Oil 
solution
Figure 3.10: Schematic of laminar flow. The outer flow was composed of alginate solution (2%  w/v) 
and the inner flow was composed of 0.1 M CaCl2 dyed with rhodamine B (1% w/v). The two flows 
were separated by water. Segmentation occurred subsequently with sunflower oil. Flow rates and 
channel dimensions are shown. Orientation of flow is specified by arrows
In an effort to reduce the extent of diffusion of Ca ions into the aqueous 
shielding flow, the fluid flows a  (0.1M CaCk) and y (2% w/v alginate) were inverted 
(Figure 3.11). Under these conditions, a similar chain of semi-hardened alginate beads 
was produced. No discrete beads could be produced via this method and as a result it 
was abandoned.
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Chip num ber 3
Flow rates: 
A lginate = 1.5m l/h  
W ater = 20m  l/h 
CaCI 2 = 1m l/h 
Oil = 20m  l/h
C hannel d im en sions: 
All ch a n n e ls  -  SOOpm
W ater CaCI 2 Oil 
solution
Figure 3.11: Schematic of laminar flow. The outer flow was composed of 0.1 M CaCl2 and the inner 
flow was composed of alginate solution (2% w/v). The two flows were separated by water. 
Segmentation occurred subsequently with sunflower oil. Flow rates and channel dimensions are shown. 
Orientation of flow is specified by arrows
3.3.3 Adaptation of an internal gelation method for use with microfluidics
An internal gelation method (See Section 1.7.2.2) was adapted as an
alternative to the more commonly employed diffusion/external methods for producing 
alginate beads. The internal gelation reaction described for cross-linking alginate is 
typically used in conjunction with emulsion polymerisation (Poncelet et al., 1992). 
Since a segmented flow stream can essentially be thought of as a “linear” emulsion, 
this was considered an ideal method to adapt.
• *7 IEquation 3.1 describes the internal gelation reaction used to supply Ca ions 
for cross-linking alginate chains. Calcium carbonate was used as the insoluble 
calcium salt, with dilute acetic acid providing protons.
CaCC>3 (s) +  2 H +  (aq) —► Ca2+ (aq) + CO2 (g) + H2O (i) Equation 3.1
As in previous experiments (Section 3.3.1), use of a classic microfluidic cross 
junction was inappropriate for this application due to alginate chains prematurely 
cross-linking at the junction. To prevent immediate reaction of alginate molecules and 
free Ca2+, CaCC>3 suspended in the alginate solution must be protected from a 
decrease in pH. The shielding junction, described previously (Section 3.3.1), was used 
to prevent this problem. Nanocrystalline calcium carbonate (Section 2.1.3, 400mM) 
suspended in alginate solution (2% w/v) was used as the functional fluid with 
sunflower oil used as the shielding flow. The reactive flow consisted of acetic acid
CaCI 2 
solutionW ater
A lginate
solution
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(125mM) in sunflower oil (final pH = 4 (Section 2.2.7)). These concentrations were 
chosen as they were used by Ribeiro et al. (2005). Junction and fluid flows are 
depicted in Figure 3.12.
Sunflow er oil and  
a ce tic  acid
Sunflower oil
A lginate solutioji 
+C aC O
Sunflower oil
Chip num ber 2
Flow rates:
Functional fluid = 1ml/h 
R eactive fluid = 10m l/h  
Carrier fluid = 25m l/h
Channel d im ensions: 
B efore junction = 500pm  
After junction = 1000pm
Sunflower oil and  
a ce tic  acid
Figure 3.12: Schematic diagram showing the shielded junction and its use for producing calcium 
alginate beads via internal gelation. Functional fluid (shown in blue) was composed of alginate 
solution (2%  w/v) containing CaC03 (400mM), shielding flow (shown in red) was composed of 
sunflower oil and reactive flow (no shading) was composed of sunflower oil containing acetic acid 
(125mM). Flow rates and channel dimensions are shown. Orientation of flow is specified by arrows
Under these conditions, alginate droplets containing dispersed CaCC>3 were 
formed. Acetic acid in the reactive flow reacted with CaCC>3 present at the interface 
between the droplets’ surface and the oil, whereupon Ca2+, H2 O and CO2 were 
produced. Alginate chains present in a droplet became cross-linked upon exposure to 
the free Ca2+ present. CaCC>3 throughout the droplet reacted to produce free Ca2+ and 
the alginate chains became completely cross-linked. A shielding flow of pure 
sunflower oil was employed to prevent CaCC>3 suspended in the alginate solution 
from coming into contact with the reactive flow containing acetic acid. The shielding 
and reactive flows remained laminar until the junction (Figure 3.13). The emerging 
alginate droplet disrupted this laminar stream and newly formed droplets almost 
immediately came into contact with the reactive flow.
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A lg in ate
solu tion
Figure 3.13: A negative image of the shielding flow junction. Alginate solution (2% w/v) was 
pumped into the channel seen entering on the left. The laminar flow of pure sunflower oil and 
sunflower oil containing acetic acid (125mM) is seen entering perpendicular to the alginate flow. The 
shielding flow was dyed with sudan red, shown in green, for ease of visualization. Alginate droplets are 
highlighted with arrowheads. Flow rates and channel sizes are defined in Figure 3.10. Orientation of 
flow is specified by arrows. Scale bar represents 500pm
Solid alginate beads were produced using the adapted internal gelation 
method. As can be seen in Figure 3.14A, beads appeared opaque due to remaining, 
unreacted, insoluble CaCC>3 . The average diameter of blank beads (n=20) made using 
this method was measured (Section 2.2.3) to be 269±4pm (Figure 3.14B). The 
coefficient of variation (CV) was 1.6%.
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Figure 3.14: Calcium cross-linked alginate beads produced using the adapted internal gelation 
method. A) A representative calcium alginate (2%  w/v) bead population produced using an adapted 
internal gelation method utilizing CaC03 (400mM) as an inert calcium source and a shielded 
microfluidic junction (as shown in Figure 3.12). Scale bar represents 250pm. B) Histogram of beads 
represented in A; grey bars show measured data, with black line representing normal distribution. 
Mean bead diameter was 269±4pm. Distribution was considered not normal (A2=1.76, p < 0.005)
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3.4 Discussion
Three different approaches were employed to develop microfluidic methods 
for producing alginate beads. Both internal and external gelation methods were 
adapted for use in a microfluidics-based device. The development of a novel circuit 
design allowed calcium cross-linked alginate beads to be produced via internal and 
external gelation. Beads thus produced were collected upon exiting the microreactor 
without requiring further processing steps. The novel circuit has been described in a 
patent application (Davies et a l, 2005).
The unique, custom-designed MicroPlant™ has many advantages over more 
commonly used PDMS microdevices. By avoiding a permanently sealed cover, a 
compression-sealed PTFE device may be dismantled, cleaned and reassembled as 
required. This is particularly useful in cases of accidental failure (e.g., channel 
blockage due to unwanted gelation), allowing rapid recovery during testing and 
optimisation of conditions. Synthesising a microfluidic device via the multi-stage 
soft-lithography, PDMS casting, oven-curing and plasma cleaning process has been 
reported to take a minimum of eight hours (Zhao et al., 2003). By using PTFE as a 
starting material for microfluidic chip synthesis, the multi-step lithography process is 
avoided, and substituted by a single, automated micro-machining operation. This 
allows microfluidic features consisting of microchannels with cross-sections of 
100pm to 1mm to be produced. Typically, a microfluidic device of this kind, 
containing multiple parallel circuits may be produced within sixty minutes. Efficient 
use of space is a major consideration when designing circuits for any microfluidics- 
based device. Spiral (Zourob et al., 2006) or serpentine channels (Choi et a l , 2007) 
are often employed to produce the longest possible path length. In this way the post­
junction channel length was increased to 14cm on a 5cm diameter chip.
Literature published since the beginning of this project shows that when using 
an organic continuous phase, droplets of alginate solution can easily be produced in 
microfluidic circuits (Sugiura et a l , 2005; Choi et a l , 2007; Shintaku et al., 2007; 
Zhang et a l , 2007). Varying approaches have been explored to generate hydrogel 
beads (for example agarose (Sakai et a l , 2005), Dextran-hydroxyethyl methacrylate 
(De Geest et a l , 2005), chitosan (Yang et a l , 2007) and Puramatrix (Um et a l , 
2008)), however only alginate microparticles will be discussed here. Various groups 
have investigated both internal and external gelation approaches to produce calcium
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cross-linked alginate beads. Each approach has been combined with alginate 
ionotropic cross-linking on- and off-chip.
Huang et al (2006) first demonstrated that alginate solutions can be 
segmented using a cross-junction microchannel. Droplets of aqueous alginate were 
generated, and then transported, along with the continuous oil phase, into a beaker 
containing a calcium (II) ion solution, thus producing beads off-chip via external 
gelation. In an adaptation of Poncelet’s internal gelation method, the same group 
segmented alginate solutions containing CaCC>3 using oil in a cross-junction 
microchannel (Huang et a l, 2007). The emulsion generated was dripped into a beaker 
containing oil, Tween80 and acetic acid. When droplets containing CaCC>3 came into 
contact with acetic acid, Ca2+ ions were produced causing polymer gelation. Thus, 
beads were produced off-chip via internal gelation. Thus, transportation off-chip for 
subsequent cross-linking has been shown to be possible but difficult to achieve, as 
droplets have a tendency to coalesce prior to exiting the device, which is a major 
drawback. This tendency for droplet coalescence prior to cross-linking leads to an 
increased size distribution of product beads produced using off-chip ionic cross- 
linking. For these reasons cross-linking of alginate droplets prior to exiting a 
microfluidics-based device is preferable and ionic cross-linking off-chip is rarely 
reported.
Continuous microfluidic fabrication of alginate beads requires polymer 
gelation on-chip. However, ionic cross-linking must be prevented from occurring at 
the junction where excess cross-linked polymer prevents emulsion formation. The 
most obvious, though least successful, technique to combine Ca2+ with aqueous 
alginate solutions in microfabricated devices is to emulate conventional production 
methods and introduce aqueous CaC^ solutions. As outlined above, attempts during 
this study to separate aqueous alginate and CaCl2 flows with an aqueous shielding 
flow stream were unsuccessful. This approach has not been reported in combination 
with alginate solutions, but a modified circuit design has been shown to be effective at 
separating reactive chemicals over short distances (Song et al., 2003). To improve the 
use of an aqueous barrier, decreasing the contact time between laminar flows is of 
paramount importance. Decreasing contact time can be achieved by decreasing the 
channel length and thus time available for Ca2+ to diffuse into the alginate flow.
The need for additional aqueous barriers has been disposed of altogether by a 
few groups. An aqueous alginate solution emanating from a central flow bought into
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contact with two flanking CaCb streams immediately prior to segmentation was 
observed not to segment into droplets. Instead, “the resulting thread” was observed to 
form into “nodules” (Zhang et a l, 2006). This was observed at a wide range of 
continuous phase flow rates. Premature polymer cross-linking prevented emulsion 
formation rendering this method unsuitable for alginate bead production. A modified 
T-junction was more successfully employed to combine aqueous CaCh and alginate 
flows (Choi et a l, 2007, junction design illustrated in Figure 3.15). Aqueous CaCh 
and alginate solutions were bought into contact at the junction where segmentation 
with a carrier fluid produced droplets which became cross-linked whilst moving down 
the microchannel.
Figure 3.15: Schematic showing a modified T-junction. A classical T-junction was modified by 
addition of a channel at 45° to the junction. Mixing between the cross-linking reagent and polymer is 
prevented by this junction design until a droplet is formed, whereupon rapid mixing and thus bead 
formation occurs
Several groups have attempted to effect alginate cross-linking on-chip via 
coalescence of aqueous CaCk and alginate droplets, with varying degrees of success. 
Separate populations of small CaCk droplets and larger alginate droplets were 
produced using oil. The CaCb droplets were produced at a higher frequency than 
alginate droplets. The two resulting sets of droplets were then collided, within the 
system, to produce solid alginate beads. Liu et al (2006) employed two fluid 
focussing devices to produce the two separate populations of droplets. Circular 
chambers were used to induce changes in velocity gradients forcing one alginate 
droplet to fuse with one CaCI2 droplet. This succeeded in producing disk-like and 
thread-like structures, but no discemable spherical beads. Shintaku et a l (2007) also 
used a flow focusing device to form larger alginate droplets, but, instead used a T- 
junction to produce the increased number of smaller diameter CaCl2 droplets required. 
The alginate and CaCl2 droplets were observed to spontaneously coalesce due to
C r o s s - l i n k i n g  
r e a g e n t  ( o r  
a c t i v a t i o n  a g e n t )
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velocity differences bought about by the discrepancies in droplet volume. The 
particles produced in this way were solid but non-spherical. Although alginate chains 
were cross-linked using both of these methods, spherical beads were not made. Whilst 
there may be applications where non-spherical products are desirable, the aim of this 
project was to produce spherical beads.
Experiments combining Ca2+ in the continuous phase have also been described 
in the literature published since this project began. Zhang et al (2006) reproduced the 
experiment described above (Section 3.3.1), replacing 1-octanol to segment alginate 
solution in a cross-junction with undecanol containing Cal2. This was more successful 
than the attempt outlined in this study (Section 3.3.1) as capsules with a distinct outer 
shell were produced. The thickness of the shell was a function of exposure time of 
alginate chains to Ca . A more cell-friendly alternative, using calcium acetate 
dispersed in soybean oil, has also been described (Zhang et a l, 2007). Kim et a l  
(2009) produced externally cross-linked alginate beads on-chip by using a flow 
focussing device. To combine enough CaCh with the carrier fluid (oleic acid) 2- 
methyl-1-propanol was used as an intermediary. CaC^ was dissolved in 2-methyl-1- 
propanol by ultrasonication and the resulting mixture combined with oleic acid. The 
alcohol was evaporated off, leaving CaCl2 in the oleic acid. As the oil used for 
segmentation contained a small amount of CaCk, cross-linking of alginate chains 
occurred.
Zhang et al (2007) also proposed adapting Poncelet’s internal gelation 
method by adding acetic acid to the continuous phase. As this experiment was carried 
out in a cross-junction microchannel this group experienced the same difficulties 
observed in this study and were unable to collect solid calcium cross-linked alginate 
beads from this endeavour. Although partially gelled beads were produced, they did 
not remain spherical upon exiting the microfluidic circuit. The most successful 
alternative described again employs a modified T-junction (see above and Figure 
3.15). A mixture of aqueous alginate solution and CaCC>3 was supplied via the 45° 
arm, with hydrolysed o-Glucone-8-lactone (GDL) flowing in the perpendicular arm 
(Amici et a l , 2008). The two flows were combined at the junction and segmented 
with sunflower oil. GDL, being weakly acidic, reacts with CaCC>3 to release Ca2+ thus 
effecting alginate chain cross-linking. Tan and Takeuchi (2007) have also 
successfully converted internal gelation with a shielding flow for use with
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microfluidic devices. Their circuit design only differs from the work presented here in 
the placement of the additional stream of acidified oil.
Of the methods discussed, only four successfully produce spherical calcium 
cross-linked alginate beads, cross-linked in situ (Choi et al., 2007; Tan and Takeuchi, 
2007; Zhang et al., 2007; Kim et al., 2009). Each method is unique and novel, with no 
replication of the techniques presented in this thesis. Previously, microfluidic laminar 
flows have been used to create chemical gradients and to perform liquid-liquid 
extractions (Surmeian et al., 2002; Maruyama et al., 2004; Atencia and Beebe, 2005). 
These reported experiments involved combinations of miscible fluids or stratified 
flows containing an immiscible “membrane” flow. However, their use has not been 
applied to the problem of premature alginate cross-linking within microfluidic circuits 
before.
Two of the methods developed in this chapter were used to produce solid 
calcium cross-linked alginate beads on-chip. In both cases bead diameters were 
<280pm with CV <2%. This is within the range of reported literature (Table 1.3, 
Section 1.12.2). By far the best size distribution of alginate beads produced using a 
microfluidic circuit reported to date is a CV of 1.1% (mean bead diameter = 79pm, 
Choi et al., 2007). These beads were produced using hexadecane as the continuous 
phase. It was acknowledged that use of an organic solvent may not be compatible 
with cell viability. The next section of work will deal with the issue of toxicity of the 
developed processes.
81
C h a p t e r  F o u r
Chapter 4. Toxicity of microfluidic encapsulation processes 
and selection of viability estimation method
4.1 In tr o d u c t io n
Two microfluidic methods were developed to manufacture solid alginate
beads. The first method employed external gelation of alginate droplets formed via 
segmentation with 1-octanol, an organic solvent. The second method was an adapted 
internal gelation method utilising CaCC>3 as an inert cross-linker, acetic acid to 
liberate Ca2+ and sunflower oil to create droplets via segmented flow. Whilst there 
was evidence that solid alginate beads of an appropriate size and narrow size 
distribution were produced using both methods, no attempt was made to incorporate 
cells within the hydrogel matrix.
It was necessary to investigate the suitability of each method for cell 
encapsulation. The method chosen to encapsulate cells was required to not harm cells 
(cytotoxic) and, ideally, minimally decrease cell viability. Each of the developed 
encapsulation methods was assessed to evaluate potential cytotoxic effects. 
Adaptations were implemented in order to decrease any observed cytotoxicity and 
ensure maximal viability of encapsulated cells. The long term effects of encapsulation 
upon cell viability were also investigated.
Various commercially available viability estimation methods have been 
described to estimate cell viability in adherent or suspension mammalian cell culture. 
To use these methods to measure viability of encapsulated cells, cells must first be 
removed from the surrounding polymer. This adds an additional step which in itself 
may compromise cell viability, acting as a potential source of experimental error. 
Therefore it was important to assess the suitability of several commercially available 
viability methods for use with encapsulated cells. An ideal method is rapid, cost 
effective and accurate, and would preferably be a simple assay, which does not 
require cells to be removed from beads and allows analysis of multiple samples 
simultaneously. The methods chosen for investigation were; trypan blue exclusion, 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide), lactate 
dehydrogenase (LDH), alamarBlue™, and LIVE/DEAD® staining. The chosen 
procedures were tested for their compatibility with encapsulated cells. Alterations to 
the recommended procedures are discussed in the following sections.
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4.2 R e s u l t s  
4.2.1 Comparison of methods for estimating viability of encapsulated cells
4.2.1.1 Adapted trypan blue
Trypan blue is a vital stain bearing two azo chromophores. As these
chromophores are negatively charged they do not interact with intact cell membranes 
and so live cells remain unstained (Strober, 2001). When a cell is dead and the plasma 
membrane is compromised the stain is no longer excluded, and so it enters the cell, 
causing the development of a blue pigmentation. It is a relatively straightforward task 
to count the number of stained and unstained cells observed, by employing a 
haemocytometer (Section 2.3.1.4). The percentage of viable cells present was 
calculated using the following equation:
_ j . . .  „ number of unstained cells countedPercentage viable cells = ------------------------------------------ x 100 Equation 4.1
total cell count
In initial experiments, trypan blue was added directly to beads on a 
microscope slide. The dye permeated the outer layer of alginate gel, but did not 
diffuse completely to the bead centre. For this reason, results gained were not 
repeatable, reliable or accurate.
Both EDTA and citrate ions have a high affinity for Ca2+ and so can be used to
<■} I
sequester Ca from solid calcium cross-linked alginate gels. For the trypan blue 
method to be effective, cells needed to be released from the beads. EDTA and sodium 
citrate solutions were tested to find the most appropriate chemical to re-dissolve 
beads. Upon ion-exchange with sodium citrate or sodium EDTA, alginate chains re­
dissolve to produce sodium alginate solution; hence cells are freed from beads. As cell 
culture medium contains metal ions (which are also chelated by these ligands), beads 
were removed from medium before chelating agents were added.
As EDTA and citrate ions are cytotoxic (Amaral et al., 2007), minimum 
exposure was required. Trypsin/EDTA solution containing 0.53mM EDTA, EDTA 
solution (125mM) and sodium citrate (55mM) were each added to alginate beads 
(100pi). Alginate beads did not dissolve upon addition of EDTA solution or 
Trypsin/EDTA, whereas treatment with sodium citrate (55mM) resulted in dissolution 
of the alginate matrix. As an equivalent concentration of sodium citrate is routinely
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used to liquefy PLL-coated alginate beads (Lim and Sun, 1980), and the encapsulated 
cells are exposed to it for much longer (~5 minutes) than in the adapted method 
described below, the toxic effects of citrate were not considered further.
Based upon these findings, cells in individual beads were counted using a 
slightly adapted method based upon trypan blue exclusion. A single bead was placed 
on each half of a haemocytometer and as much medium as possible was removed. 
Sodium citrate (55mM, 5pi) was added to each bead followed by trypan blue (5pi). 
After 10 seconds a coverslip was placed over the beads, which had dissolved to give a 
cell suspension. Total cell and viability counts were carried out as described (Section
2.3.1.4). Using this method, cell viability and total cell numbers could be measured 
for each individual bead.
4.2.1.2MTT
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide) is a 
yellow dye, which is reduced to insoluble purple formazan crystals in the presence of 
mitochondrial reductase enzymes. The resulting intracellular purple formazan can be 
solubilised and quantified colourimetrically. As mitochondrial reductase enzymes are 
only active in viable cells, this conversion can be used as a direct measurement of 
viable cell numbers (Mosmann, 1983).
Reconstituted MTT was added to adherent HEK293 cell cultures or bead 
samples as described in Section 2.3.4.1. Solubilisation of formazan using the 
solubilisation solution provided in the kit used (consisting of 10% Triton X-100 plus 
0.1M HC1 in anhydrous isopropanol; Sigma, UK) was successful for adherent cell 
cultures. However, once formazan had been formed by encapsulated cells, it remained 
trapped within the beads and could not be dissolved by the solubilisation solution 
provided. Other groups have bypassed this issue by applying DMSO to solubilise 
formazan instead (Rollan et a l , 1996; Rokstad et a l , 2002). This modification makes 
it necessary to introduce washing steps into the protocol. Whilst washing was not 
problematic for large beads, this proved extremely difficult when combined with the 
smaller beads produced by the microfluidic methods. It was found that smaller beads 
were easily lost whilst carrying out necessary washes with a micropipette. Also, 
sufficient formazan to produce a colour change was not present until 7 days after 
encapsulation, as low numbers of cells were present within the beads. Early stage 
viability could therefore not be obtained using this method.
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4.2.1.3 LDH
The presence of lactate dehydrogenase (LDH) can be used to estimate the 
number of dead cells present in a given population. Upon cell death, LDH is released 
into surrounding medium, where it converts pyruvate to lactate, thus reducing NAD to 
NADH (Decker and Lohmannmatthes, 1988; Legrand et al., 1992). The reduced 
NADH stoichiometrically converts a tetrazolium dye, thus producing a measurable 
colour change at 490nm.
To test this assay, encapsulated cells (40 beads) were added to medium 
(100pi) in a 96-well plate. This was carried out in quadruplicate. Beads and medium 
were incubated for 24 hours. The assay was then carried out on medium taken from 
encapsulated cells and medium taken from a serial dilution of cells, which had been 
killed by addition of LDH assay lysis solution (Section 2.3.4.2). The standard curve 
produced using the serial dilution of cells was linear between 7.8 x 104 and 2.5 x 106 
cells per ml (Figure 4.1). A linear best fit line was fitted between these points 
(y=0.3747x + 0.0809). The R2 value was 0.987. The slope of this line gives the 
relationship between cell concentration and absorbance reading. The number of cells 
present in the unknown samples was then calculated from absorbance.
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Figure 4.1: Graphical representation of absorbance obtained with varying cell numbers. LDH
assay was carried out after 24 hour incubation of HEK293 cells with medium. Absorbance readings 
were taken at 490nm, background was subtracted at 690nm
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The assay was carried out over 7 days after encapsulation of 4 separate cell 
populations (Figure 4.2). The standard deviation of the four replicates was large and 
the results gained were inconsistent. Hence this method was deemed to be of limited 
use.
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Figure 4.2: Graph showing number of dead cells estimated using LDH assay over time. Each point 
is from four replicate assay readings. Error bars show standard deviation
4.2.1.4 alamarBlue™
The alamarBlue™ assay contains a proprietary REDOX indicator, which is
soluble and stable in cell culture medium and non-toxic to cells, thus allowing cells to 
be continuously monitored in cell culture medium (Ahmed et a l , 1994). 
AlamarBlue™ is reduced from its oxidised, blue form (absorbance peak at 600nm) to 
its reduced red form (absorbance peak at 570nm) after cellular uptake and metabolic 
activity. The resulting colour change from reduction of alamarBlue™ by living cells 
can be monitored using a spectrophotometer.
To test this assay with encapsulated cells, varying bead numbers were added 
to a 96-well plate. Approximately 50 beads were counted in quadruplicate into 
separate wells. As this proved to be very time consuming, for the remaining trial 
varying amounts of medium containing beads were measured volumetrically into 
wells. Flasks containing beads and medium were agitated to obtain a dispersed
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mixture. Medium containing beads was pipetted in quadruplicate into separate wells 
of a 96-well plate. Different pipettor tips were chosen to investigate the 
reproducibility of this technique and to attempt to measure different volumes of 
encapsulated cells. In the first instance, lOOpl of medium containing beads was 
pipetted with a 200pl pipettor tip. In the second instance, 200pl of medium containing 
beads was measured with a lOOOpl pipettor tip. The assay was carried out on 
encapsulated cells as described (Section 2.3.4.3). A change in peak absorbance was 
observed over time (Figure 4.3). This correlates to a reduction of alamarBlue™, and 
thus cell proliferation. Samples containing the highest numbers of beads did not show 
an additional increase in absorbance between 16 and 24 hours. For comparison, fully
TW TW
reduced alamarBlue was obtained by autoclaving alamarBlue solution (10% v/v) 
according to the manufacturers’ protocol (Section 2.3.4.3).
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Fully reduced 
alamarBlue™
2 30
20 -
o 5 10 15 20 25 30
Time (hours)
Figure 4.3: Graph showing percentage reduction of alamarBlue™ over time. Fifty beads (■), 
100pl of beads (A ) and 200pl of beads (•) were present per well. All bead samples were incubated 
with alamarBlue™ (10%) in medium. Dashed line at 30% represents fully reduced alamarBlue™ 
obtained by autoclaving alamarBlue™ solution (10% v/v). Error bars show standard deviation of 4 
replicates
4.2.1.5 LIVE/DEAD* staining
The commercially available LIVE/DEAD® Viability/Cytotoxicity Kit for
mammalian cells (Molecular Probes, Paisley, UK) allows live and dead cells to be 
detected via fluorescent probes. Calcein AM is non-fluorescent and cell-permeant. It 
is converted to the highly fluorescent calcein by intracellular esterase activity. Calcein
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is retained within living cells giving an intense green fluorescence (479nm excitation 
and 517nm emission). Ethidium homodimer-1 binds to nucleic acids, but is excluded 
by living cell membranes. When bound to DNA of cells with damaged membranes, 
ethidium homodimer-1 fluoresces bright red (528nm excitation and 617nm emission). 
The dual fluorescence can be detected by fluorescent microscopy, multiwell plate 
scanners, and flow cytometers. In this investigation, flow cytometery and microscopy 
(both fluorescent and confocal) were evaluated as potential platforms to quantify 
relative cell viability.
4.2.1.5 a) Microscopic quantification
Dyes were added directly onto encapsulated cells, in medium without serum,
in 96-well U-bottom plates (Section 2.3.4.4). Use of a haemocytometer or 384-well 
plate was not possible with the available microscope. Small volume U-bottom plates 
were deemed most suitable for observation of single beads. Although cells were 
observed to glow green and red, cell counting was unreliable and inaccurate due to 
weak overall fluorescence from individual cells. Photographs could not be taken using 
this method as the microscope was not equipped with a camera and so counting had to 
be carried out rapidly at the microscope.
4.2.1.5 b) Confocal microscopy
Beads were observed using confocal microscopy (Leica DM600B upright
microscope) after LIVE/DEAD® staining (Figure 4.4). Again, stains were added 
directly to beads in medium without serum (Section 2.3.4.4). As the fluorescent signal 
became attenuated by passing through more than 200pm of cross-linked alginate, 
beads were not imaged in their entirety; instead imaging began at the top of the bead 
and was continued until the fluorescent signal could no longer be collected. Therefore 
images shown are representative of the uppermost 200pm area of bead.
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Figure 4.4: Confocal image of encapsulated HEK293 cells stained with LIVE/DEAD® stain.
Image shows distribution of live and dead HEK293 cells encapsulated within alginate microcapsules, 1 
day after encapsulation. Green fluorescence is emitted from intracellular esterase-converted calcein in 
live cells, whereas red fluorescence is emitted from ethidium homodimer present in the nuclei of dead 
cells. Scale bar represents 300pm
4.2.1.5 c) Flow cytometry
Flow cytometry is a technique where a stream of cells is forced to flow in a
restricted fluid channel, thus allowing characteristics of an individual cell to be 
assessed. In modem flow cytometers, laminar flow systems are used so that a 
focussed flow of cells can be achieved without blocking the flow cytometer nozzle. 
Cell detection is by fluorescent emissions and light scatter from the cells following 
laser excitation. Light scatter, which occurs with all particles passing through the 
flow cytometer allows the size and density of the cell to be measured. Forward (or 
low angle scatter) increases with cell size, whilst side (or high angle) scatter increases 
with cell density and granularity. In addition to the scatter characteristics, if the cells 
are labelled with fluorescent probes (such as antibodies conjugated to fluorochromes), 
laser excitation of the probes results in emissions of specific wavelengths, which are 
captured through one set of collection lenses, separated according to wavelength by 
dichroic mirrors, individually amplified and detected by photomultiplier tubes.
As encapsulated cells were too large to pass through the cytometer nozzle, 
cells had to be released from beads before this technique could be used. Sodium 
citrate (55mM, 1ml) was used to dissolve beads (1ml) after medium had been 
removed. Beads and sodium citrate were incubated for 10 minutes at 37°C. Cells
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liberated in this way were washed in D/MEM-F12, counted as described in Section
2.3.1.4 and then resuspended at a concentration between 0.1 and 5xl06 cells per ml in 
D-MEM/F12 (1ml). Cells from culture were trypsinised (Section 2.3.1.2), and 
washed. Dyes were added to cells, both from culture and released from beads, as 
described (Section 2.3.4.4) and detected using FACScanto (488 nm excitation and 
measuring green fluorescence emission for calcein (530/30 bandpass filter) and red 
fluorescence emission for ethidium homodimer-1 (670 longpass filter)). As can be 
seen from Figure 4.5 and Table 4.1, live and dead cells could be detected from both 
populations of cells.
Number of live Number of dead Cells alive
cells cells (%)
Cells 13010 5613 69.9
Cells from beads 5908 7741 43.3
Table 4.1: Summary of data collected using flow cytometry
Calcein Cacer
Figure 4.5: Diagram showing fluorescence of HEK293 cells stained with ethidium homodimer 
and calcein. A) HEK cells from culture and B) HEK cells released from beads. Green fluorescence is 
emitted from intracellular esterase-converted calcein in live cells, whereas red fluorescence is emitted 
from ethidium homodimer present in the nuclei of dead cells. Fluorescence was detected using 
FACScanto (488 nm excitation and measuring green fluorescence emission for calcein (530/30 
bandpass filter) and red fluorescence emission for ethidium homodimer-1 (670 longpass filter)). Each 
dot represents one cell
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Comparison o f trypan blue exclusion andflow cytometry
Cell populations used above were counted using trypan blue exclusion 
(Section 2.3.1.4) to estimate the number of cells to stain using LIVE/DEAD® staining. 
Live and dead cells were analysed using flow cytometry (Table 4.1). Cells from 
culture had a viability of 68% when counted using trypan blue exclusion, compared 
with 70% when using flow cytometry. The viability of the cells used for this 
experiment was lower than that seen in previous experiments (for example, see 
Section 4.2.2.1). The reason for this reduced viability was not clear. Cells from beads 
had a viability of 52% when counted using trypan blue exclusion, compared with 43% 
when using flow cytometry.
As a result of the above experiments, trypan blue was used to estimate cell 
viability in all subsequent experiments. The adapted trypan blue method was used to 
obtain estimates of encapsulated cell viability at regular time points throughout 
experiments, with observations of encapsulated cells carried out visually using a light 
microscope. At key time points, for example, when clusters began to form, viability 
was estimated using LIVE/DEAD® staining and detected using a confocal 
microscope.
4.2.2 Toxicity of developed encapsulation procedures
As an appropriate combination of methods had been developed to assess
encapsulated cell viability, the cytotoxicity of each developed encapsulation method 
could now be investigated. As previously stated (Sections 4.1 and 1.6) the method 
chosen to encapsulate cells should not be cytotoxic and cell viability should not be 
substantially decreased.
4.2,2,1 Toxicity testing of components used in external gelation method
For this experiment only, reactivated hepatocytes were used to test the
cytotoxicity of the components used in the microfluidic external gelation method 
(Section 3.3.1). Hepatocytes supplied by Abcellute (Cardiff, UK) were reactivated 
according to the manufacturers’ instructions, outlined in Section 2.3.2. Reactivated 
hepatocytes were resuspended at a cell concentration of 4.4x106 cells per ml. Cell 
viability prior to any testing was carried out using trypan blue exclusion (Section
2.3.1.4).
An aliquot (1ml) of hepatocytes in suitable medium was split in half, with one 
half placed in a humidified 5% CO2 incubator at 37°C for the duration of the
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experiment as a control. The remaining cells in medium were used to test the effect of 
transit through the MicroPlant™. This was repeated using cells resuspended in 
alginate solution (2% w/v). A final sample of cells was encapsulated using the 
microfluidic method developed using 1-octanol as a carrier fluid. After each process 
cell viability was estimated again using trypan blue. Viability was expressed as the 
percentage of cells surviving each process, as shown in Figure 4.6.
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Figure 4.6: Stack diagram showing percentages of cells alive and dead from varying components 
of the encapsulation process. A represents control cells in medium placed in an incubator for the 
duration of the experiment, B represents cells transported through the MicroPlant™ in medium, C 
represents cells transported through the MicroPlant™ in alginate (2% w/v) and D represents cells 
encapsulated using the microfluidic method developed using 1-octanol as a carrier fluid. Viability was 
estimated using trypan blue exclusion
Passage through the microfluidic device was not harmful, in medium or 
alginate solution. This also showed that alginate solution was not harmful to the cells. 
Use of 1-octanol however was extremely detrimental to cell viability, with no cells 
surviving the encapsulation process.
Figure 4.7A shows dead hepatocytes encapsulated within alginate beads 
produced via the microfluidic external gelation method. Product beads containing 
cells (n=40) had a slightly smaller mean diameter (249±4pm, with a CV of 1.6%; 
Figure 4.7B) than plain alginate beads produced previously using this method
nrr
B D
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(Section 3.3.1; 277±5pm; h i  = -29.30, p < 0.005). This method was rejected due to 
the observed cytotoxic effects of 1-octanol.
200 220 240 260 280 300
Size (microns)
Figure 4.7: Rat hepatocytes encapsulated in alginate beads. A) A representative bead population 
containing rat hepatocytes produced by segmenting alginate with 1-octanol using a shielded 
microfluidic junction, as shown in Figure 3.7. Scale bar represents 100pm. B) Histogram of beads 
represented in A; grey bars show measured data, with black line representing normal distribution. 
Mean bead diameter was 249±4pm. Distribution was considered not normal (A2=0.84, p < 0.028)
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4.2,2,2 Toxicity testing of components used in the internal gelation method
From this point onwards in this chapter Human Embryonic Kidney (HEK293)
cells were used to optimise the microfluidic internal gelation (MIG) method. HEK293 
cells are epithelial in origin and can be grown as an adherent culture or in suspension 
(Parekh et a l, 2000; Park et al., 2006). This cell line was chosen as it exhibits a high 
growth rate and is straightforward to culture.
All components of the MIG reaction were tested to determine if any 
components, in isolation or in combination, decreased cell viability. Components 
were tested as described in Section 2.3.3. Alginate solution (2% w/v), CaC03  
(400mM) suspended in alginate solution (2% w/v) and sunflower oil were tested at 30 
minute intervals for 5 hours. Acetic acid (125mM) in D-MEM/F12 medium and acetic 
acid (125mM) in sunflower oil were tested at 1, 5 and 10 minute periods. All samples 
were stored in a sterile hood between testing points, with the exception of cells in 
control medium which were stored in a humidified 5% CO2 incubator at 37°C.
Alginate solution, calcium carbonate and oil were shown to be non-toxic over 
5 hours (Figure 4.8). However, acetic acid at the concentration used, was shown to 
have a negative effect upon viability after one minute and was fatal to cells after 10 
minutes (Figure 4.9). The addition of oil to acetic acid appeared to ameliorate the 
toxic effect observed, as after 10 minutes of exposure cell mortality had reduced by 
50%. HEK293 cells did not survive encapsulation with components at stated 
concentrations.
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Figure 4.8: Viability of HEK293 cells exposed to components of the MIG method over 5 hours.
Cytotoxic effect of alginate (2% w/v 0), alginate and calcium carbonate (400mMA) and oil (o) on 
cells over 5 hours. Medium kept in an incubator (■) and medium kept in the hood (□) for the duration 
of the experiment are included as control points. Viability was estimated using trypan blue exclusion. 
Error bars show standard error of the mean of 3 replicate samples
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Figure 4.9: Viability of HEK293 cells exposed to components of the MIG method for lOminutes.
The effect on cell viability of acetic acid (125mM*) and acetic acid (125mM) plus oil (o), over 10 
minutes. Medium kept in the hood (•) for the duration of the experiment is included as a control. 
Viability was estimated using trypan blue exclusion. Error bars show standard error of Jhajnean of 3 
replicate samples
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4,2,2,3 Optimising concentration of components used in the internal gelation 
method
Although acetic acid was shown to be toxic to cells at the concentration used 
(125mM in medium), this effect was ameliorated in the presence of sunflower oil. 
Thus, the presence of acetic acid did not, in isolation, account for the toxic effect the 
entire process had on cells. It was observed that excess CaCC>3 was present in beads 
produced using the MIG method (Section 3.3.3). As solid beads were produced, there 
was obviously sufficient Ca liberated to cross-link all alginate chains present within 
a droplet. Hence, it was concluded that, since a surfeit of CaCC>3 was present, the 
concentration used could be reduced. From Equation 1.1 (Section 1.7.2.2) 
stoichiometric amounts of CaCC>3 and acetic acid react to form Ca . If CaCC>3 
concentrations can be reduced, then a concomitant decrease in acetic acid 
concentration can occur.
Concentrations of CaCC>3 and acetic acid were reduced as shown in Table 4.2. 
Reaction components at these concentrations were used in the microfluidic circuit 
shown in Figure 3.10, as previously described (Section 3.3.3). Beads produced thus 
were observed via a light microscope and photographs were taken (Table 4.2). Size 
was determined (Section 2.2.3) and diameters calculated (n=20). CaC03  
concentrations of less than 50mM resulted in non-spherical, unstable beads. A distinct 
interface between beads and the aqueous medium was not observed using a light 
microscope. Upon reducing acetic acid concentrations to 50mM (pH = 4.5, Section 
2.2.7), solid beads were produced. Hence, acetic acid and calcium carbonate 
concentrations of 50mM were used in all subsequent experiments with HEK293 cells.
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Average
diameter ± CV% Photograph 
SD (pm)______________________
Concentration Concentration Solid 
ofCaCO of acetic acid beads?
400mM 125mM Yes 268±4.2
300mM 125mM Yes 298.4±4.9
200mM 125mM Yes 2.4275.6±6.6
lOOmM 125mM Yes 3.4329.8±11.1
50mM 125mM Yes 2.4378.9±8.9
50mM 50mM Yes 2.0377.3±7.6
25mM 50mM No
Table 4.2: Formation of alginate beads using differing concentrations of calcium carbonate and 
acetic acid. Beads were made using 2% alginate
4.2.3 Extended viability measurements
Using the concentrations determined above, four independent bead replicates
(numbered sequentially from 1 to 4 in order of encapsulation) were generated from 
four separate flasks of HEK293 cells. Each flask of cells was trypsinised (Section 
2.3.1.2), washed and counted (Section 2.3.1.4) immediately prior to encapsulation. 
Cells were encapsulated at a concentration of 2x107 cells per ml. Beads were collected 
from the MicroPlant™ in the carrier fluid. The following steps were carried out on 
beads collected over a 5 minute period, with each encapsulation experiment lasting 20 
minutes. Medium was added to beads in carrier fluid and the mixture subsequently
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centrifuged to remove beads into medium. Beads were then transferred to a T25 flask 
with D-MEM/F12 supplemented with serum (25ml). Roughly 500pl of beads were 
produced in each encapsulation experiment. To maintain cell viability, medium was 
changed twice a week.
The adapted trypan blue method (described in Section 4.2.1.1) was used to 
establish any effects of encapsulation on long-term viability of the four encapsulated 
cell replicates. For each time point, four beads from each replicate were taken and 
viable cells counted (Figure 4.10). Time point zero represents cell viability measured 
after cells were trypsinised, prior to addition of CaCC>3 and alginate mixture and 
subsequent encapsulation. An initial decrease in cell viability was observed, the 
decrease in cell viability continued until 14 days post-encapsulation, after which time 
cell viability was seen to increase to near pre-encapsulation levels. The increase in 
cell viability was coincident with the appearance of cells growing in aggregates 
(Figure 4.11).
Although initial cell counts were easy to perform using the adapted trypan 
blue exclusion method, as cell numbers increased, counts became more problematic. 
Initially, low cell numbers were present and cells were observed to be discrete and 
randomly distributed throughout each bead. Subsequently, as cell aggregates grew, 
cells were very difficult to count accurately. Viability counts were continued until no 
beads remained for each replicate. Replicate 4 showed a much larger decrease in 
viability than any of the other three replicates. After 14 days it was decided that as so 
few cells were alive further viability measurements would be discontinued.
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Figure 4.10: Graph showing percentage celi viability of four replicates of encapsulated cells. Each replicate of cells, Replicate 1 (■), Replicate 2 (A ), Replicate 3 
(•) and Replicate 4 (X), was taken from a separate flask and encapsulated individually. Pre-encapsulation viability was 96% for Replicates 1 and 3 and 97% for 
Replicate 2 and 4. Viability was estimated using the adapted trypan blue method. Error bars show standard deviation of 4 individual beads
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Figure 4.11: Aggregates of encapsulated HEK293 cells. A) Aggregates observed in beads 12 days 
after encapsulation. Scale bar represents 250pm. B) Aggregates observed on a haemocytometer after 
alginate bead dissociation and trypan blue staining. Scale bar represents 50pm
Encapsulated cells were also observed using LIVE/DEAD® staining and 
confocal microscopy (Section 4.2.1.5 b) at 1, 5, 12 and 20 days post-encapsulation 
(Figure 4.12). Both live and dead cells were detected at all time points. Cells were 
seen to be separate and individual at 1 and 5 days post-encapsulation (Figure 4.12A- 
C). When beads were observed 5 days after encapsulation, a proportion contained 
cells which appeared to be swollen in comparison to cells in other beads (Figure 
4.12B -  normal compared with C -  swollen). By 12 days after encapsulation, 
aggregates of cells were observed inside beads, which had not been present prior to 
this time point (Figure 4.12D). By increasing the magnification, individual cells 
within the aggregates could be seen (Figure 4.12E). These aggregates of cells 
continued to expand and were much larger by day 20 (Figure 4.12F).
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Figure 4.12: Confocal images of encapsulated HEK293 cells. Images show distribution of live and 
dead HEK293 cells encapsulated within alginate microcapsules, 1 day (A), 5 days (B,C), 12 days (D,E) 
and 20 days (F) after encapsulation. Swollen cells can be observed in C when compared with B. A-D 
and F represent all cells within the top hemisphere of an individual bead. E represents Aggregates of 
cells present in D magnified. Green fluorescence is emitted from intracellular esterase-converted 
calcein in live cells, whereas red fluorescence is emitted from ethidium homodimer present in the 
nuclei of dead cells. Scale bars represent 100pm
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4.3 D isc u ssio n
4.3.1 Comparison of cell viability methods
Methods were investigated to assess their suitability for estimating viability of
encapsulated cells. It was essential that the method ultimately chosen gave an accurate 
estimate of cell viability and was quick and easy to carry out. It would be useful, 
although not necessary, for the chosen method to consist of minimal steps, allow 
multiple samples to be analysed simultaneously and cells to remain in situ. Although 
all the methods investigated have been successfully utilised by other groups 
investigating encapsulated cells (e.g. MTT (Roberts et al., 1996), LIVE/DEAD® 
staining (Choi et al., 2006), alamarBlue™ (McGuigan et al., 2008) and LDH (Khattak 
et al., 2006)), they proved difficult to use in combination with beads produced using 
the MIG method. There were several issues arising from the use of beads produced 
using the MIG method, which will be discussed below.
To ensure comparability, an equal number of beads must be measured at each 
time point and in each replicate sample. This is not problematic if beads are much 
larger than the inner diameter of a pipette tip, such as those produced via commonly 
used droplet production methods (Section 1.9). As beads are too large to enter the 
pipette tip they are held on to it by suction, thus allowing manipulation. In contrast, 
beads generated via MIG are of a diameter slightly smaller than the inner diameter of 
a pipette tip. This means beads are too small to be manipulated via suction on the tip 
of a pipette. For this reason it is difficult to count beads produced using the MIG 
method accurately and quickly. So, although MTT, LDH and alamarBlue™ have been 
shown to be suitable for use with traditionally generated beads, problems were 
encountered when used in conjunction with beads produced using the MIG method.
Another problem arising from bead size is that washing steps were extremely 
difficult to carry out. MTT has been used extensively to estimate cell viability in 
encapsulated cell populations. Modifications are extremely common, although this is 
not surprising, as even when used with un-encapsulated cell lines, modifications are 
needed to solubilise the formazan produced, as it is not fully soluble in aqueous 
solutions (Kwack and Lynch, 2000). Various alternatives to isopropanol have been 
suggested, for example: acidified sodium dodecyl sulphate (Tada et al., 1986) or 
DMSO (Sladowski et al., 1993; Uludag and Sefton, 1993; Roberts et a l, 1996). 
Stevens and Olsen (1993) propose that MTT is inappropriate and that XTT (2,3-bis[2-
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Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) is preferable as 
water soluble formazan is produced by its conversion. All of the discussed adapted 
MTT protocols require wash steps and whilst this has not been reported as 
problematic for large beads, smaller beads were easily lost whilst carrying out 
necessary washes with a micropipette. As more care is required when washing smaller 
beads, washing steps take longer to carry out and any advantages conferred with 
respect to time are lost. Accuracy also decreases if beads are lost as samples are no 
longer equivalent. Thus, all the advantages of the MTT method, that is, rapid, one- 
step, in situ viability estimates, were lost with the addition of washing steps.
The LDH assay did not prove to be a consistent method for determining 
numbers of dead cells. Also, due to upregulation of per cell function of several 
proteins due to encapsulation (Selden et al., 1999), it may be problematic to compare 
LDH release from monolayer cells to LDH release from encapsulated cells. A better 
comparison would be to compose a standard curve from different numbers of beads 
(Khattak et al., 2006).
MTT, LDH and alamarBlue™ assays are relatively easy and quick to carry 
out. LDH and alamarBlue™ are simple, one-step assays. Initial steps of the MTT 
assay can be carried out and then stored to enable multiple samples to be analysed 
together (Rokstad et al., 2002). All of these protocols require beads to be counted as 
an initial step.
Few measurements can be performed in a given time using trypan blue to 
estimate cell viability, as counts have to be performed sequentially. This makes it one 
of the more time consuming methods investigated. Although staining cells using the 
LIVE/DEAD® protocol is rapid and easily carried out, downstream steps i.e. 
microscopy and flow cytometry, require optimisation and care to be taken. Confocal 
microscopy and analysis via flow cytometry are more time consuming for this reason. 
As counting must be carried out immediately after trypan blue or LIVE/DEAD® 
staining, samples cannot be stored or analysed in parallel. This adds to the time taken 
to estimate cell viability.
All tested methods are cytotoxic or destructive apart from alamarBlue™ and 
LDH. Thus, it is theoretically possible to re-introduce beads into the culture flask after 
using alamarBlue™ and LDH assays leaving the population undiminished. 
Unfortunately, as plates containing beads are read without a lid, in a
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spectrophotometer, sterility is not ensured. Consequently the observed readings may 
be due to micro-organism contamination.
As the only method tested which allows measurements to be taken of 
individual beads, trypan blue does not require as many beads to estimate cell viability 
as the other methods. Trypan blue is also the only method tested which allows 
individual bead measurements to be taken as opposed to average values from multiple 
beads. Due to the many data points collected, flow cytometry is statistically better 
than any other method investigated. However, the disadvantage of this is that many 
encapsulated cells are needed for each time point. Three times more beads than can be 
produced in a single encapsulation experiment are required for each time point. This 
means that to produce data for 20 time points, 60 encapsulation experiments are 
required. LDH assay also required many more beads at each time point than those 
tested. The numbers of cells present in the 40 beads taken for each replicate were at 
the lower limit of detection for the assay. To give readings within the linear range of 
the LDH assay, 4000 beads should be taken for each time point. This is roughly half 
the beads produced in one encapsulation experiment.
The most appropriate detection method tested in combination with 
LIVE/DEAD® staining was confocal microscopy. Unfortunately, this detection 
method is extremely expensive as specialised equipment and personnel are required. 
For this reason, it was only used to take limited measurements. As trypan blue is very 
cheap, it was used more often to give estimates of viability. This compromise was 
deemed the most accurate method for estimating viability.
Difficulties in quantifying cells in aggregates were encountered when using 
methods requiring visual counts, i.e. trypan blue and LIVE/DEAD® staining. 
Although cell morphology is retained when LIVE/DEAD® staining is used in 
conjunction with confocal imaging, this is not true of trypan blue counts. Not only is 
cell cluster morphology unobservable when using trypan blue, large numbers of cells 
may be compressed when covered with a coverslip. This leads to an overestimation of 
dead cells and a decrease in estimated overall cell viability. However, it was observed 
that trypan blue diffused to the centre of aggregates, thus enabling accurate estimates 
to be made. Use of an o-ring to raise the coverslip would allow counts to be carried 
out without compressing the encapsulated cells, and thus more accurate counts would 
be obtained.
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Analysis via flow cytometry requires filtering steps which unavoidably 
exclude cell clusters. To remove the cells from beads, harsh pipetting steps are 
required which may cause dead cells to disintegrate or indeed kill fragile cells. This 
may help to explain the observation that percentage viability of encapsulated cells 
appeared lower when estimated using flow cytometry than with trypan blue (Section 
4.2.1.5 c). Other methods tested, with the exception of trypan blue, do not require 
beads to be dissolved prior to analysis and would hopefully be more accurate than 
FACs or trypan blue.
In summary, although the methods investigated have been used by other 
groups analyzing encapsulated cells produced using common techniques, only trypan 
blue and LIVE/DEAD® staining were appropriate for use with cells encapsulated 
using the MIG method. This was due to difficulties encountered when counting and 
washing smaller beads. In addition, there were various problems specific to each 
method. In these investigations the LDH assay was extremely unreliable and difficult 
to carry out. This is probably due to difficulties in counting beads. AlamarBlue™ was 
found to be inaccurate as microbial contamination is difficult to avoid and so any 
observed reduction may be due to micro-organism contamination.
Of all the methods tested, the adapted trypan blue exclusion method developed 
was deemed most suitable, as it proved to be both simple and rapid to carry out. There 
were difficulties accurately counting cell clusters at later time points. As cells became 
ruptured by the pressure applied with the coverslip, dye was able to pass inside. This 
led to possible overestimation of dead cell numbers. Encapsulated cells were labelled 
using LIVE/DEAD® stain and observed using confocal microscopy at various key 
time points. This allowed 3D cell morphology to be seen, which was impossible with 
trypan blue exclusion. Using both methods in conjunction allowed encapsulated cell 
viability to be estimated for extended time periods, cheaply and easily. This approach 
has also been employed by Choi et al. (2006).
4.3.2 Toxicity of developed encapsulation methods
Although two microfluidic methods were developed which produced alginate
beads, only one was deemed suitable for encapsulating cells. The external gelation 
method utilising 1-octanol for segmentation was extremely toxic to cells. Two groups 
have successfully used organic solvents in microfluidic circuits to produce calcium 
cross-linked alginate beads. Choi et al. (2007) observed GFP expression in alginate
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encapsulated yeast cells after encapsulation using hexadecane. GFP expression is not 
the most accurate or reliable way of demonstrating cell viability as GFP protein can 
still be seen in dead, fixed samples (Chalfie et a l , 1994). No further methods were 
used to establish cell viability, nor was viability shown for extended periods of time. 
Zhang et al. (2006) did not attempt to encapsulate cells using the previously discussed 
method (Section 3.4) utilising Cab in undecanol, indeed their next publication utilised 
soybean oil as an alternative to undecanol (Zhang et a l , 2007).
Viable cells could not initially be encapsulated using the MIG method. Upon 
testing, acetic acid was the only component used in the MIG method found to be 
cytotoxic. However, when sunflower oil was also present, this toxic effect was 
lessened. Therefore the presence of acetic acid, in isolation, could not completely 
explain why the encapsulation process should cause total cell death. In addition, acetic 
acid was seen to be toxic after five minutes of exposure, whereas, cells are exposed to 
acetic acid in sunflower oil for approximately 30 seconds whilst in the MicroPlant™. 
This short exposure is unlikely to result in complete cell death, as a 5 minute exposure 
to acetic acid in sunflower oil was shown to reduce viability by 50%.
^ i
It was proposed that excess Ca , produced from excess CaCC>3 and acetic 
acid, was responsible for the extreme toxicity of the MIG process. As only a finite 
number of cross-linking points are present in a given sample of alginate, only a finite 
amount of Ca2+ can be utilised for cross-linking. Once Ca2+, liberated from the CaC03  
by acetic acid, has been sequestered by all available alginate chains any excess will 
serve to increase the extracellular Ca2+ concentration. Excess Ca2+ influx into cells is 
known to trigger apoptosis (Burek et a l , 2003), thus causing cell death. A reduction 
in acetic acid and CaC03  concentrations allowed solid alginate beads to be produced. 
These concentrations were also suitable for encapsulating HEK293 cells with little 
loss of observed viability. This represents the first successful synthesis of calcium 
alginate beads containing live mammalian cells in a microfluidic chip (Workman et 
a l , 2007; Workman et al., 2008).
The MIG method with reduced concentrations of CaCC>3 and acetic acid was 
used to encapsulate four separate populations of HEK293 cells. All populations, 
except one, showed an initial decrease in viability followed by recovery and an 
increase in viability. In contrast, population 4, did not increase in viability, but 
continued to decrease. Population 4 was encapsulated last, but as all encapsulation 
experiments were carried out immediately following trypsinisation of cell populations
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all cells were exposed to alginate and CaCC>3 for the same length of time. The 
microfabricated device was not taken apart and cleaned between each encapsulation 
experiment, this may have affected the operation and hence the viability of this 
encapsulated cell population.
During this experiment some encapsulated cells appeared swollen in 
comparison to cells in other beads. This apparent swelling was not observed at all 
time points. Swelling of cells occurs in response to changes in osmotic pressure 
(Macknight, 1988). Changes in osmotic pressure bought about by the encapsulation 
process would be expected to cause cells to swell almost immediately after 
encapsulation. As the apparent swelling was observed 5 days after encapsulation it is 
unlikely to have been due to the encapsulation process. A more likely explanation is 
that cells were beginning to form the aggregates observed at later time points. These 
aggregates appeared to be groups of daughter cells produced by division and 
contained by the matrix near their parent cells. The increase in observed viability can 
be explained by this cell division producing increased numbers of viable cells.
Microfluidics-based devices have previously been used to encapsulate cells in 
lipid vesicles (Tan et al., 2006a) and droplets (He et al., 2005). However, these 
systems are more commonly used for analytical testing of cells/organelles or on-chip 
cell culture (Clausell-Tormos et a l , 2008; Koester et a l , 2008). Various micro­
systems have been developed to encapsulate cells in alternative hydrogels (for 
example; puramtrix (Um et al., 2008) and chitosan (Yang et a l , 2007)). Of the 
methods discussed previously (Section 3.4), very few groups successfully 
encapsulated live cells. Shintaku et al (2007) encapsulated murine erythroleukemia 
cells, but presented no short- or long-term viability data. Tan and Takeuchi (2008) 
encapsulated viable Jurkat cells using a similar internal gelation technique as outlined 
in this thesis. Kim et al (2009) successfully encapsulated mouse stem cells (PI9 EC), 
HepG2, and human breast cancer cells (MCF-7) in alginate beads and reported 
viability 0, 3 and 7 days after encapsulation. As such the MIG method is the only 
microfluidics-based continuous alginate bead production technique that has been 
shown to allow viable cell encapsulation with extensive viability data.
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Chapter 5. Encapsulation of a therapeutic cell line
5.1 In t r o d u c t io n
HEK293 cells were successfully encapsulated using the microfluidic internal
gelation (MIG) method developed in Chapter 3. After optimisation of component 
concentrations, minor adverse effects were observed upon cell viability. Although, 
HEK293 is a very robust, adherent cell line, it has no clinical significance. A cell line 
which expresses a therapeutic product was required to move closer to the goal of 
treating Parkinsonism in a rodent model.
The application of cell replacement to cure CNS disorders, such as 
Huntington’s and Parkinson’s disease, has largely been focussed upon the use of 
primary cells. Although there has been some success with tissue obtained from human 
foetuses (for example, Lindvall et al., 1992), the ethical and practical considerations 
concerning use of this cell source are restrictive. Use of immortalised cell lines is 
preferable for several reasons, including; unlimited supply, ease of maintenance, and 
precisely defined genotype and phenotype.
The clonal cell line PC 12 was derived from a rat pheochromocytoma; a 
vascular tumour of chromaffin tissue, of the adrenal medulla (Greene and Tischler, 
1976). This cell-line synthesizes, stores and secretes clinically useful catecholamines, 
including dopamine (DA) and norepinephrine (NA) (Greene and Rein, 1977). 
Secretion of NA and DA by PC 12 cells is bought about by depolarizing 
concentrations of K+ by similar mechanisms to those in normal chromaffin cells 
(Greene and Rein, 1977). PC 12 cells transplanted into the brains of Sprague Dawley 
rats stained intensely for tyrosine hydroxylase (TH), the first enzyme in the 
biosynthesis of dopamine (Levitt et al., 1965), thus proving that dopamine is still 
expressed (Jaeger, 1985).
Although immortalised cell lines are preferable to primary cells, the major 
disadvantage to their use is tumour formation. PC 12 cells are no exception and have 
been observed to form tumours after transplantation into the brains of Sprague 
Dawley rats (Jaeger, 1985). Grafts grew up to 60 times their original size within two 
months of transplantation. This effect was seen only when large pellets (1.5 -  3mm) 
of cells were transplanted as opposed to cell suspensions. PC 12 cells were observed to 
be destroyed when transplanted without encapsulation or immunosuppression into 
guinea pig brain (Aebischer et al., 1991a).
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It has been proposed that undesirable cell division could be controlled by pre- 
treatment with mitotic inhibitors (Gash et al., 1986) or by integration of temperature 
sensitive Large T antigen of SV40, which halts cell division at 37°C (Lundberg et al., 
1996). Polymer encapsulation has also been suggested as a means to prevent cell line 
overgrowth (Winn et al., 1991). Encapsulation of PC 12 cells for implantation into the 
brain has been investigated with both hollow fibre-based technology, so called 
macroencapsulation (Aebischer et al., 1991b), and microencapsulation within small 
polymer microspheres (for example, Roberts et al., 1996).
The MIG method was used to encapsulate PC 12 cells in calcium cross-linked 
alginate beads. Maximal viability of the cells was paramount and long term effects of 
encapsulation were investigated. Levels of the therapeutic molecule dopamine were 
measured to ensure encapsulation did not adversely affect PC 12 cells ability to release 
dopamine and that the bead structure did not prevent dopamine from diffusing out of 
the beads.
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5.2 R e su l t s
5.2.1 Optimisation of the MIG method for encapsulation of PC12 cells
PC 12 cells were encapsulated using the previously developed method (Section
3.3.3), which was non-cytotoxic to HEK293 cells (Section 4.2.2.2). As PC 12 cells 
grow in small aggregates, trituration was required to obtain a single cell suspension.
The functional fluid was composed of 50mM CaC03  suspended in sodium 
alginate solution (2% w/v). Following trituration, PC 12 cells were resuspended in the 
previously prepared functional fluid. The reactive fluid was composed of acetic acid 
(50mM) dissolved in sunflower oil and the shielding flow was composed of sunflower 
oil. After encapsulation using these conditions >90% of the encapsulated PC 12 cells 
were observed to be dead when stained with trypan blue (Section 4.2.1.4).
Cytotoxicity testing was carried out as described in Section 2.3.3, to 
investigate the effect of the components used in the encapsulation protocol. PC 12 
cells were triturated and split into three, with one third being resuspended in D- 
MEM/F12 medium as a control, one third resuspended in 50mM acetic acid in 
sunflower oil, and the remaining third resuspended in 50mM acetic acid in D- 
MEM/F12 medium. Samples were taken at 1, 5 and 10 minute intervals and viability 
was estimated using trypan blue exclusion (Section 4.2.1.4). Viability estimates are 
shown in Figure 5.1.
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Figure 5.1: Viability of PC12 cells exposed to components of the MIG method. Graph showing 
effect upon viability of PC 12 cells exposed to medium (■), 50mM acetic acid (□) and 50mM acetic 
acid in sunflower oil (X). Viability was estimated using trypan blue exclusion. Error bars show 
standard error of the mean of 3 replicate samples
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In a separate experiment, triturated PC 12 cells were observed to survive for 2 
hours in alginate solution (2% w/v) with 50mM CaCC>3 . Further time points were not 
tested as it was not expected that cells would be exposed to the functional fluid for 
longer than the duration of an encapsulation experiment, i.e. ~ 20 minutes.
PC 12 cells showed a 13 percentage point decrease in viability upon exposure 
to acetic acid in medium, and a 42 percentage point decrease in viability upon 
exposure to acetic acid dissolved in sunflower oil. Cells were exposed to acidified oil 
for approximately 30 seconds in the MicroPlant™. Upon exiting the MicroPlant™, 
encapsulated cells remained in the acidified oil for a further 5 minutes prior to 
removal into medium. It was postulated that prolonged exposure to acidified oil after 
exiting the MicroPlant™ might account for the reduced viability of encapsulated cells 
observed.
In order to increase PC 12 viability upon encapsulation, the acid concentration 
needed to be decreased and product beads needed to be rapidly removed from 
acidified oil. A new chip was designed to transfer product beads into medium on-chip. 
Two new channels were introduced via two T-junctions at right angles to the exit 
channel. Medium was introduced via these two additional channels. At sufficiently 
high flow rates (>50ml/h) alternating segmentation of the oil occurred (Figure 5.2). At 
these high flow rates, hydrogel spheres overcame the surface tension of the oil and 
broke through into the aqueous medium. The additional flow of medium was referred 
to as the flushing flow.
A B
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Figure 5.2: Schematic diagram representing alternating segmentation at double T-junction.
Flushing flow is represented in pink. Orientation of flow is specified by arrows
Medium
Oil
Medium
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As the new design required more fluid inputs than were available with the 
MicroPlant™ used thus far, a new MicroPlant™ was designed by Q Chip. The new 
MicroPlant™ was rectangular as opposed to circular, and incorporated the same 
features as those described for the circular MicroPlant™ (Section 2.2.1). A 
rectangular shape was chosen to allow a longer straight channel to be incorporated 
into circuit designs (Appendix 2). The surface area of the rectangular MicroPlant™ 
was 7.6 times greater than the circular MicroPlant™. This allowed a longer channel 
length after the junction; 3900mm for the rectangular as opposed to 160mm for the 
circular MicroPlant™ (compare Chip 1 to Chip 3 in Appendix 1). The new flows 
were introduced after 2840mm, 1060mm before the exit. The new chip is shown 
schematically in Figure 5.3, with the actual circuit diagram shown in Appendix 1.
Sunflow er oil and  
a c e tic  acid M edium
Sunflow er oil
A lginate solution  
+ C aC O s
Sunflow er oil
Chip num ber 4
Flow  rates:
Functional fluid = 0 .75m l/h  
R eactiu s fluid = 10m l/h  
Carrier fluid = 25m l/h  
Flushing flow = 70m l/h
C hannel d im en sion s:  
Before junction  = 300p m  
After junction  = 6 00p m
Sunflow er oil and  
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M edium
Figure 5.3: Schematic diagram showing the shielded junction with additional flushing flow for 
introducing aqueous medium. Functional fluid (shown in blue) was composed of alginate solution 
(2% w/v) containing 40mM CaC03, shielding flow (shown in red) was composed of sunflower oil and 
reactive flow (no shading) was composed of sunflower oil containing 40mM acetic acid. Flushing flow 
was D-MEM/F12 medium (shown in pink). Flow rates and channel dimensions are shown. Orientation 
of flow is specified by arrows
Using chip number 4 and the new MicroPlant™, beads were made using 
varying concentrations of CaC0 3  and acetic acid. Narrow range pH paper capable of 
measuring pH in the range 3.0 to 7.0 was used to measure pH of medium exiting the 
device. Flow rates were as described in Figure 5.3. Observations of beads produced 
using differing concentrations of acetic acid and CaCOs are shown, along with pH of 
exiting medium, in Table 5.1.
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Concentration
0 fCaCO3
(mM)
Concentration 
of acetic acid 
(mM)
Observations
pH of 
exiting 
medium
50 50 Solid beads 6.0
50 45 Solid beads 7.0
50 40 Beads were opaque due to excess CaC03 7.0
40 40 Solid beads 7.0
50 20 Beads not solid Notmeasured
Table 5.1: Optimisation of components used to encapsulate PC 12 cells. Beads were produced 
using 2% (w/v) alginate. pH was measured using narrow range pH paper
Acetic acid concentration was reduced, which led to the pH of exiting medium 
becoming neutral. CaCC>3 concentration was also reduced to limit excess CaCC>3 in 
the beads. The final concentrations tested were 40mM for both acetic acid and 
CaCC>3, as these allowed solid beads to be produced with a neutral final pH.
PC 12 cells were encapsulated using the optimised concentrations. The 
functional fluid used was composed of 40mM CaCC>3 suspended in alginate solution 
(2% w/v). PC 12 cells were triturated and resuspended at a final cell concentration of
n
1x10 cells per ml in the functional fluid. Chip number 4 was used with the reactive 
flow composed of 40mM acetic acid in sunflower oil and the shielding flow 
composed of sunflower oil. D-MEM/F12 medium was introduced via the flushing 
flow. Viable PC 12 cells were encapsulated using the optimised component 
concentrations and the new chip design incorporating a flushing flow (Figure 5.4A). 
Cells were not successfully triturated to a single cell suspension as cell aggregates can 
be seen in the product beads. The average diameter of these beads (n=10) was 
measured to be 378±10pm (Figure 5.4B). The CV was 2.8%.
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Figure 5.4: PC12 cells encapsulated in calcium cross-linked alginate beads. A) A light microscope 
image of encapsulated PC 12 cells in calcium cross-linked alginate beads. It is possible to observe small 
cell aggregates present within the ionically cross-linked beads. Scale bar represents 250pm. B) 
Histogram of beads represented in A; grey bars show measured data, with black line representing 
normal distribution. Mean bead diameter was 378±10pm. Distribution was considered to be 
approximately normal (A2=0.39, p > 0.303)
The viability of produced encapsulated cells was estimated using the adapted 
trypan blue exclusion method (Section 4.2.1.1) over a 50 day period (Figure 5.5). 
Percentage viability was seen to decrease gradually between encapsulation and day 
21, after which point a gradual increase was observed. A substantial decrease in 
viability was observed between day 35 and the next time point at day 50. As there 
were a limited number of beads, no further time points were tested between these two.
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Figure 5.5: Graph showing percentage viability of encapsulated PC12 cells. Pre-encapsulation 
viability was 74%. Viability was estimated using the adapted trypan blue method. Error bars show 
standard deviation of 4 individual beads
Confocal images were taken of the encapsulated PC 12 cells after 
LIVE/DEAD® staining 24 hours, 21 days and 60 days after encapsulation (Figure 
5.6). Cell clusters were observed at 24 hours and 21 days. By 60 days, flattened discs 
of cells could be seen. Viability, when estimated using trypan blue exclusion, was 
seen to be lower than that estimated from confocal images. As can be seen from 
confocal images, encapsulated cells showed good viability at all time points tested. 
However, cell proliferation was limited and cell numbers were not observed to 
increase substantially.
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Figure 5.6: Confocal images showing encapsulated PCI 2 cells after LIVE/DEAD® staining. A) 24
hours after encapsulation, B) 21 days after encapsulation, C) 60 days after encapsulation (dotted red 
lines show bead boundary). Green fluorescence is emitted from intracellular esterase-converted calcein 
in live cells, whereas red fluorescence is emitted from ethidium homodimer present in the nuclei of 
dead cells. Scale bars represent 100pm
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5.2.2 Optimisation of cell concentration
It was hypothesised that changes to initial cell concentration at the time of
encapsulation may affect cell proliferation. To investigate this hypothesis, varying cell 
concentrations were encapsulated: 1x10 cells per ml (referred to as low initial 
density, Figure 5.7A-C), 2xl07 cells per ml (referred to as medium initial density, 
Figure 5.7D-F) and 4x107 cells per ml (referred to as high initial density, Figure 5.7G- 
I). Viability was estimated using trypan blue prior to encapsulation, and at 1, 7, 10 
and 14 days after encapsulation. Viability was observed to remain high and consistent 
over time (Figure 5.8). However, the low initial density population showed a slight 
decrease in viability which increased to a similar level to the other encapsulated 
populations after 10 days.
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Figure 5.7: Encapsulated PC12 cell populations. A-C: Low initial cell density, D-F: medium initial cell density, G-I: high initial cell density. A, D and G: Day of 
encapsulation, B, E and H: 7 days after encapsulation, C, F and I: 14 days after encapsulation. Scale bar represents 250pm
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Figure 5.8: Graph showing effect upon encapsulated PC12 cell viability as a function of initial 
cell concentration. Initial cell concentrations were lxlO7 (•), 2xl07 (■) and 4xl07 (A ) cells/ml. Pre­
encapsulation viability was 68%. Viability was estimated using the adapted trypan blue method. Error 
bars show standard deviation of 4 individual beads
Although cell proliferation was observed in all three encapsulated populations 
(Figure 5.9), higher initial concentrations of cells allowed increased cell expansion. 
The rate of increase in cell numbers was similar for the two higher initial cell 
concentrations (medium = 41.6 and high = 47.6 cells per day), whereas the rate of 
increase was lower (18.9 cells per day) for the low initial cell concentration (Table 
5.2).
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Figure 5.9: Graph showing increasing numbers of PC12 cells over time. Differing initial cell 
concentrations were encapsulated, lx l07 (•), 2xl07 (■) and 4xl07 (A ) cells/ml. Viability was 
estimated using the adapted trypan blue method. Mean number of cells from 4 beads was calculated 
and error bars show standard error of the mean. Asterisks (*) denote estimated data from cell 
concentration and bead diameter
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Initial cell concentration Rate of increase of cell numbers
(cell/ml) (cells/day)
Low (lx l O') 18.9
Medium (2xl07) 41.6
High (4xl07) 47.6
Table 5.2: Rate of cell increase for three different cell encapsulation concentrations. Values 
calculated from linear fit of plot of cell numbers against days after encapsulation. R2 values in all cases 
>0.94
5.2.3 Dopamine expression
An ELISA to detect dopamine was carried out on the above populations
(Section 5.2.2) and single cell suspensions of PC 12 cells. After 14 days in culture, 50 
beads were taken from each population and incubated for 2 hours with D-MEM/F12 
medium (600pl), as were single cell suspensions. All medium was removed and wells 
were washed with Hank’s balanced saline solution (HBSS). To detect basal 
expression HBSS (600pl) was added to wells. To detect induced expression HBSS 
with 56mM KC1 (600pl) was added. Beads and medium or cells and medium were 
incubated for 45 minutes, after which time medium was removed and frozen. An 
ELISA to detect dopamine was carried out according to the manufacturer’s 
instructions (Section 2.3.5) on lOOpl of defrosted medium and standard dopamine 
samples provided by the manufacturer. Technical replicates (two) were carried out for 
each sample and standard. Absorbance of the wells was measured at 450nm with 
background subtraction at 630nm.
The standard curve produced was linear between 100 and 6400 pg of 
dopamine (Figure 5.10). A linear best fit line was fitted between these points (y=- 
0.3587x + 1.8924). The R2 value was 0.9682. The slope of this line gives the 
relationship between log dopamine concentration and absorbance reading. Dopamine 
concentration of unknown samples was then calculated from absorbance.
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Figure 5.10: Graph showing absorbance obtained with standard concentrations of dopamine.
Dopamine ELISA was carried out on standards provided by the manufacturer. Absorbance readings 
were taken at 450nm with background subtraction at 630nm
Basal dopamine secretion was undetectable from the samples taken both from 
beads and single cell suspensions. After potassium induction, dopamine was 
detectable in all bead samples (Table 5.3), but not from cell suspensions. The 
measured values all fell within the range of the standard curve.
Initial cell concentration Number of cells present Dopamine secretion
(cell/ml) ± SD (day 14) (pg/bead/45minutes)
Low (lxl07) 366±51 10.5±1.0
Medium (2xl07) 793±108 12.4±1.2
High (4xl07) 1058±79 12.7±1.2
Table 5.3: Amount of dopamine, secreted per bead, for three different initial encapsulation 
concentrations. Cells were allowed to grow within beads for 14 days before measurements were taken. 
Mean number of cells per bead for 4 beads was counted. Beads were incubated for 45 minutes before 
ELISA to detect dopamine secretion was carried out in duplicate. Confidence interval of dopamine 
secretion reported is error of ELISA assay as quoted by manufacturer (10%)
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5.3 Discussion
As PC 12 cells grow slowly (doubling time is ~92 hours (Greene and Tischler, 
1976) compared with HEK293 at ~26 hours (Schwarz et a l , 2006)), it takes a long 
time to expand enough cells to work with. Consequently, smaller scale experiments 
were carried out than those utilising HEK293. In addition, as more cells were 
encapsulated cell counts took much longer and were less accurate as trypan blue is 
taken up by viable, as well as non-viable cells, after prolonged exposure.
5.3.1 Optimisation of microfluidic encapsulation of PC12 cells
Initial attempts to encapsulate PC 12 cells using the MIG method previously
described (Section 3.3.3) were unsuccessful as cells were not viable after the process. 
Viable PC 12 cells were successfully encapsulated after optimisation of the method. 
Cytotoxicity testing showed that acetic acid in combination with sunflower oil was 
toxic to PC 12 cells (42 percentage point decrease in viability), whereas acetic acid in 
isolation did not have such a pronounced effect (13 percentage point decrease in 
viability). Sunflower oil may affect PC 12 cell membranes making cells more 
susceptible to acetic acid. Toxicity may have been decreased by using different types 
of acid and oil, but it was decided to investigate reducing cell exposure to acid.
The effects of acidified oil upon PC 12 cells were observed after 10 minutes of 
exposure during cytotoxic testing. Although cells were exposed to acidified oil for 
less than 30 seconds within the MicroPlant™, encapsulated cells were collected in the 
acidified oil for a further 5 minutes prior to transfer into medium. It appears that this 
time period is too long for cells to remain viable, as under these conditions 
encapsulation was fatal to cells.
Estimation of pH of exiting medium in this experiment was estimated using 
narrow range pH paper, range 3-7. It is acknowledged that this was not the most 
accurate range to choose and that pH paper in the range 6.8-8.2 would have been 
more appropriate for the physiological experiments carried out. Obviously, use of a 
pH meter would give even more accurate results. However, the amounts of medium 
exiting from the device were too small to be measured in this way.
To enable encapsulation of viable PC 12 cells the exposure of cells to acidified 
oil needed to be reduced. This was achieved by decreasing the acid concentration 
utilised in the MIG method and reducing the amount of time prior to transferring
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beads into medium. A new circuit was designed to rapidly remove encapsulated cells 
from the acidified continuous phase into medium, on-chip.
An additional flow of medium, termed the flushing flow, was introduced into 
the circuit via two T-junctions at right angles to the exit channel. At empirically 
determined, rapid flow rates (>50ml/h), segmentation between the continuous phase 
and the flushing phase occurred. Upon coming into contact with another fluid stream 
liquid droplets will coalesce with the introduced stream. To prevent coalescence of 
liquid alginate droplets with the flushing flow, the additional T-junctions were 
positioned such that solid calcium cross-linked alginate beads had formed prior to 
coming into contact with the aqueous phase. After the introduction of the flushing 
flow, solid calcium cross-linked alginate beads were observed to overcome the 
surface tension of the oil phase and thus enter the aqueous fluid segments.
In combination with the new circuit design, the minimum acid concentration 
that permitted production of solid beads with no excess CaCC>3 present was 40mM. It 
is interesting to note that alterations to the microfluidic circuit require modifications 
to the acetic acid and CaC03  concentrations. Although conditions required for a 
chemical reaction are known/constant at the macro scale, this is obviously different at 
the micro scale. Both the reduction in acetic acid concentration and the modified chip 
design allowed viable PC 12 cells to be encapsulated within alginate beads using a 
microfabricated device.
5.3.2 Behaviour of encapsulated PC 12 cells
Under culture conditions PC 12 cells grow in small clumps (Greene and
Tischler, 1976). This is also observed in encapsulated cell populations, and is 
consistent across a number of investigated polymers, including alginate (Winn et al., 
1991; Zielinski and Aebischer, 1994), agarose/Poly(styrene sulfonic acid) (Miyoshi et 
a l , 1996) and hydroxyethyl methacrylate-methyl methacrylate copolymer (HEMA- 
MMA) (Roberts et al., 1996). PC 12 cells encapsulated using the MIG method also 
formed small clusters and eventually grew to form disc-like structures.
All the above groups, except one (Miyoshi et a l , 1996), observed cell necrosis 
within encapsulated cell clusters after two weeks of encapsulation. Cell necrosis was 
observed with PC 12 cells encapsulated using the MIG method after 60 days of 
culture. Necrosis is thought to occur at the centre of cell clusters due to limited
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exchange of nutrients and waste products when cell aggregates reach >200pm in 
diameter (Uludag et al., 1993).
The group (Miyoshi et al., 1996) which did not observe cell necrosis within 
encapsulated cell clusters investigated beads with much smaller (300 - 600pm) 
diameters than other groups (>600pm). Beads produced using the MIG method were 
also smaller (-370pm) than those produced by alternative methods. As beads become 
larger the matrix hinders diffusion of nutrients and waste materials (Ogbonna et al., 
1991). Smaller beads are seen to be advantageous as diffusion can still occur and cells 
remain viable for longer.
Initial observations of PC 12 cells encapsulated using the MIG method showed 
that although viability was consistent over time, cell numbers did not substantially 
increase. Confocal images taken of beads stained with LIVE/DEAD® reagents at 1 
and 21 days after encapsulation are virtually indistinguishable. Cell clusters did not 
appear to increase in size between encapsulation and 21 days later. PC 12 cells 
encapsulated at lxlO7 cells per ml did not form the large cell aggregates observed 
with encapsulated HEK293 cells (Section 4.2.3).
There is evidence that microstructure within beads effects cell growth and 
expression of biomolecules (Stabler et al., 2001). Increased osmotic pressure is 
known to decrease cell growth rate and affect protein expression in batch culture of 
baby hamster kidney cells (Yi et a l, 2004). Mouse insulinoma cells exhibited 
decreased growth rates when encapsulated in high G content alginate beads, and solid 
core beads reduced growth rates more than liquid core beads (Constantinidis et al., 
1999). Only G residues in alginate form bonds with divalent ions, and the strength of 
the interaction increases with frequency and length of G blocks (Section 1.7.2.1). 
Thus, high G content alginate beads are stronger and more rigid than beads composed 
of high M content alginate. The increased rigidity of high G content alginate leads to 
increased stress or pressure exerted on encapsulated cells. Decreased growth rate 
occurs when cells are encapsulated in alginate beads with enhanced stability,
* r*  2 +specifically Ba treated or those constructed of alginate epimerised to increase the G 
content (Rokstad et al., 2003). Conditions within beads produced using the MIG 
method must be unsuitable for PC 12 cells to proliferate at low cell concentrations. 
The internal structure of beads produced using the MIG method will be investigated 
in the following chapter.
124
C h a p t e r  F iv e
It was postulated that increasing initial cell density may increase subsequent 
cell proliferation, as Roberts et al observed such an effect with PC 12 cells 
encapsulated in HEMA-MMA capsules. High (4xl06 cells per ml) and low (4xl05 
cells per ml) initial cell densities were encapsulated and cell numbers estimated using 
MTT at various time periods over 28 days. Both encapsulated cell populations 
exhibited an initial decrease in viable cell numbers. Viable cell numbers were 
observed to increase in the high density population from day 3 until a plateau at day 
14. In contrast, the low density population entered a quiescent period from day 7 to 
day 21, followed by an increase in cell numbers from day 21 to day 28 (Roberts et a l, 
1996).
Similar effects were observed in PC 12 cells encapsulated using the MIG 
method. An increase in the rate of cell proliferation was observed when initial cell 
density was doubled from lx l07 to 2xl07 cells per ml. However, the rate of cell 
proliferation did not increase substantially when the initial cell density was doubled 
from 2xl07 to 4xl07 cells per ml. Again, conditions within the beads may not be 
conducive to enhanced cell growth or cells may have reached their proliferation limit. 
Beads with low initial cell concentrations (lxlO7, Section 5.2.2) were observed to 
decrease in cell viability until 21 days, in agreement with Roberts et al. (1996).
PC 12 cells are known to form tumours (Jaeger, 1985); therefore, decreased 
cell division may be advantageous in preventing uncontrolled growth and tumour 
formation. However, the rate of cell proliferation is not the most important factor 
when encapsulated PC 12 cells are used to treat neurodegenerative diseases, rather that 
the cells must continue to secrete dopamine.
Dopamine secretion was observed after PC 12 cells were encapsulated using 
the MIG method. However, no dopamine secretion was detected in suspensions of 
PC 12 cells. Thus, this encapsulation method does not affect PC12’s ability to secrete 
dopamine and the encapsulation matrix does not prevent dopamine from diffusing 
from the beads. In addition, encapsulation and subsequent aggregate formation 
enhances dopamine secretion compared with growing cells in a monolayer.
A summary of studies discussed above (Table 5.4) shows that researchers 
detect varying amounts of dopamine secreted from encapsulated cells. An order of 
magnitude difference was reported between the lowest amount of dopamine released 
(4.3 pg/capsule/15 minutes) and the highest (1.5 ng/capsule/15 minutes). This is most 
probably due to the differing cell numbers present in the capsules produced and the
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diverse range of matrix materials employed. It is interesting to note that the group 
which reported the lowest dopamine release did not observe large cell aggregates or 
necrotic areas (Miyoshi et a l , 1996).
Although PC 12 cells encapsulated using the MIG method secreted dopamine 
after encapsulation, the release observed is roughly in line with the lower reported 
values (Table 5.4). This may be due to smaller cell aggregates forming than those 
observed in studies where more dopamine was observed. Tyrosine hydroxylase (TH) 
is the first and rate-limiting enzyme in the biosynthesis of dopamine (Levitt et al., 
1965). Growing PC2 cells at high densities (>105 cells/cm2) increases TH activity and 
specific cell contact between PC 12 cells is required for this effect to be seen (Lucas et 
a l , 1979). In addition, aggregation enhances catecholamine secretion in cultured cells 
(Baldwin and Saltzman, 2001). Larger aggregates (16,600±700pm2) produce more 
dopamine, in a shorter time period (6 days), than smaller aggregates (2800±50pm2, 
taking 10-12 days). Secretion of dopamine appears to be independent of cell number 
and instead is related to aggregate size. In this study, there was no significant increase 
in dopamine secretion between medium and high initial cell concentration 
populations. The level of cell aggregation may have been similar between the two 
populations even though cell numbers were different.
Cell-binding domains have been used to enhance cell binding to biomaterials. 
Increased PC 12 cell growth and dopamine secretion was observed when cells were 
encapsulated in polymers incorporating the pentapeptide Gly-Arg-Gly-Asp-Ser (Park 
et a l , 2004) or Arg-Gly-Asp (Park and Yun, 2004; Orive et a l , 2009). Further 
investigation into extra-cellular matrices to enhance cell attachment or encapsulation 
of pre-formed aggregates may help to improve dopamine secretion from encapsulated 
PC12 cells.
In human patients with Parkinson’s disease, the daily dose of L-dopa is 
roughly lg, although, as less than 1% penetrates the CNS due to limited 
bioavailability (Gilman, 2001), only lOmg of DA is required daily. This would 
require implantation of ~37,000 beads produced using the MIG method (~2.4ml in 
volume). A standard amount of dopamine required to see behavioural effects in a 
rodent model of Parkinson’s disease has not been reported. Only two of the studies 
discussed above implanted encapsulated PC 12 cells into rodents, but both observed 
behavioural effects. Winn et al. (1991) implanted 7 beads into rats which secreted 
0.18pg of dopamine/24 hours. An equivalent amount of dopamine would be provided
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by 700 beads produced using the MIG method (45pi in volume). Aebischer et al. 
(1991b) implanted 14 beads into rats which secreted 0.053 pg of dopamine/24 hours. 
An equivalent amount of dopamine would be provided by 200 beads produced using 
the MIG method (13pl in volume).
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Encapsulated cell No of cells/bead Bead Dopamine release
Bead matrix concentration
(cell/ml)
(at
encapsulation)
diameter
(pm) Basal K* induced
Ehringer and 
Homykiewicz Post mortem dopamine levels in the caudate nucleus
Range 2.7-5.5 pg/g 
Mean 3.5 pg/g
270
pg/capsule/15minutes2 
1.5
Winn et al 
Zielinski and
APA
APA
lxlO6
lxlO7
300-500 560±65 100 pg/capsule/hour1 
NDAebischer ng/capsule/1 Sminutes1
Miyoshi et al Agarose/PSSa 3x10s 300 300-600
2.27±0.18 
pg/capsule/15minutes
4.30±0.35 
pg/capsule/15minutes3
Roberts et al HEMA-MMA 4x10s 270 660±44 ND 110 pg/capsule/hour1
4xl06 2700 660±44 ND 856 pg/capsule/hour1
Current study Alginate lxlO7 100* 370±10 ND 10.5±1.0pg/bead/45minutes1
2xl07 200* 370±10 ND 12.4±1.2pg/bead/45minutes1
4x107 400* 370±10 ND 12.7±1.2pg/bead/45minutes1
. APA = alginate-PLL-alginate
2 weeks after encapsulation pSSa = poly(styrene sulfonic acid)
Peak dopamine expression at 2 days after encapsulation HEMA-MMA = Hydroxyethyl methacrylate-methyl methacrylate
3 weeks after encapsulation ND = not detectable 
* Cell numbers estimated from cell concentration and bead diameter
oo Table 5.4: Summary of studies examining encapsulated PC12 cells and dopamine expression
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Chapter 6. Production of alginate beads suitable for 
implantation into the central nervous system
6.1 Introduction
Implantation of cells into the brain has been carried out in an attempt to treat
several diseases, for example; CNS disorders, such as Huntington’s disease 
(Borlongan et a l, 2008), Parkinson’s disease (Ando et a l, 2007), and brain tumours 
(Kuijlen et a l, 2006). Stereotactic surgery is used to implant cell suspensions, small 
cell aggregates or encapsulated cells in precisely defined areas of the brain through 
use of three-dimensional coordinates. Provided that a small cannula (<2.5mm outer 
diameter) is used to introduce the cellular material, this technique is minimally 
invasive. Smaller cannulae (50-70pm outer diameter) have been shown to cause less 
damage than large cannulae (500pm outer diameter) (Nikkhah et a l, 1994).
It has been found that beads with a diameter smaller than 200pm are needed to 
ensure efficient loading of a 500pm inner diameter cannula (Ross and Chang, 2002). 
Only a few of the groups implanting encapsulated cells into animal brains utilise 
beads of this size, however, those that do report superior properties for smaller beads. 
For example, Ross and Chang (2002) reported an increased packing density of small 
beads (100-200pm in diameter) compared with medium-sized beads (500-700pm in 
diameter), which resulted in an increased number of cells and more protein expression 
per volume of beads. The same beads were also found to be more resistant to osmotic 
pressure. Other studies have found small beads to be more biocompatible (Robitaille 
et a l, 1999), have improved oxygen transport properties (Ogbonna et a l, 1991) and 
reduced response time of encapsulated islets to glucose (Chicheportiche and Reach, 
1988).
An important property for therapeutically useful encapsulated cells is their 
ability to survive after implantation. Calcium cross-linked alginate beads are known to 
be unstable in biological environments (LeRoux et a l, 1999, Section 1.7.2.1). In 
physiological solutions, ion-exchange of Ca2+ with Na+ occurs, as well as calcium 
sequestration by various species, such as phosphate, both of which lead to bead 
dissolution. Additionally, bead properties may alter through processes such as ion- 
exchange, which causes osmotic swelling and leads to larger pore sizes (Thu et a l, 
1996b).
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Various approaches have been employed to stabilise alginate beads prior to 
implantation (Sections 1.7.2.4 and 1.8). The simplest of these is use of barium as an 
alternative cross-linking ion. Barium ions have a stronger affinity for alginate than 
calcium ions, and as such form stronger bonds and more rigid gels (Smidsrod, 1974). 
High concentrations of barium are cytotoxic, as K+ channels are inhibited. However, 
protein biosynthesis is not affected at concentrations of barium below lOmM (Howell 
and Tyhurst, 1976) and so concentrations below this level are preferred.
The most commonly investigated technique for producing stabilised alginate 
beads is production of a polycation/alginate complex membrane around the beads. 
Since its inception in 1980 by Lim and Sun, the most extensively studied polycation 
for this purpose is poly-L-lysine (PLL). As most polycations are cytotoxic and 
immunogenic, an additional alginate layer is applied to the beads, generating alginate- 
PLL-alginate (APA) capsules, to prevent tissue fibrosis. Although APA capsules are 
resistant to destabilisation in biological systems, as the liquefied core is contained by 
a membrane, the mechanical stability is decreased due to increases in osmotic 
pressure (Thu et a l , 1996a).
Investigations into the concentration of alginate present within individual 
beads led to the proposal of two alternative structures for alginate beads; 
homogeneous and non-homogeneous (Skjakbraek et a l, 1989). Homogeneous beads 
are characterised by an equal concentration of alginate throughout the bead (equal 
alginate density), whereas non-homogeneous beads have a higher concentration of 
alginate near the surface of the bead (variable alginate density, Figure 6.1). Non- 
homogeneous beads are formed as alginate molecules diffuse towards the droplet 
surface where the concentration of calcium ions is highest. Homogeneous beads are 
formed by disrupting diffusion of alginate molecules to the surface by addition of 
non-gelling ions, such as sodium. External gelation (Section 1.7.2.2) typically forms 
non-homogeneous beads, whereas homogeneous beads are typically formed through 
internal gelation (Section 1.7.2.2). Non-homogeneous beads are deemed more suitable 
for implantation as they have a lower porosity and increased stability (Thu et a l, 
1996a) compared to homogeneous beads.
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Figure 6.1: Comparison of alginate gradient in homogeneous and non-homogeneous alginate 
beads. Homogeneous beads are characterised by an equal concentration of alginate throughout, 
whereas non-homogeneous beads are characterised by a higher concentration of alginate at the surface, 
with a decreasing alginate concentration towards the centre. Note that homogeneous beads have a 
lower concentration of alginate at the surface than non-homogeneous beads for beads made with the 
same concentration of alginate. Adapted from Uludag et al. (2000)
Adaptations to the method previously developed (Section 3.3.3) were made to 
enable smaller beads to be manufactured using a microfabricated device. The inner 
diameter of the cannula used for implantation into rats’ brains was 300pm, requiring 
beads with diameters of 100-250pm. After some method development the robust, test 
cell line HEK293 and the therapeutic cell line PC 12 were encapsulated to show that 
the method developed to decrease the size of beads was suitable for encapsulating 
cells.
Barium cross-linking and polycation secondary coatings were investigated in 
an attempt to stabilise calcium cross-linked alginate beads produced using the MIG 
method. The effect of barium on encapsulated cells was evaluated by observing cell 
viability. The internal structure of beads produced using the MIG method was 
observed via confocal microscopy. Adaptations to the production method were 
investigated to produce small, stabilised alginate beads. The small, stabilised alginate 
beads produced were implanted into rats’ brains to investigate in vivo stability.
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6.2 Results
6.2.1 Production of small (<200pm in diameter) alginate beads
6.2.1.1 Adaptations to microfluidic process to produce small beads
Beads with diameters measuring less than 200pm were required to implant
using a cannula; the target size is referred to as “small”. To produce beads with 
smaller diameters, channel dimensions were decreased to 200pm wide x 100pm deep 
(chip number 5; Figure 6.2, Appendix 1). Smaller diameter channels led to increased 
pressure within the device, which made fluids more difficult to control. For this 
reason it was more problematic to prevent premature alginate gelation in these smaller 
channels than the larger ones used previously.
Sunflower oil and  
a ce tic  acid
Sunflower oil
A lginate solution  
+CaCC>3
Sunflower oil
Chip num ber 5
Flow rates:
Functional fluid = 0 .1m l/h  
R eactive fluid = 4m l/h  
Carrier fluid = 1m l/h
Channel d im en sion s:
Before junction = 200p m  x 100pm  
After junction = 200p m  x 200 |jm
Sunflower oil and  
a ce tic  acid
Figure 6.2: Schematic diagram showing the shielded junction and its use for producing calcium 
alginate beads via internal gelation. Functional fluid (shown in blue) was composed of alginate 
solution (2% w/v) containing 40mM CaC03, shielding flow (shown in red) was composed of sunflower 
oil and reactive flow (no shading) was composed of sunflower oil containing 40mM acetic acid. Flow 
rates and channel dimensions are shown. Orientation of flow is specified by arrows
By constricting the channels through which the continuous phase entered and 
decreasing the dimensions of the channel through which the functional fluid was 
introduced, oil was prevented from flowing into the channel containing the functional 
fluid. In this way premature cross-linking of the functional fluid was prevented. In 
addition, the reactive flow was not introduced into the device until stable 
segmentation between the dispersed and continuous phases had been established. As 
smaller channels were utilised, flow rates were very much reduced (Figure 6.2). 
Unacceptable leakage of continuous phase occurred when a PFA gasket was used to
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seal the device. Nescofilm was instead used to seal the device, this prevented leakage 
of the reactive fluid, thus averting it flowing back into the functional fluid channel 
and causing premature cross-linking. Product beads (n=30) were measured (Section
2.2.3) and found to have a mean diameter of 151±5pm with a CV of 3% (Figure 6.3).
Ractat 75.1 um 
ATM 17711 osqum 
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Size (m icrons)
Figure 6.3 Small alginate beads produced using the MIG method. A) A representative small 
calcium alginate (2%  w/v) bead population. Scale bar represents 100pm. B) Histogram of alginate bead 
diameter; grey bars show measured data, with black line representing normal distribution. Mean bead 
diameter was 151±5pm. Distribution was considered to be approximately normal (A2=0.55, p > 0.146), 
with an outlier at 163 pm, represented by an asterisk (*)
6.2.1.2 Changes to cell processing to encapsulate cells in small beads
Aggregations of cells present within the functional fluid disrupt segmentation
at this reduced scale, preventing aggregations of cells from being encapsulated. 
Aggregations of HEK293 cells were observed if cells were trypsinised for less than 
three minutes. PC 12 cells grow in aggregations which can be broken by trituration 
(production of a homogeneous mixture). Varying methods for triturating PC 12 cells 
were investigated. A sample of cells were triturated with a 22 gauge needle (Figure 
6.4A), another sample was triturated using a 200pl pipette tip (Figure 6.4B), and a 
final sample was triturated with a 200pl pipette tip after 2 minute exposure to trypsin 
(Figure 6.4C).
133
C h a p t e r  Six
Figure 6.4: PC12 cells after varying trituration treatments. A) PC12 cells after trituration with 22 
gauge needle, B) PC 12 cells after trituration with a 200pl tip, C) PC 12 cells after excess medium was 
removed, 200pl trypsin added and left for 2 minutes, cells were then triturated with a 200pl tip. Scale 
bars represent 500pm
Treating PC 12 cells with trypsin prior to trituration with a 200pl pipette tip 
was the only treatment which gave a single cell suspension. To remove any remaining 
clumps of cells and thus produce a single cell suspension, the cell solution was passed 
through a 30pm filter.
6.2.1.3 HEK cells encapsulated in small beads
As viability of encapsulated cells was seen to improve after rapid transfer into
medium on-chip, an additional chip was designed combining small channels with a 
flushing flow (chip number 6; Figure 6.5, Appendix 1). Beads consisting of MVM 
and MVG alginate without cells were produced using chip number 6. MVM alginate 
beads were 233±10pm (n=20) in diameter and MVG alginate beads were 232±10pm 
(n=20) in diameter (Figure 6.6).
150 200 250
Size (microns)
150 200 250
Size (microns)
300
Figure 6.5: Histograms of MVM and MVG alginate beads. A) Histogram of MVM alginate beads; 
grey bars show measured data, with black line representing normal distribution. Mean bead diameter 
was 233± 10pm. Distribution was considered to be approximately normal (A2=0.62, p > 0.091). B) 
Histogram of MVG alginate beads; grey bars show measured data, with black line representing normal 
distribution. Mean bead diameter was 232±10pm. Distribution was considered not normal (A2=1.80, p 
> 0.005), with outliers at 212pm, 253pm and 260pm represented by asterisks (*)
134
C h a p t e r  S ix
Chip number 6
Flow rates:
Functional fluid = 0.05ml/h 
Reactive fluid = 4ml/h 
Carrier fluid = 1ml/h 
Flushing flow = 30ml/h
Channel dimensions: 
Before junction = 200pm 
After junction = 300pm
Figure 6.6: Schematic diagram showing the shielded junction with additional flushing flow for 
introducing aqueous medium. Functional fluid (shown in blue) was composed of alginate solution 
(2% w/v) containing 40mM CaC03, shielding flow (shown in red) was composed of sunflower oil and 
reactive flow (no shading) was composed of sunflower oil containing 40mM acetic acid. Flushing flow 
was D-MEM/F12 medium (shown in pink). Flow rates and channel dimensions are shown. Orientation 
of flow is specified by arrows
Using chip number 6, HEK293 cells were successfully encapsulated in small 
MVM alginate beads. The encapsulation experiment was repeated twice with two 
different cell concentrations; lx l0 7 and 3xl07 cells per ml. The number of cells per 
bead was counted (n=45) and the diameter was measured (n=22, Section 2.2.3). These 
data are summarised in Table 6.1 and Figure 6.7. Both bead samples produced were 
larger than alginate beads without cells (233± 10pm) and were too large to fit inside 
the implantation cannula.
Cell concentration Number of Mean diameter CV
(cells/ml) cells/bead ± SD ±  SD (pm ) (%)
1x10' 16±5 249±5 2.2o
*X 75±15 272±12 4.3
Table 6.1: Diameter of alginate beads containing varying cell concentrations. Beads were 
produced using 2%  alginate and two different cell concentrations. Beads were measured as described in 
Section 2.2.3
Sunflower oil and 
acetic acid Medium
Sunflower oil
Alginate solution 
+ CaCOs
Sunflower oil
Sunflower oil and 
acetic acid
Medium
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Figure 6.7: Small alginate beads containing HEK293 cells. A) Representative image of HEK293 
cells encapsulated in small alginate beads at a concentration of lx l0 7 cells per ml, B) representative 
image of HEK293 cells encapsulated in small alginate beads at a concentration of 3xl07 cells per ml, 
C) histogram of beads shown in A; grey bars show measured data, with black line representing normal 
distribution. Mean bead diameter was 250±5pm. Distribution was considered to be approximately 
normal (A2=0.51, p > 0.05), D) histogram of beads shown in C; grey bars show measured data, with 
black line representing normal distribution. Mean bead diameter was 272±12pm. Distribution was 
considered not normal (A2=0.73, p > 0.005), with an outlier at 236pm, represented by an asterisk (*). 
Scale bars represent 500 pm
6.2.1.4 PC12 cells encapsulated in small beads
Using chip number 6, as described in Figure 6.5, PC 12 cells were successfully
encapsulated in small MVM alginate beads. PC 12 cells were resuspended in the 
functional fluid at a concentration of 3x107 cells per ml. Beads were manufactured 
which contained 47±19 cells (n=30) and were 237±8pm (n=20) in diameter (Figure 
6.8). The same concentration of PC 12 cells were encapsulated as in the equivalent 
experiment with HEK293 cells (Section 6.2.1.3). However, fewer cells per bead were 
observed in encapsulated PC 12 beads than in encapsulated HEK293 beads (47±19 
compared with 75±15, = 6.64, p < 0.001).
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Figure 6.8: Small alginate beads containing PC12 cells. A) Representative image of PC12 cells 
encapsulated in small alginate beads at a concentration of 3xl07 cells per ml. Scale bar represents 
500pm. B) Histogram of beads shown in A; grey bars show measured data, with black line 
representing normal distribution. Mean bead diameter was 237±8pm. Distribution was considered not 
normal (A2=1.65, p < 0.005)
Small calcium cross-linked alginate beads were produced via modifications to 
the microfluidic process. Cells were encapsulated using this adapted microfluidic 
method. The next step was to stabilise beads using two alternative methods; barium 
cross-linking and secondary coating using polycations. Large beads (>300pm in 
diameter) were used due to better handling capabilities and the ability to carry out 
viability measurements. Cell viability cannot be measured in beads <300pm in 
diameter due to problems with manipulating individual beads.
6.2.2 Stabilisation of alginate beads using barium cross-linking
6.2.2.1 Internal barium cross-linking
To produce barium cross-linked alginate beads within a microfluidic system
the original MIG method was altered by substituting BaCC>3 for CaCC>3 as the inert 
ion source in the functional fluid. Liquid sodium alginate mixtures (2% w/v) 
containing high concentrations (50-25mM) of BaCC>3 were too viscous to introduce 
into a syringe. The viscosity of a sodium alginate solution (2% w/v) was measured 
(Section 2.2.4) to be 128mPa-s at 25°C. The viscosity of a sodium alginate solution 
(2% w/v) containing 50mM BaC03 was measured (Section 2.2.4) to be 671mPa-s at 
25°C. A sodium alginate solution (2% w/v) containing 12.5mM of BaC(> 3  could be 
pumped into the MicroPlant™ and onto the chip (Chip number 2, Section 3.3.1). 
However, segmentation did not occur with regularity and spherical beads were not 
produced. This method was abandoned due to these technical difficulties.
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6.2.2,2 Batch processing
An alternative approach to generate barium cross-linked alginate beads
involved producing calcium cross-linked alginate beads using the MIG method, with 
subsequent ion exchange of Ca2+ with Ba2+. A batch process was developed to allow 
ion exchange to occur in beads produced using the MIG method. The amount of 
barium required to fully substitute for calcium was investigated. Calcium cross-linked 
alginate beads were manufactured using the MIG method, as previously described 
(Section 3.3.3). After extensive washing, equal volumes of beads were exposed to five 
different concentrations of BaCl2 (20, 10, 5, 2.5 and ImM dissolved in saline) for 5 
minutes. After exposure, excess BaCl2 was washed from the beads; each bead sample 
was added to a 100pm filter and 1L of water was allowed to flow over them for 20 
minutes. Extensive washing allowed excess unbound ions to diffuse out of the bead 
samples. Alginate beads cross-linked with higher concentrations (>10mM BaCl2) of 
barium were visually observed to have a more “glassy” appearance when compared 
with calcium cross-linked alginate beads.
The BaCb treated beads and a control sample of untreated calcium cross- 
linked alginate beads were prepared (Section 2.2.5) and then analysed using atomic 
absorption spectroscopy to detect amounts of Ca2+ and Ba2+ present. The 
concentration of calcium ions present in beads prior to barium treatment was 
5.1pmoles/bead (Figure 6.9). Treating beads with 2.5mM BaCl2 reduced the calcium 
ion concentration to 1.4pmoles/bead. Further addition of Ba2+ ions did not decrease 
the calcium ion concentration. As more BaCl2 was added to the beads, more Ba2+ ions 
were present in the beads, until the maximum concentration of Ba2+ detected in beads 
was 1.2pmoles/bead. The maximum concentration of barium in the bead samples 
corresponded to 10 and 20mM of BaCl2 added. As barium is extremely toxic to cells, 
it was decided to utilise 5mM BaCl2 when batch processing beads. The decrease from 
lOmM to 5mM BaCl2 reduced the amount of barium in the beads from 
1.2pmoles/bead to 1 .Opmoles/bead, a 17% reduction from the maximum Ba2+ 
concentration.
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Figure 6.9: Concentration of barium added to bead sample compared to amount of calcium and 
barium present in bead sample. Open symbols represent calcium concentration, closed symbols 
represent barium concentration as determined by atomic absorption spectroscopy
Assuming a droplet with diameter 600pm was produced; each droplet has a 
volume of 113nl and was thus calculated to contain 5.5pmoles of CaC0 3 , based upon 
a CaCC>3 concentration of 0.05mmoles/ml. The amount of calcium detected in cross- 
linked beads (5.1pmoles) was similar to the calculated expected value of 5.5pmoles. 
The exact diameter of droplets produced cannot be measured without high-speed 
video equipment. Although most of the calcium present within beads is displaced by 
the addition of barium, an equal amount of barium does not replace the displaced 
calcium; the amount of barium detected (1.2pmoles) is much lower than the amount 
of calcium present within beads.
6,2,2,3 Effect o f barium on cell viability
As previously stated, barium is toxic to cells at low doses (<10mM). The
effect of cross-linking beads with 5mM BaCh on HEK293 and PC 12 cell viability 
was investigated.
6,2,23 a) Effect o f barium on encapsulated HEK viability
Two separate encapsulation experiments were carried out with individual
populations of HEK293 cells (as described in Section 4.2.3). Cells were resuspended 
at a concentration of lxlO6 cells per ml in the functional fluid. An hour after 
encapsulation, each sample of beads was split in half. Batch treatment with 5mM
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BaCl2 was carried out on one half (as described in Section 6.2.2.2) and the other half 
was washed in medium only. Viability of the encapsulated cell populations was 
observed for 45 days (Figure 6.10) using the adapted trypan blue exclusion method 
(Section 4.2.1.1).
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Figure 6.10: Effect of barium exposure on encapsulated HEK293 cell viability. Open symbols 
represent viability of HEK293 cells encapsulated in calcium cross-linked alginate beads, closed 
symbols represent viability of HEK cells encapsulated in barium cross-linked alginate beads. Pre­
encapsulation viability was 90%. Viability was estimated using the adapted trypan blue method. Error 
bars show standard error of the mean measured in 4 individual beads
Populations of cells encapsulated in both calcium and barium cross-linked 
alginate beads were observed to decrease in viability immediately following 
encapsulation. Cells encapsulated in barium cross-linked alginate beads decreased to 
25% viability 1 day after encapsulation, but increased in viability thereafter. Viability 
of cells encapsulated in calcium cross-linked alginate beads decreased to 55% after 5 
days, after which point viability increased. An increase in viability was observed in 
both bead types until day 30 when viability began to decrease slightly. Cells 
encapsulated in barium cross-linked alginate beads were observed to be ~20 
percentage points lower in viability, between days 7 and 14, than cells encapsulated in 
calcium cross-linked alginate beads. The difference in viability dropped to ~10 
percentage points between days 28 and 42. From day 17 onwards the viability of cells 
encapsulated in barium cross-linked alginate beads was significantly lower than the
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viability of cells encapsulated in calcium cross-linked alginate beads (F i,^  = 36.05, p 
< 0.001).
6.2,23 b) Effect o f  barium on encapsulated PC12 viability
Three separate encapsulation experiments were carried out with individual
populations of PC 12 cells (as described in Section 5.2.1). Each batch of cells was 
resuspended at a concentration of 4xl07 cells per ml in the functional fluid. An hour 
after encapsulation each sample of beads was split in half. Batch treatment with 5mM 
BaCh was carried out on one half (as described in Section 6.2.22) and the other half 
was washed in medium only. Viability was observed for 8 days using adapted trypan 
blue exclusion method (Section 4.2.1.1). Viability of each of three separate 
encapsulation experiments is shown (Figure 6.11 A), with mean viability also shown 
for clarity (Figure 6.1 IB). Viability of cells encapsulated in calcium and barium 
cross-linked alginate beads was not significantly different (F i^  = 0.000, n.s.).
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Figure 6.11: Effect of barium exposure on encapsulated PC12 cell viability. A) Viability of PC12 
cells, and B) mean viability of PC 12 cells encapsulated in alginate beads after treatment with 5mM 
BaCl2, for each of three replicate encapsulations is shown. Open symbols (with dashed lines in upper 
panel) represent cells encapsulated in calcium cross-linked alginate beads, closed symbols represent 
cells encapsulated in barium cross-linked alginate beads. Pre-encapsulation viability was 71% (A), 
74% (■) and 73% (0). Cell viability was estimated using the adapted trypan blue method. Error bars 
show standard error of the mean of 3 individual beads from three separate encapsulation experiments
6,2.2.4 Implantation of small calcium and barium cross-linked alginate beads
Previously, small calcium cross-linked alginate beads were produced
containing cells (Sections 6.2.1.3 and 6.2.1.4). Cross-linking large alginate beads with 
barium was shown to have little effect on the therapeutic cell line PC 12 (Section
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6.2.1.4). Prior to implanting PC 12 cells encapsulated in small barium cross-linked 
alginate beads, initial attempts at implantation were carried out with small barium 
cross-linked alginate beads minus cells. The ultimate goal was to observe behavioural 
changes in a rodent model of Parkinson’s disease; therefore, beads were required to 
remain within the striatum for over 6 weeks (Borlongan et al., 2004). An initial time 
point of 21 days was decided upon to observe beads within the striatum after 
implantation.
Calcium cross-linked alginate beads were prepared from MVM and MVG 
alginate using chip number 5 (Figure 6.2). Each bead sample produced was split in 
half. Batch treatment with 5mM BaC^ was carried out on one half of each sample (as 
described in Section 6.2.2.2) and the other half of each sample was washed in medium 
only. All beads were measured prior to implantation (Section 2.2.3) to ensure bead 
diameter was <150pm for cannula implantation. Beads were implanted into rat 
striatum using stereotactic apparatus (Figure 6.12, Section 2.4.2). Beads made of 
MVM alginate were implanted into two rats and beads made of MVG alginate were 
implanted into another two rats. In each case calcium cross-linked alginate beads were 
implanted into the right striatum and barium cross-linked beads were implanted into 
the left striatum.
An animal from each group was perfused 7 days after implantation. No 
evidence of any beads was observed in sections of brain tissue prepared (Section
2.4.3) 7 days after implantation (Figure 6.13A and D). The remaining animal from 
each group was perfused 15 days after implantation. Barium cross-linked alginate 
beads were observed in sections of brain tissue prepared (Section 2.4.3) 15 days after 
implantation (Figure 6.13B, C, E and F). MVG beads left a large, well-defined cavity 
in the brain tissue (Figure 6.13B and E) with some evidence of scar formation around 
the beads. However, MVM beads appeared to have cells growing around them, with 
no clearly-defined border around the cavity left by beads (Figure 6.13E and F). No 
evidence of beads was observed 7 days after implantation; however, barium cross- 
linked beads were observed 15 days after implantation, hence, there was some 
uncertainty as to whether beads had been reliably implanted.
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Figure 6.12: Schematic showing sterotactic positions of bead implantation into rat striatum. Red
lines indicate position of needle for bead implantation
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Figure 6.13: Cresyl violet stained sections showing implantation sites of alginate beads. A and D)
calcium cross-linked MVM alginate beads 7 days after implantation, B and E) barium cross-linked 
MVG alginate beads 14 days after implantation, C and F) barium cross-linked MVM alginate beads 14 
days after implantation. D, E and F show enlarged versions of A, B and C respectively. Scale bars 
represent 500pm
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As calcium cross-linked alginate beads had not been observed in any sections, 
it was decided not to continue implanting these beads and to focus instead on barium 
cross-linked beads. To ensure that beads were being implanted into the striatum, MRI 
was carried out to visualise implanted beads immediately following implantation. 
Barium cross-linked MVM alginate beads were implanted into two rats (Section 
2.4.2). Control injections of artificial cerebrospinal fluid were carried out on the left 
hand side of the brain and beads were injected into the right hand side of the brain. 
MRI was carried out immediately after surgery (Section 2.4.4). One rat was scanned 3 
and 15 days after implantation.
A bolus of beads was clearly observable in the striatum of both animals 
immediately following surgery (Figure 6.14A and D). The needle track associated 
with the control injection was also visible (Figure 6.14A and D). The beads were still 
observable 3 days after implantation (Figure 6.14B); however by 15 days after 
implantation there was no noticeable difference between the control injection and the 
injection of beads (Figure 6.14C). Upon sectioning and staining (Section 2.4.3) the 
brain, no evidence of beads could be found.
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Figure 6.14: MR images of rats’ brains after implantation of barium cross-linked MVM alginate 
beads. A) rat 1, 1 hour after implantation, B) rat 1, 15 days after implantation, C) rat 1, 3 days after 
implantation and D) rat 2, 1 hour after implantation. Left hand side o f brain was injected with artificial 
cerebral spinal fluid and right hand side was injected with 3pi of barium cross-linked MVM alginate 
beads. Red boxes highlight areas of implantation. Scale bar represents 0.5cm
Additional implantation experiments were carried out to further investigate the 
scar formation previously observed upon implantation of MVM and MVG alginate 
beads (Figure 6.13). The differences in scar formation around the implanted beads 
observed may have been due to inter-animal differences as the MVM and MVG 
alginate beads were implanted into separate rats. To investigate inter-animal 
differences an additional implantation experiment was carried out.
Barium cross-linked MVM beads were implanted into the right striatum of 3 
rats. Barium cross-linked MVG beads were implanted into the left striatum of the 
same 3 rats. A rat was perfused and its brain sectioned 1 week after implantation. 
Beads were observed in both the left and right striatum (Figure 6.15), no scar
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formation was observed, but cells were seen to grow around each bead type. Sections 
taken from rats perfused 21 and 28 days post-implantation did not show any evidence 
of beads remaining.
Figure 6.15: Cresyl violet stained sections showing implantation sites of alginate beads. A) Barium 
cross-linked MVG alginate beads and, B) barium cross-linked MVM alginate beads 7 days after 
implantation. Scale bar represents 1mm
All sections shown were stained with cresyl violet (Section 2.4.3). Cresyl 
violet staining requires that slides are agitated in various solutions. During this 
agitation it appeared that beads were lost from the slides as no evidence of beads 
remained, but there are clearly voids where they were previously located. Brains were 
sectioned using a sledge microtome and then collected into PBS. It was thought that 
the beads may be washed from the sections during this stage. To investigate further, a 
single brain was sectioned using a cryostat and sections were collected directly onto 
slides. In this way it was proposed that beads would remain in the sections. To further 
ensure retention of beads within sections, a wet mounting technique was employed. 
Slides with sections on were mounted directly with polyvinyl alcohol-1,4- 
diazabicyclo[2.2.2]octane (PVA-DABCO) without any staining. Many beads were 
observed to remain in the voids seen in tissue (Figure 6.16).
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Figure 6.16: Section of brain tissue mounted using PVA-DABCO. Barium cross-linked MVG 
alginate beads seen in sections of brain tissue taken 7 days after implantation. Scale bar represents 
500pm
6.2.2.5 Internal structure o f alginate beads produced using the MIG method
As previous groups implanting small alginate beads into rodent brains were
able to recover beads 56 days after implantation (Ross et al., 1999), the above result 
was somewhat unexpected. There is evidence that alginate bead structure has an 
influence on stability in vitro, with homogeneous alginate beads being less stable than 
non-homogeneous (Thu et al., 1996a). The structure of alginate beads can be 
elucidated via confocal microscopy of beads manufactured using fluorescent alginate 
(Strand et al., 2003). Alginate beads produced using the MIG method were imaged in 
this way to reveal their internal structure.
Alginate was labelled with the fluorophore fluoresceinamine, using a 
procedure adapted from Strand et al. (2003, Section 2.2.8). Beads were produced 
from the fluorescent alginate using the MIG method (Section 4.2.2.3) and visualised 
using confocal microscopy (Section 2.2.9.1). Images were acquired from the equator 
of the beads, with an intensity profile being collected across the bead diameter (Figure
6.17). The concentration of alginate across the beads was observed to be 
homogeneous.
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Figure 6.17: Internal structure of alginate beads produced using the MIG method. A) Image 
taken using confocal microscopy of beads manufactured using fluorescent alginate. B, C and D) 
Representative micrographs of optical sections taken through the equator of beads shown in A, 
showing the intensity of fluorescence, across the bead diameter. Scale bar represents 500pm
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6.2.3 Stabilisation of alginate beads via secondary polycationic coating
As barium cross-linked alginate beads were shown to be unsuitable for 
implantation into rodent striatum, the use of polycation secondary coating was 
investigated as an alternative. Again, preliminary experiments were carried out on 
large (>300pm in diameter) beads. Modifications of the MIG method were 
subsequently carried out to produce small beads.
6.2.3.1 Batch coating
As secondary coating of alginate beads is frequently carried out after bead
generation, batch coating procedures have been described many times in the literature 
(For example, Lim and Sim, 1980; Fritschy et al., 1991; King et al., 2003). Batch 
coating of alginate beads manufactured using the MIG method was carried out using a 
protocol adapted from Rokstad et al. (2003, Section 2.2.6). The major change to the 
protocol was reduction in exposure time of beads to PLL. Upon exposure to PLL for 
10 minutes, alginate beads produced using the MIG method collapsed; therefore 
exposure time was reduced to 7 minutes, after which bead collapse was not observed.
6.2.3.2 Effect o f  secondary coating procedure on cell viability
In order to establish viability, trypan blue was added to encapsulated cells
within PLO- and PLL-coated alginate beads. The coating chemicals employed 
became stained with trypan blue and, as a consequence, cells could not be observed. 
In addition, treatment with sodium citrate did not dissolve the PLL- or PLO-coated 
beads, as an insoluble surface polyplex had been formed between the alginate and 
polycation (Section 1.8). For these reasons, viability measurements on coated beads 
were not carried out using trypan blue exclusion.
6.2.3.3 Secondary coating using fluorescent PLL
To investigate whether beads were indeed being coated using the developed
method and to observe any possible differences between different bead types, alginate 
beads were coated using PLL labelled with FITC (PLL-FITC) and imaged using 
confocal microscopy. Beads produced using the MIG method (internal gelation) and 
beads produced using an external gelation method were also compared for any 
differences in PLL binding.
Calcium cross-linked alginate beads were produced using the MIG method 
(Section 3.3.3). Half of the bead sample was batch treated with BaCl2 to give barium
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cross-linked alginate beads (Section 62.2.2). Calcium cross-linked alginate beads and 
barium cross-linked alginate beads were coated with either high MW (30-70 kDa) or 
low MW (15-30 kDa) PLL-FITC (Section 2.2.6). Calcium cross-linked alginate beads 
were also produced using an air-assisted droplet break-up method (ADB, Section 
2.2.10) and coated with high or low MW PLL-FITC (Section 2.2.6). PLL-FITC was 
dissolved in 0.3M mannitol solution and washes were carried out in mannitol solution 
to preserve internal structure (Strand et al., 2003). Images of beads were acquired 
using confocal scanning laser microscopy (CSLM, Section 2.2.9.1). An intensity 
profile was collected from bead equators.
Fluorescent signals were collected from all samples of beads prepared (Figure
6.18). The images were all taken at constant laser power, with images being optimised 
to the dynamic range of the detectors used. During this optimisation process the laser 
voltage was adjusted for each image taken of different bead samples. As the laser 
voltage used for each image was different, quantitative comparisons could not be 
made between samples. Strand et al (2003) were able to measure the thickness of the 
PLL-FITC layer coating the alginate beads and compare layer thickness between 
different kinds of beads. As quantitative comparisons of this kind were impossible to 
make using the data gained during this experiment an alternative approach was used 
to enable qualitative comparisons to be made. By comparing the laser voltage used for 
a given image a qualitative estimate of the amount of PLL-FITC present was made 
(Table 6.2). A lower laser voltage was used to detect larger quantities of PLL-FITC. 
So, laser voltage is inversely proportional to the amount of PLL-FITC present.
Method of manufacture Cross-linking ion MW of PLL Laser voltage
MIG Calcium Low 312.3
MIG Barium Low 327.1
ADB Calcium Low 283.4
MIG Calcium High 414.1
MIG Barium High 425.7
ADB Calcium High 340.5
Table 6.2: Comparison of bead type with laser voltage required to obtain an image using confocal 
microscopy. MIG refers to the microfluidic internal gelation method of manufacture, whilst ADB 
refers to air assisted droplet break-up
From the table above it can be seen that beads produced using the widely used ADB 
method were more fluorescent than beads produced using the MIG method. Calcium
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cross-linked beads were more fluorescent than barium cross-linked beads. Beads 
coated with low molecular weight PLL-FITC were more fluorescent than beads 
coated with high molecular weight PLL-FITC. The amount of PLL-FITC present can 
be summarised as follows:
ADB, calcium cross-linked, coated with low MW PLL > MIG, calcium cross-linked, 
coated with low MW PLL > MIG, barium cross-linked, coated with low MW PLL > 
ADB, calcium cross-linked, coated with high MW PLL > MIG, calcium cross-linked, 
coated with high MW PLL > MIG, barium cross-linked, coated with high MW PLL
Alginate beads produced using the MIG method with subsequent cross-linking 
with barium and secondary coating with high MW PLL did not survive the process. 
Many beads were observed to have burst open (Figure 6.18F). As only PLL-FITC was 
used and not fluorescent alginate as well, it was impossible to visualise the alginate 
and so it remains unclear as to whether the PLL coating had peeled away from the 
alginate beads, leaving them intact, or if the alginate chains had destabilised and re­
dissolved.
Alginate beads produced using the MIG method with subsequent coating with 
PLL had a different appearance than any of the other bead types. Beads coated with 
low MW PLL were observed to have a wrinkled appearance (Figure 6.18C), whereas, 
beads coated with high MW PLL were observed to be unevenly coated, with areas of 
intense fluorescence (Figure 6.18D).
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Figure 6.18: Distribution of PLL-FITC in various alginate beads coated. A) ADB generated 
alginate beads, cross-linked with calcium and coated with high MW fluorescent PLL. B) ADB 
generated alginate beads, cross-linked with calcium and coated with low MW fluorescent PLL. C) 
Alginate beads generated using the MIG method, cross-linked with calcium and coated with high MW 
fluorescent PLL. D) Alginate beads generated using the MIG method, cross-linked with calcium and 
coated with low MW fluorescent PLL. E) Alginate beads generated using the MIG method, cross- 
linked with barium and coated with low MW fluorescent PLL. F) Alginate beads generated using the 
MIG method, cross-linked with barium and coated with high MW fluorescent PLL, gradations present 
are a scanning artefact. The micrographs are optical sections taken through the equator of beads 
showing the intensity of the fluorescence emitted across the bead diameter. Scale bars represent 100pm
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6.2,3.4 Production of small coated alginate beads
Large alginate beads coated with a secondary polycation layer were previously
produced using a batch method (Section 6.2.3.1). An attempt was made to produce 
small alginate beads with a secondary polycation coat on-chip. The chip designed 
previously (chip number 6; Figure 6.5), combining small channels with a flushing 
flow, was used for this purpose. PLL, PLO and chitosan solutions were introduced via 
the flushing flow. The concentration of coating species utilised was reduced from 
0.05% to 0.025% (w/v). A secondary coating of alginate caused the layer of coating 
compound to be removed at concentrations (0.15% w/v) used by Rokstad et al 
(2003). By reducing the alginate concentration to 0.075% (w/v), spherical beads with 
a secondary chemical coat and an outer layer of alginate were produced. Calcium 
cross-linked alginate beads without coating were also produced and then batch treated 
with BaCL (Section 6.2.2.2). Samples from all bead types were measured (n=20, 
Section 2.2.3). Size distributions are summarised in Table 6.3.
Type of bead Mean diameter ± SD (pm) CV (%)
Barium alginate 307±8 2.6
PLL coated alginate 319±37 11.5
PLO coated alginate 319±22 6.8
Chitosan coated alginate 362±13 3.6
Table 6.3: Alginate bead diameter made using chip number 6. Beads were produced using 2% 
(w/v) alginate. Coating was carried out on-chip using reduced PLL and alginate concentrations. Beads 
were measured as described in Section 2.2.3
As these beads were all too large to pass through the implantation cannula, 
calcium cross-linked alginate beads for implantation were made using chip number 5 
with subsequent coating carried out using a batch method (Section 2.2.6). Samples 
from all bead types were measured (n=20, Section 2.2.3). Size distributions are 
summarised in Table 6.4.
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Type of bead Mean diameter ± SD (pm) CV (%)
Calcium alginate 134±5 3.7
Barium alginate 130±5 4.1
PLL coated alginate 102±6 6.3
PLO coated alginate 107±5 4.6
Chitosan coated alginate 233±7 2.9
Table 6.4: Alginate bead diameter made using chip number 5 and batch processed. Beads were 
produced using 2% (w/v) alginate. Coating was carried out using a batch method described in Section 
2.2.6. Beads were measured as described in Section 2.2.3
6,2.3,5 Implantation of small coated alginate beads
Implantation of each of the four alginate bead types (Section 6.2.3.4; barium
cross-linked and alginate with PLL, PLO and chitosan secondary coat) was carried 
out. Two groups of rats with three rats in each group were used for this experiment. 
The first group received barium cross-linked alginate beads in the left hand striatum 
and chitosan coated alginate beads in the right hand striatum. The second group 
received PLL coated alginate beads in the left hand striatum and PLO coated alginate 
beads in the right hand striatum. An animal from each group was perfused and 
sections were taken of the brain 21 days after implantation. As there was no evidence 
of any of these beads remaining at this time point, the remaining animals were 
perfused 10 days later. Again, there was no evidence of any beads remaining in 
sections prepared from the brains of these animals.
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6.3 D isc u ssio n
6.3.1 Adaptation of the MIG method to produce small alginate beads
The MIG method was adapted to successfully produce alginate beads below 
150pm in diameter. Microfluidic devices are ideally suited to produce alginate 
droplets below 150pm in diameter and several groups have indeed achieved this 
(Sugiura et a l , 2005; Zhang et al., 2006; Choi et a l, 2007; Zhang et al, 2007).
The major advantage to using microfluidic devices as opposed to other 
emulsion formation methods is that small diameter beads with a narrow size 
distribution are easily obtainable. For example, Zourob et al. (2006) reported standard 
emulsion formation to produce molecularly imprinted polymer beads (diameter 
10 pm) with a CV of 67% compared to microfluidic production, which produced 
beads (diameter 24pm) with a CV of 1.8%. Typically groups utilising microfabricated 
devices report beads with a CV of less than 2% (Seo et a l, 2005; Choi et a l, 2007; 
Zhang et a l, 2007). As many properties of alginate beads are dependant upon size, a 
small size distribution is important to ensure a homologous population of beads which 
will all respond in the same manner (Strand et a l, 2002).
6.3.2 Encapsulating cells in small beads using the MIG method
Cells were successfully encapsulated in small beads produced using the 
adapted MIG method. However, a higher concentration of cells was needed to allow 
encapsulation of large numbers of cells. Ross and Chang (2002) also reported the 
necessity of increasing cell concentration (2.5-fold) to prevent formation of empty 
capsules. The viability of cells encapsulated in small beads was unchanged as 
compared to medium sized (500-700pm in diameter) beads, although more cells per 
unit volume were observed (Ross and Chang, 2002). Addition of cells in a 
heterogeneous mixture to alginate solutions disrupts segmentation at a microfluidic 
junction (for example, see Shintaku et a l, 2007). The effects of disrupted 
segmentation are not as noticeable when microfluidic channels are many times larger 
than cells. However, when channel sizes are decreased to a few times the diameter of 
a cell, the disruption to segmentation becomes problematic. Beads produced 
containing cells were observed to be of larger diameter than beads which did not 
contain cells (Section 6.2.1.3) for this reason. Several groups have also succeeded in 
encapsulating cells in beads <150pm diameter using microfluidic devices (Sakai et
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al, 2005; Sugiura et a l, 2005; Tan et a l, 2006b; Hong et a l, 2007; Sugiura et a l, 
2007; Kim et a l, 2009), although none have carried out further investigations into 
long term viability of cells, stability of beads, suitability for implantation, etc.
6.3.3 Stabilisation using barium cross-linking
Barium cross-linked alginate beads could not be made by adapting the 
previously described MIG method to utilise BaCC>3 as the inert cross-linker. The 
viscosity of alginate solutions markedly increased upon addition of BaCC>3 and 
satisfactory segmented flow could not be achieved. Capretto et al. (2008) recently 
investigated three microfluidic approaches to producing barium cross-linked alginate 
beads. In the first method, fluid alginate droplets were formed via segmentation with 
oil and then cross-linked by dropping into a BaCl2 solution, which produced a high 
proportion of beads with a comet-like appearance. The second method investigated 
was identical to the one outlined above (Section 6.2.2.1) i.e. internal gelation using 
BaCC>3. The concentrations of BaC03  tested by Capretto et al. were substantially 
lower (5-10mM) than those tested in this study (50-12.5mM), with the optimum 
concentration found to be 7.5mM. The third and most successful method investigated 
was addition of small amounts of BaCb to the functional fluid, to increase the 
viscosity and reduce coalescence of product beads prior to falling into BaCl2. 
Although barium cross-linked beads were produced using a microfabricated device, 
cross-linking on-chip was not achieved.
Instead of developing a microfluidic method to produce barium cross-linked 
alginate beads, a batch method was developed to allow ion exchange of Ca2+ for Ba2+. 
Calcium cross-linked alginate beads were produced using the MIG method and 
equilibrated in BaCl2 to promote ion exchange. Beads were batch treated with 
varying concentrations of BaCb. Ba2+ and Ca2+ concentrations present in each sample 
were obtained using atomic absorption spectrometry. The collected data showed that 
concentrations of BaCl2 higher than lOmM did not increase the amount of Ba2+ 
detected within the batch treated beads. Decreasing the concentration of BaCl2 to 
5mM reduced the concentration of Ba2+ detected in beads by 17%. This reduction was 
deemed negligible and 5mM BaCh was used in all subsequent experiments. This 
concentration of barium is below the level found to affect protein biosynthesis 
(Howell and Tyhurst, 1976) and it was postulated that this amount of barium would 
not be acutely toxic to cells upon exposure.
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The amount of calcium detected by atomic absorption spectrometry in beads 
produced using the MIG method (5.1pmoles/bead) was extremely similar to the 
amount of CaC03  calculated to be present in an alginate droplet (5.5pmoles/droplet). 
All Ca2+ liberated by the reduction in pH is therefore utilised in cross-linking of
2d- # « 24"alginate chains. Ca concentration was seen to decrease with increasing Ba 
concentration, indicating ion exchange. However, barium did not replace Ca in a 1:1 
ratio. The amount of Ba2+ present in the beads reached a maximum of 
1.2pmoles/bead, whereas the maximum amount of Ca present in beads was 
5.1pmoles/bead.
The mechanism of ion binding to alginate chains may account for this 
difference. CaCC>3 is present throughout fluid alginate droplets, and so, upon pH 
decrease, Ca ions are liberated in this ordered arrangement. Upon treatment with
•y,
BaCh a concentration gradient of barium is present with no Ba inside calcium cross- 
linked alginate beads and a high surrounding concentration of BaCl2. As barium ions 
have a larger radius (1.35A) compared to calcium ions (0.97A) it has been argued that 
they are expected to fill a larger space between alginate chains (Al-Musa et al., 1999; 
Choonara et al., 2008). This tight arrangement is somewhat dubiously argued to limit 
diffusion of further barium ions into the alginate bead. Barium ions in conventionally 
produced barium cross-linked alginate beads (i.e. external gelation by dropping into 
BaC^) have been shown, using confocal microscopy, to be limited to the outside of 
the bead (Zimmermann et al., 2003). The present study did not allow the position of 
barium ions to be visualized, so this theory could not be investigated further. 
However, this limitation of diffusion is unlikely to occur as alginate gels have a 
macro-porous structure. Large proteins have been shown to diffuse through an 
alginate gel (Strand et a l, 2002). The likelihood of Ba2+ ion binding preventing 
further diffusion of barium ions to the centre of the bead is small. A more probable 
explanation for the observed Ba2+/Ca2+ inequality is that there are fewer binding sites 
available for Ba2+ than Ca2+. Ca2+ and Ba2+ differ in charge density and ionic radius. 
These differences allow Ba2+ to bind more strongly to carboxyl groups present in 
alginate than Ca does.
There is evidence that fewer residues are required to cross-link alginate with 
barium than calcium (Stokke et a l, 1991) and that binding of metal ions to alginate 
depends upon the physical state of the alginate i.e. solution or gelled (Seely and Hart, 
1974). Beads used in this experiment were already in a gel state when Ba2+ ions were
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added. In addition to these explanations, the amount of calcium detected in this 
experiment was at the lower limit of detection of the spectrometer. A more accurate 
estimation of the amount of calcium present could be obtained by analysing larger 
numbers of beads. A more accurate estimate may reveal that more calcium is present 
than the current experiment indicates.
6.3.3.1 Effect of barium treatment upon encapsulated cell viability
The acute effects of barium exposure via the developed batch process on
HEK293 and PC 12 cells were investigated. HEK293 cells encapsulated in barium 
cross-linked alginate beads showed a larger decrease in viability than cells 
encapsulated in calcium cross-linked alginate beads, but recovered more rapidly. 
HEK293 cells encapsulated in calcium cross-linked alginate beads continued to 
decrease in viability until day 5, whereas HEK293 cells encapsulated in barium cross- 
linked alginate beads began to show an increase in viability after day 1.
Barium encapsulated PC 12 cell viability did not decrease by more than 20 
percentage points at any time point observed. The two later time points showed a 10 
percentage point difference between calcium and barium cross-linked alginate beads. 
The effect of barium treatment upon encapsulated PC 12 viability was not statistically 
significant.
In this study, the long term effects of encapsulation in barium cross-linked 
alginate beads were investigated for HEK293 cells. Viability of cells encapsulated in 
barium cross-linked alginate beads was consistently lower than cells encapsulated in 
calcium cross-linked alginate beads. As discussed in the previous chapter (Section 
5.3.2), the microstructure of beads can affect cell growth and proliferation. As 
alginate chains have a greater affinity for Ba2+ than Ca2+, the ionic interactions 
between alginate chains and Ba2+ are stronger than with Ca2+. A more rigid structure 
prevents cells from growing and forming large aggregations. The long term effects of 
encapsulation in barium cross-linked alginate beads were not investigated using PC 12 
cells, due to time constraints.
The most commonly used protocol for the production of barium cross-linked 
beads utilises small amounts (ImM) of BaCl2 in combination with 50mM CaCl2 as a 
gelling agent, which has been shown to stabilise alginate beads against swelling 
(Morch et a l , 2006). In addition, barium is not considered toxic at this concentration 
(Howell and Tyhurst, 1976) and so the effect on viability is not expected to be high.
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Even under these relatively benign conditions, HEK293 cells were found to grow 
significantly slower than in calcium cross-linked alginate beads (Rokstad et a l, 2003). 
Decreased cell growth was proposed to be due to increased gel strength due to 
stronger cross-links between Ba2+ and alginate, although this effect was not observed 
in other studies with the same cells (Visted et a l , 2003). In contrast, encapsulation in 
alginate beads cross-linked with 20mM barium did not appear to affect any of three 
cell lines (MDCK epithelial cell, D6 myoblast and 2A50 fibroblasts) investigated in a 
separate study (Peirone et a l, 1998).
6.3.4 Structure of beads produced using the MIG method
Alginate beads produced using the MIG method were observed to have a 
homogeneous distribution of alginate. Alginate beads cross-linked using internal 
gelation have previously been found to contain a homogeneous concentration of 
alginate across a bead (Quong et a l, 1998). SEM and confocal microscopy have also 
shown that beads cross-linked using internal gelation have a looser structure, with 
larger pores than beads produced using external gelation (Liu et a l, 2002). Porosity 
was also shown to increase in both studies.
Alginate beads produced using the MIG method are likely to have a 
homogeneous structure for the following two reasons. Firstly, CaCC>3 is 
homogeneously distributed throughout the alginate solution prior to droplet formation, 
and upon pH reduction, Ca2+ is liberated in situ throughout the bead. Therefore, a 
concentration gradient of alginate cannot form under these conditions. Secondly, 
droplets moving through a microchannel undergo velocity profile mixing, i.e. material 
from near the wall of the channel is re-circulated into the centre. This recirculation 
constantly redistributes material within a fluid droplet. Again, a gradient of alginate 
cannot form under these conditions.
6.3.5 Stability of beads produced using the MIG method
Calcium cross-linked alginate beads produced using the MIG method did not 
survive washing in phosphate buffered saline (PBS) without Ca2+. Washing alginate 
beads in buffers which do not contain calcium is know to cause Ca2+ to leach from the 
beads thus destabilising the cross-links (Smidsrod and Skjakbraek, 1990). Barium 
treatment stabilised alginate beads sufficiently to enable PBS washes. Calcium cross- 
linked alginate beads are susceptible to phosphate treatment as Ca2+ is leached from
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the beads, forming calcium phosphate. Many previous studies have found that barium 
cross-linked alginate beads are more stable than calcium cross-linked ones. Alginate 
beads cross-linked with 30mM barium remained intact after exposure to distilled 
water for three hours (Moskalenko et a l , 2007). Alginate beads stabilised with ImM 
BaCh in combination with 50mM CaCl2 were found to be stable using the osmotic 
pressure test (Section 1.8.1) for 21 days after manufacture, however, addition of cells 
to the beads led to rapid destabilisation (Rokstad et a l , 2002). Non-homogeneous 
beads were also found to be more stable than beads with a homogeneous distribution 
of alginate (Rokstad et a l , 2003). Although the stability of alginate beads produced 
using the MIG method was not tested in vitro, it is expected that barium cross-linked 
beads would be more stable than calcium cross-linked beads, and that alginate beads 
coated with polycations would be more stable than either of these.
6.3.6 Stabilisation using secondary polycationic coating
Preliminary experiments were carried out to coat small beads, produced using 
the MIG method, with polycations on-chip. Calcium cross-linked alginate beads were 
produced using the MIG method, and a PLL solution was introduced via the flushing 
flow (Section 5.2.1, Figure 5.3). The concentration of PLL was empirically reduced to 
0.025% (w/v)to form spherical beads with a secondary coating layer. The batch 
coating procedure usually employed utilises twice this concentration (0.05% w/v). 
The concentration of alginate used for the last layer was also reduced. At alginate 
concentrations higher than 0.075% (w/v), beads did not survive the coating procedure. 
Further experiments were not carried out on beads produced using the MicroPlant™ 
as the beads produced were too large to enter the implantation cannula (>300pm in 
diameter). Instead the small alginate beads used for implantation were coated using 
the batch method discussed below. In addition, the batch method proved to be more 
convenient and reproducible and the results gained were comparable to other studies. 
There have been no reports of secondary coating being carried out in a 
microfabricated device; hence, the novel method described here is the first to be 
reported.
A batch method was adapted from Rokstad et al. (2003) to coat beads 
produced using the MIG method with PLL and PLO. Using fluorescent PLL and 
confocal microscopy it was possible to show that alginate beads produced using the 
MIG method were successfully coated using this technique. There was some evidence
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that less PLL-FITC bound to beads produced using the MIG method. Previous studies 
have observed that non-homogeneous beads bind slightly more PLL-FITC than 
homogeneous alginate beads (Thu et a l, 1996b). The observation that more PLL- 
FITC bound to calcium cross-linked alginate beads than to barium cross-linked 
alginate beads may be accounted for if less alginate were present at the surface of 
barium cross-linked beads, although evidence for this was not collected during these 
experiments.
By optimising the images gained using confocal microscopy, the voltage used 
to obtain each image was different. Therefore, the images could not be compared as 
the settings used to obtain each image were different. To gain images which could be 
analysed to obtain an estimate of the thickness of each coat, which could then be 
compared to each other, an alternative approach would have to be followed. The use 
of an internal control, such as commercially available fluorescent polystyrene beads, 
would allow settings to be kept consistent between samples and would even allow 
comparison at different time points (personal communication, Anthony Hayes).
The beads produced using the MIG method were smaller than the beads 
produced using the ADB method. Strand et al observed that smaller (200pm) alginate 
beads collapsed upon treatment with low concentrations of PLL (0.05% w/v) after 5 
minute exposures, whereas larger (500 pm in diameter) beads only occasionally 
collapsed after prolonged (>10 minutes) exposure to higher concentrations (0.1% w/v) 
of PLL (Strand et a l, 2002). Washing beads in 0.3M mannitol prior to coating with 
PLL was found to prevent the observed collapse of small beads. This step was not 
used with the beads produced for implantation, but was used with the beads produced 
for the experiment utilising fluorescent PLL, as the same group observed that 0.3M 
mannitol also helps to preserve the non-homogeneous structure of the alginate beads 
(Strand et a l, 2003).
6.3.6.1 Effect o f secondary coating on encapsulated cell viability
Exposure to PLL solution is toxic to most cells (Sgouras and Duncan, 1990;
Strand et a l, 2001), however, the protocol formulated by Lim and Sim (1980) does 
not appear to affect cell viability or proliferation of encapsulated cells (for example, 
Rokstad et a l, 2002). The problem with PLL coating does not seem to be one of 
toxicity to encapsulated cells, rather, fibrosis of tissue around implanted APA beads 
preventing in vivo survival longer than several months (De Vos et a l, 1993).
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Although viability testing was not carried out on cells encapsulated in PLL-coated 
alginate beads produced during this study, there appears to be no evidence in the 
literature that the protocol used should be cytotoxic.
6.3.7 Implantation of beads produced using the MIG method
Small alginate beads (<35 Opm in diameter) coated with PLL have been 
implanted in various sites; rat epididymal fat pads (Robitaille et a l, 1999), rat portal 
hepatic vein (Leblond et al., 1999) and lateral ventricles of the mouse brain (Ross et 
a l , 1999). All of these studies observed beads to remain intact in the implantation 
sites, albeit for differing time periods; from 2 weeks (Robitaille et a l, 1999) to 16 
weeks (Ross et a l, 1999). In this study, small alginate beads produced using the MIG 
method and then cross-linked with barium via a batch process were implanted into rat 
striatum and showed some evidence of remaining 2 weeks after implantation, but not 
at 21 days. There was no evidence of small alginate beads coated with PLL 21 days 
after implantation.
Beads produced using the MIG method have been shown to consist of a 
homogeneous concentration of alginate (Section 6.2.2.5). All of the studies discussed 
above utilise non-homogeneous beads, which have a higher concentration of alginate 
at the surface than in the centre. The stability of homogeneous beads is known to be 
lower than in non-homogeneous beads (Thu et a l, 1996a). Smaller beads have a 
greater surface area to volume ratio than larger beads, thus more surface is available 
for reactions to take place. Thus, small beads will degrade faster than larger beads. 
The homogeneity of the beads, coupled with their small size, accounts for the 
disappearance of small beads produced using the MIG method in a short time period 
after implantation into rat striatum.
In summary, the MIG method was adapted to enable production of small 
alginate beads. Using this method cells were also encapsulated in small alginate 
beads. Barium treatment did not acutely affect encapsulated PC 12 cells, but did 
appear to affect HEK293 cells, both acutely and long term. Although barium 
treatment appeared to affect the rate of dissolution via ion exchange with phosphate 
solutions, barium cross-linked alginate beads were not stable in a rodent brain for 
longer than 15 days. Alginate beads produced using the MIG method were found to 
have a homogeneous concentration of alginate throughout, which appears to adversely 
affect stability. Secondary coating of alginate beads with polycations was shown to be
164
C h a pte r  S ix
possible both on-chip and using a batch method. Less PLL was shown to bind to 
beads produced using the MIG method, which may account for the fact that coated 
beads were not observed to have increased stability.
C h a pte r  Seven
Chapter 7. General Discussion
Cell encapsulation, as a concept, was first discussed in 1964 (Chang) and first 
used to reverse diabetes in rats in 1980 (Lim and Sun). Since then hundreds of studies 
have been published which utilise cell encapsulation. Alginate is the most commonly 
used polymer to encapsulate cells, as it is biocompatible and biodegradable (Orive et 
a l , 2004). In addition, alginate gels can be cross-linked under physiological 
conditions and the reaction is not harmful to cells (Smidsrod and Skjakbraek, 1990). 
There are several reasons why cell encapsulation has not become the cure for many 
diseases that it promised to be. Among these reasons is a major problem with current 
production methods. Currently, methods for producing encapsulated cells are not 
reproducible, are only capable of producing small batches of encapsulated cells, and 
cannot produce beads of small diameter. If these challenges could be addressed, the 
field of cell encapsulation would move closer to the goal of treating a multitude of 
diseases.
The aims of this study were to develop and investigate a method to 
encapsulate viable cells in alginate utilising microfluidic techniques, evaluation of the 
short and long term impact of this process on cell viability, to validate the 
encapsulation process with therapeutically relevant cells (PC 12) and determine 
dopamine release. In addition, modification of the microfluidic method developed in 
the previous steps was required to produce smaller beads suitable for cannula 
implantation and in vivo stability was determined.
At the start of this study there were very few published studies on the use of 
microfluidic devices to encapsulate cells. A few groups had shown that alginate 
solutions could be segmented within a microfabricated device to form droplets 
(Sugiura et al., 2005; Huang et al, 2006) and alginate had been ionically cross-linked 
on-chip (Braschler et a l, 2005), but there was no evidence of both droplet formation 
and on-chip polymer cross-linking being combined.
During the course of this study, two approaches to cross-link alginate solutions 
on-chip were investigated; external and internal gelation. External gelation was used 
to successfully produce alginate beads cross-linked on-chip. Unfortunately, the carrier 
fluid used was cytotoxic and so this method was unsuitable for encapsulating viable 
cells. By adapting a method already in use (internal gelation, Poncelet, 2001) for use
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with a microfluidic circuit, viable cells were successfully encapsulated. There was 
some mortality of encapsulated HEK293 cells following encapsulation using this 
method (Chapter 4). Through minor alterations to the microfluidic internal gelation 
(MIG) method, therapeutic PC 12 cells were successfully encapsulated with less than 
20% loss of viability (Chapter 5). PC 12 cells were shown to continue to produce 
dopamine after encapsulation. Dopamine was also able to permeate the encapsulation 
matrix and be detected outside the beads.
Since the start of this project several groups have successfully produced 
alginate beads cross-linked on-chip (Huang et al., 2006; Liu et al., 2006; Zhang et al., 
2006; Choi et al., 2007; Huang et al., 2007; Shintaku et al., 2007; Tan and Takeuchi, 
2007; Zhang et al., 2007; Kim et al., 2009), however, the experiments outlined in this 
thesis were among the first to be published (Workman et al., 2007; Workman et al.,
2008). Attempts have been made to produce alginate beads using methods very 
similar to those outlined in Chapter 3, with some success (Zhang et al., 2006; Tan and 
Takeuchi, 2007; Zhang et al., 2007). Although some groups have reported the 
encapsulation of viable cells using microfabricated devices (Choi et al., 2007; 
Shintaku et al., 2007; Tan and Takeuchi, 2007; Kim et al., 2009), there have been no 
studies published which show viability data for periods of more than 7 days for cells 
encapsulated using these techniques.
The circuits and microfluidic techniques which form this thesis are entirely 
novel. Not only are these techniques and circuits routinely used by the sponsoring 
company, Q Chip, other groups working in the field of microfluidics have also taken 
inspiration from these studies. Several groups have cited the publications originating 
from this thesis, and have based their work upon them (Kim et al., 2009; Wong et al.,
2009).
The goal of the present study was to produce beads capable of implantation 
into a rodent model of Parkinson’s disease. This goal was further sub-divided into two 
parts; production of beads <200pm in diameter and beads stable in vivo for more than 
6 weeks.
Production of beads <200pm in diameter is problematic with most currently 
used techniques (Section 1.10). There is a limit to the size of nozzle which can be 
reproducibly manufactured and thus the size of beads which can be produced using a 
nozzle. In addition, although many methods can be scaled-up, this is difficult to do 
with devices capable of producing smaller bead diameters, as discussed in Section
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1.10.3. Droplets with small diameters can be produced using microfluidic circuits by 
decreasing the size of the channel or increasing the flow rates of the dispersed and 
continuous phases, without loosing mondispersity.
By manufacturing a circuit composed of smaller channels, beads with 
diameters of <200pm were produced. Modifications to the processing steps carried 
out on cells prior to encapsulation allowed cells to be encapsulated in beads <300pm 
in diameter. These beads were not suitable for implantation as they were too large to 
fit in the implantation cannula. By further decreasing the size of the microchannels 
used, cells may be encapsulated in beads <200pm in the future.
Although cells were successfully encapsulated in alginate beads <300pm in 
diameter using the microfluidic-based method, no viability measurements were 
carried out due to problems with the viability methods chosen (Chapter 4). It was not 
possible to count cells in individual beads of diameter ~300pm using the adapted 
trypan blue method. Further investigations into viability using MTT assay and 
multiple beads would be beneficial. However, a large number of beads would be 
required for each time point as MTT is not sensitive enough to detect low cell 
numbers.
Experiments investigating growth rates of encapsulated PC 12 cells and 
dopamine expression were carried out in large (-350pm diameter) beads (Chapter 5). 
Although these findings showed that the encapsulation process did not harm cells and 
that cell numbers could be optimised to find the best growth rate and dopamine 
expression, it is not known whether these would be similar in small (<200pm 
diameter) beads. Growth rates and dopamine expression levels would need to be 
determined for small beads prior to their use in an animal model.
Other groups have successfully implanted alginate beads <200pm in diameter 
into rats’ brains. For example, APA beads were observed to remain intact within 
lateral ventricles of the brain for 16 weeks (Ross et al., 1999). Calcium cross-linked 
alginate beads produced using the MIG method were not observed to survive 
implantation into rats’ brains. Barium cross-linked alginate beads were observed to be 
present within sections of rats’ brains 14 days after implantation. Stabilising beads 
using secondary polycation coating (Chapter 6) did not increase the time which beads 
were observed to remain intact in vivo. Upon further investigation it was found that 
beads produced using the MIG method had a homogeneous alginate density (Chapter
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6). Beads of this type are known to be less stable during in vitro testing (Thu et a l , 
1996a), but no studies appear to have attempted to implant beads of this kind.
Beads produced using the MIG method have an equal density of alginate 
throughout for two reasons; firstly, CaC03  is present throughout the droplet and so 
upon lowering pH Ca2+ is released equally throughout the bead and secondly, velocity 
profile mixing constantly re-circulates material throughout the droplets. These issues 
appear to be inherent in the production method chosen. There is some evidence that 
velocity profile mixing can be overcome. Zhang et a l have published evidence 
showing that by using external gelation in combination with a microfluidic device, 
beads with varying thickness of cross-linked alginate shells can be produced (2006).
Initial attempts to test beads produced using the MIG method for stability 
using the osmotic pressure test (Van Raamsdonk and Chang, 2001) were not 
reproducible. Beads produced on different days responded very differently and 
showed that the method of production and/or post-processing steps (such as washing 
and coating) were not repeatable. In addition, the failure of one cell encapsulation 
experiment (Section 4.2.3) out of four also shows that the method is not as repeatable 
as required. Further work on the reproducibility and repeatability of the method and 
post-processing steps would need to be carried out before additional information 
could be collected. Lack of repeatability may also explain the variability observed in 
the length of time beads remained intact after implantation.
The issue of stability would have to be addressed before more attempts were 
made to implant beads produced using the MIG method. Optimisation of the 
secondary coating using polycations and in vitro testing of the beads produced using 
the osmotic pressure test should be carried out. There is evidence that increasing the 
exposure time of alginate beads to PLL, or increasing the concentration and 
decreasing the MW of PLL makes alginate beads more resistant to osmotic pressure 
(Thu et a l , 1996a).
Attempts to covalently cross-link alginate beads have succeeded in increasing 
stability. However, only enzymes (Li et a l , 2007; Ortega et a l , 2009) and yeast cells 
(Bimbaum et a l , 1981) have been immobilised, possibly due to the toxicity of the 
processes involved. Improvements to stability without affecting cell viability have 
been made by covalently linking PLL to a photoactivatable cross-linking molecule. 
After bead formation, the cross-linking molecule was activated to form a covalent link 
between the PLL and alginate. Beads formed in this way have proved stable both in
169
C h a pte r  Seven
vitro and in vivo (Dusseault et al., 2005; Dusseault et a l , 2008). Investigations into 
covalent cross-linking or use of co-polymers may result in beads which are more 
stable and able to be produced using a microfabricated device. Use of microfluidic 
devices would allow cells to be exposed to toxic chemicals for minimal time periods, 
thus permitting further use of such chemicals.
Instead of attempting to manipulate the beads produced to make them more 
stable for implantation, a different use could be investigated for the beads. To see 
effects in a rodent model of Parkinson’s disease encapsulated cells are required to 
persist for at least 6 weeks (Borlongan et a l , 2004). The beads that have been 
examined so far are not stable for this time period. A model where the therapeutic 
agent is required for a shorter time period, such as wound repair or vaccination 
against cancer with granulocyte-macrophage colony-stimulating factor, may be more 
suited to treatment through use of these beads.
Beads of small diameter can be made using microfluidic circuits. Although the 
batch size produced using the MIG method is currently 500pl, there is scope for 
increasing this considerably. Microfluidic circuits can be run in parallel with no loss 
of production rate. Through use of multiple parallel circuits, Nisisako and Torii 
(2008) estimated that a device with 128 circuits could produce 320ml of product 
beads per hour. The use of microfluidic techniques to encapsulate cells has 
considerable scope and this thesis goes some way towards showing this.
Viable, therapeutic cells were encapsulated in alginate beads and were still 
able to produce therapeutic agent. Various post-processing steps were introduced on- 
chip and in this way washing, coating and barium stabilisation of alginate beads has 
been demonstrated. The beads produced were not stable enough to allow behavioural 
changes to be observed in a rodent model of Parkinson’s disease. However, further 
work suggested may allow this to be achieved in the future.
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Cellular transplantation is a promising technology with great clinical potential in 
regenerative medicine and disease management. However, effective control over 
patient immunological response is essential. The encapsulation of cells within hy­
drogel microspheres is an increasingly prevalent method for the protection of cel­
lular grafts from immune rejection. Microfluidic “chip” reactors present elegant 
solutions to several capsule generation issues, including the requirement for inter­
capsule uniformity, high reproducibility, and sterile, good manufacturing practice 
compliance. This study presents a novel method for the on-chip production of 
stable, highly monodisperse alginate microspheres and demonstrates its utility in 
the encapsulation of an immortalized human-derived cell line. Four populations of 
immortalized human embryonic kidney cells (HEK293) were encapsulated on chip 
within monodisperse alginate capsules. Cell viability measurements were recorded 
for each of the four encapsulated populations for 90 days. © 2007 American Insti­
tute o f Physics. [DOI: 10.1063/1.2431860]
I. INTRODUCTION
The term “cell therapy” is now widely used to describe the process of transplanting nonauto- 
logous cells for therapeutic purposes. The scope of cellular therapy continues to broaden, and now 
extends into many areas of regenerative medicine, involving stem cells,1 bone augmentation,2 
neuron stimulation,3 and artificial skin.4 The implantation of stable, allogeneic or xenogeneic cells, 
which are engineered to continually secrete functional molecules, is a highly promising approach 
to disease treatment. The simplest and most widely investigated approach to date has been the 
encapsulation of cells within cross-linked natural polysaccharide hydrogels such as alginate (a 
linear block copolymer of D-mannuronic acid and L-guluronic acid). Calcium-linked alginate 
hydrogels have been extensively tried and tested, and in many cases have given promising results 
in immuno-isolation in animals.5’6
The prospect of long-term therapies for diseases such as Type I diabetes has attracted wide­
spread interest. The World Health Organization (WHO) estimates that more than 180 million 
people worldwide suffer from diabetes, and this number is predicted to more than double by 
2030. The National Diabetes Information Clearinghouse estimates that diabetes costs $132 billion 
in the United States alone every year. The prospect of replacement of insulin-producing pancreatic
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islet beta cells has been described as “the ultimate treatment for Type I diabetes.”8 Clearly, the 
market for cell therapy is massive. Recently, the first clinical trials in nonimmunosuppressed 
human patients were undertaken.9 Preliminary data shows that two patients responded to Ca- 
alginate encapsulated islet grafts, although exogenous insulin was only decreased and not with­
drawn completely.
There are many reasons why this considerable potential has not (yet) been fully realized, only 
some of which are discussed here. Cell-containing microspheres are often of a large diameter 
(>500 f im), with a broad size distribution. This means that nutrient diffusion to the center of the 
microspheres becomes an issue,10 and standardization of cell number per microsphere is difficult. 
There is also an inability to produce clinical-scale volumes of cell-containing microspheres. Good 
manufacturing practice (GMP) compliance becomes paramount when producing microspheres for 
use in clinical applications.
In response to this, the use of microfluidics is ideally suited to production of cell-containing 
microspheres. Linear emulsions can easily be produced in a sealed microenvironment, utilizing the 
phenomenon of segmented flow.11 The diameter of the product microspheres can be accurately 
controlled, with size distributions of <1% coefficient of variance. Microfluidic devices containing 
flow-focusing junctions have previously been used as effective droplet generation systems. How­
ever, in most reports, alginate droplets thus formed are crosslinked off-chip, falling from the 
microfluidic chip into a setting bath of calcium ions.12 Using such an approach, both standardiza­
tion and sterility are difficult to achieve. Zhang et a l.13 have succeeded in curing alginate droplets 
in situ, in a microfluidic device, using undecanol as a solvent for calcium ions. This methodology 
was used to demonstrate the encapsulation of polystyrene microbeads. However, cells were not 
encapsulated using this device. A method similar to that of Zhang e t al. was previously employed 
in our laboratory, where a solution of calcium cyclohexanebutyrate was dissolved in octanol. Solid 
alginate microspheres were successfully produced via this method (unpublished observations).
The primary objective of this work is to simplify and further develop the encapsulation and 
immunoisolation of live, therapeutically-active cells. It is therefore clear that the encapsulation 
process should not have any detrimental effect on the cellular payload. In our preliminary studies, 
aliphatic alcohols such as octanol were found to have an extremely cytotoxic effect on cultured 
human embryonic kidney cells (HEK293) and primary murine hepatocytes. This encapsulation 
method was therefore abandoned. In this article we will report the successful encapsulation of 
cells using an internal gelation method adapted for a microfluidic reactor.
II. MATERIALS AND METHODS
A. Microsphere formation
The microfluidic device consists of a 316 stainless steel manifold into which high perfor­
mance liquid chromatography fluid connectors are introduced equatorially. Vertical through holes 
were sealed with nitrile rubber O rings, allowing fluid to flow to the top surface of a virgin 
polytetrafluoroethylene (PTFE) disc (50 X 3 mm) located on the manifold. A circular polyfluoro- 
alkoxy polymer film gasket was placed in between the PTFE chip and a borosilicate glass disc 
(50X5 mm) cover. A 316 stainless steel clamping piece was bolted to the fluidic manifold, 
allowing the entire laminated assembly to be compression sealed. Microfluidic channels were 
machined into PTFE discs (Polyflon, Staffordshire, UK) using a Computer Numerical Controlled 
milling machine (Roland, Swansea, UK). A series of microfluidic “chips” was produced with 
varying channel dimensions. In one example, the fluidic input channels were of the dimension 
500 jj.m2, opening out to 1000 /mi2 in the sphere forming channel. This cross-sectional ratio (1:4) 
was conserved throughout the scalar series of fluidic chips.
Fluids were introduced into the microfluidic circuit using syringe drivers (KD Scientific— 
Linton Instrumentation, Norfolk, UK). In all cell encapsulation experiments, the stainless steel rig, 
glass, gasket, fittings, and PTFE chip were autoclaved and then air dried in an oven at 50 °C. 
Syringe drivers were cleaned with bactericidal wipes before being placed in a Class II hood to 
maintain sterility. All experiments were carried out in a Class II hood.
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Nanocrystalline precipitated CaC03, with an average particle size of 70 nm (donated by 
Speciality Minerals, Birmingham, UK) was suspended in either water or D-MEM/F12 medium 
(Invitrogen, Paisley, UK) at a concentration of 0.5% (w/v). Pronova UP MVM alginate (NovaMa- 
trix™, Drammen, Norway) was added to the CaC03 suspension at a final concentration of 2% 
(w/v). The carrier phase contained sunflower oil (Statfold, Staffordshire, UK) and sunflower oil 
containing 0.5% acetic acid (v/v; Sigma, Dorset, UK). All cell encapsulation experiments used the 
human embryonic kidney cell line HEK 293 (American Type Culture Collection CRL-1573). 
These were resuspended in the alginate/CaC03 mixture at a concentration of 1 X 106 cells/ml.
B. Cell culture
HEK293 cells and cell-containing microspheres were cultured in complete medium consisting 
of Dulbecco’s modified Eagle medium (Invitrogen, Paisley, UK) with 10% fetal bovine serum 
(Autogen Bioclear, Wiltshire, UK) in an atmosphere of 5% C 02/95% air at 37 °C. Cells were 
dissociated using 0.02% (w/v) trypsin/0.05% (w/v) EDTA in PBS (Invitrogen, Paisley, UK).
C. Size measurement
Microsphere radii were measured using a light microscope (Motic, Suffolk, UK) with an 
attached camera. The coefficient of variance was calculated as the standard deviation of the 
derived diameters of microspheres as a percentage of mean diameter.
D. Viability measurement
Direct cell counts of individual microspheres were carried out using an adapted trypan blue 
exclusion method. Individual microspheres were placed on a haemocytometer and all excess 
medium removed. Alginate microspheres were dissolved by addition of 55 mM sodium citrate 
(Sigma, Dorset, UK). Cell viability (%) was subsequently determined by trypan blue exclusion.
E. Confocal microscopy
The viability of encapsulated cells was determined using live/dead viability/cytotoxicity kit 
for mammalian cells (Molecular Probes), according to the manufacturer’s instructions. Briefly, the 
gels were incubated in 1 mL of Hank’s buffered salt solution containing 2 pM  calcein stain and 
4 pM  of ethidium homodimer-1 for 15 min at room temperature in the dark. Subsequently, the 
distribution of red (dead) and green (live) cells was visualized using a fluorescent microscope 
(Leica DM6000B upright microscope) at 20 X.
III. RESULTS
A. Microfluidic method for microsphere formation
The heterogeneous process, first developed by Poncelet et al.,14 involving an insoluble cal­
cium salt (CaC03), was considered to be the most applicable to a microfluidic flow reaction.
A mixture of nanocrystalline calcium carbonate and sodium alginate solution was used as the 
functional phase in the microfluidic reaction. Alginate droplets containing CaC03 were produced 
via segmentation with an immiscible hydrocarbon. Acetic acid in the reactive carrier phase reacted 
immediately with the immobile crystals of calcium carbonate (present at the interface between the 
droplets’ surface and the organic phase), producing Ca2+, H20 , and C 02. The free Ca2+ ions were 
sequestered by the dissolved alginate chains and produced the desired ionotropic hydrogel.
The reaction between H+ and calcium carbonate in the aqueous phase is fast, and resulted in 
rapid Ca2+ release and subsequent gelation. In the microfluidic device, the first point of contact for 
these two reagents is the junction. Consequently, as an aqueous fluid packet began to emerge from 
the junction, its interface immediately underwent reaction and crosslinking. As a result, a thin 
hydrogel skin formed across the junction (Fig. 1). The presence of this hydrogel solid caused the
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Acidified
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fluid
Functional Fluid
FIG. 1. Schematic showing immediate interfacial hydrogel formation in a crossroads fluidic junction. The calcium car­
bonate in the functional fluid (shown in blue) reacts rapidly with the acidified oil. The Ca2+ ions thus released a form of 
solid hydrogel at the junction.
fluid flows to decelerate, and quickly produced further solid masses of alginate gel within the 
microfluidic channel. These eventually occluded the channel, thereby terminating the microsphere 
synthesis experiment.
B. Shielded segmented flow
To remedy the problem of immediate gelation, it was postulated that a two-component laminar 
flow could be used as the carrier phase stream. At the micron scale, turbulent fluid flow, which is 
responsible for fluid mixing, is constrained and indeed replaced by laminar flow. Under these 
conditions, fluids move in planes and with the exception of slow interfacial diffusion, do not 
undergo mixing. Therefore, it is possible to create a laminar flow of two miscihle liquids, and 
maintain separation of the two for some considerable time.
The microfluidic device and junction was enhanced to include an additional fluid flow, into 
which pure sunflower oil was introduced. Hence, the carrier phase can be thought of as a reactive 
stream of acidified sunflower oil, containing a stripe of inert, unmodified sunflower oil; hereafter 
referred to as the shielding flow (Fig. 2). The two-phase laminar flows were created at microfluidic 
T-junctions, and approached the aqueous alginate mixture from either side, at an angle of 90°. The 
fluid flows were oriented such that the nonreactive shielding flows contacted the aqueous alginate 
flow at the junction. However, the acidified sunflower oil did not come into contact with the 
emerging aqueous droplets at the junction. This is pictorially demonstrated in Fig. 2(b).
CARRIER FLUID:
CHjCOOH + Sunflowa ail
SHIELDING FUNCTIONAL Sunflower oil (1)
FLOW: FLUID:
Sunflower oil (1) Alginate + CaCOj (*)
FIG. 2. (a) Schematic showing microfluidic shielding junction with fluid inputs. Laminar streams of sunflower oil and 
acidified sunflower oil are shown, (b) A negative image of the shielding flow junction. The shielding flow is dyed in blue 
for ease of visualization. Beads are highlighted with arrows.
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FIG. 3. Graphical representation of 5 alginate microsphere populations showing size distribution. A separate microfluidic 
chip and optimized flow rates were used to produce each sample.
This modification allowed the problem of immediate gelation at the junction to be overcome. 
The emerging droplets were insulated from the acidified fraction of the carrier phase by a layer of 
the shielding fluid [colored blue in Fig. 2(b)]. Spherical droplets of the alginate mixture were 
successfully generated at the junction, and these proceeded through the reactor channel. As the 
droplets were carried through the circuit, the shielding layer that surrounds them became gradually 
acidified, as protons diffused from the acidic surroundings. The eventual reaction between calcium 
carbonate and H+ was seen to be slower and more controllable, since the relative flow rates (and
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FIG. 4. Percentage cell viability measured using an adapted trypan blue method, as described in Sec. IID. Note that the 
increase in cell viability is concomitant with observing cell clusters. Error bars show standard error for four replicates.
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consequently the thicknesses) of the two components of the laminar flow were entirely variable. 
Hence, by varying the relative proportion of the shielding fluid within the carrier phase, the rate of 
microsphere gelation could be adjusted.
The use of the shielding junction described above allowed monodisperse alginate micro­
spheres to be produced in a microfluidic reactor. The diameter of the resulting microspheres could 
be accurately controlled, and this was found to be inversely proportional to carrier phase flow rate 
(in agreement with Ref. 13). The optimized microreactor ran unperturbed for several hours, until 
the feed syringes were exhausted. Using this method, approximately 1 ml of monodisperse mi­
crospheres was produced per hour. In order to investigate the flexibility of the chemical method 
and shielded segmentation junction, a series of microfluidic chips was manufactured, in which the 
channel dimensions were varied in a scalar fashion. It was observed that monodisperse alginate 
microspheres of any desired diameter in the range 80-400 /im  could be produced by selecting the 
appropriate fluidic chip and corresponding fluid flow rates. Several samples of alginate micro­
spheres were produced in this manner, their diameters and size distributions are shown in Fig. 3.
C. Microfluidic encapsulation of human cells
The microfluidic procedure for alginate microsphere synthesis described above was further 
adapted to enable the encapsulation of cellular material. The functional fluid formulation was 
modified to include the cell growth-medium D-MEM/F12. Four separate populations of HEK-293 
cells were dissociated to form single-cell suspensions. Four samples of monodisperse alginate 
microspheres were obtained, containing approximately one hundred HEK293 cells, randomly 
distributed throughout each sphere. Approximately 500 /j l \ of microspheres were produced for 
each population of cells. Using a modified trypan blue exclusion assay, the viability of each 
sample of encapsulated cells was quantified. Cell viability was measured at several time points, 
beginning immediately after the dissociation step (time point zero). The alginate capsules were 
seen to be stable in the cell growth medium and remained intact through numerous manipulations 
during medium changes. Weekly viability measurements were taken over the next 12 weeks. Over 
this time the viability of the encapsulated cells continued to increase. After 12 weeks no more cell 
capsules remained, and the viability measurement experiment was terminated. Live/dead cell 
ratios (for each sample at each time point) are reported in Fig. 4.
FIG. 5. (a) Light microscope image of cell-containing microspheres. (b) Confocal images of cell-containing microspheres 
stained with live/dead stains (24 h post encapsulation), (c) Confocal images of cell-containing microspheres stained with 
live/dead stains (14 days post encapsulation showing cell clusters. Live cells are stained green, and dead cells are stained 
red).
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In addition to trypan blue viability readings, confocal microscopy using live/dead staining was 
carried out. Cells were seen to be randomly distributed through the microspheres 24 h after 
encapsulation [see Figs. 5(a) and 5(b)]. After 14 days of encapsulation, cells were observed in 
clusters. When observed using confocal microscopy, cell clusters were seen to be alive, while 
individual cells appeared dead [Fig. 5(c)]. Between one and four cell clusters of variable size were 
observed per microsphere.
IV. DISCUSSION
The interfacial reaction between CaC03 and H+ is immediate, producing Ca2+, C02, and 
water. In a solution of sodium alginate, Ca2+ ions (liberated upon acidification) are immediately 
chelated by alginate molecules to form the widely accepted helical “eggbox” structures.15 This 
ionic crosslinking produces solid hydrogel, which has been widely used in cell encapsulation and 
immunoisolation experiments.5,6,16 The “internal” gelation method was adapted to suit a microflu­
idic flow reactor, as described above. However, it became immediately clear that the rapid, un­
controlled cross-linking (and therefore gel-forming) reaction at the emerging interface of a droplet 
caused problems at the fluidic junction. The presence of solid hydrogel at the junction greatly 
affects the surface properties of the PTFE microfluidic chip, which is intrinsically hydrophobic. 
The hydrophilic nature of the hydrogel solid causes the aqueous flow stream to be attracted to the 
surface, thereby disrupting the segmented flow conditions and precluding the formation of drop­
lets.
It was postulated that the gelation reaction could in effect be “postponed” if the aqueous 
droplets were formed in the absence of H+, and exposed a moment later to the acidified immiscible 
phase. Previously, microfluidic laminar flows have been used to create such chemical gradients 
and to perform liquid-liquid extractions.17-19 These reported experiments involve combinations of 
miscible fluids or stratified flows containing an immiscible “membrane” flow. By introducing an 
unreactive laminar stream into the carrier fluid a diffusion barrier was created, which served to 
delay the interfacial reaction.
The “shielded” segmented flow described above was designed, and proved to be effective in 
this application. As the aqueous droplet emerges from the fluidic junction, it meets only the 
nonreactive portion of the carrier phase. Hence, the droplet elution is not hindered by the forma­
tion of thin hydrogel film as before. Diffusion of H+ within the laminar oil flow begins to occur 
post segmentation, and thus the reaction of calcium carbonate with H+ is more gradual. This 
allows the aqueous droplets to crosslink more slowly as they travel through the microchannel.
As described above, it is imperative that the capsule-forming reaction is compatible with the 
survival and growth conditions for a cellular payload. In order to limit the possible deleterious 
effect of H+ and Ca2+ on cells, the minimum concentrations of glacial acetic acid and calcium 
carbonate required to induce the cross-linking reaction were identified. Using these conditions, the 
microfluidic flow reaction produced stable, extremely monodisperse alginate microspheres.
HEK293 was used as a model cell line in these experiments due to its high growth rate, 
hardiness, and ease of transformation. In the future, this novel method could allow the encapsu­
lation of a wide variety of cells and cell lines, designed for different therapeutic applications, 
under reproducible and sterile conditions. The immortalized cell-line HEK293 was successfully 
encapsulated using the described method. Initially, viability of cells was seen to decrease sharply 
after encapsulation. Upon investigation (using confocal microscopy), dead cells were found to be 
randomly distributed throughout the microspheres [Fig. 5(a)]. It is unclear whether the encapsu­
lation method itself or a lack of cell-cell interactions is the cause of this decrease. Here we present 
only preliminary results, and further work into investigating the cause of the initial drop in cell 
viability has yet to be carried out. After approximately 14 days, cell clusters were observed inside 
the microspheres [Fig. 5(b)], with a corresponding increase in viability readings. The increase in 
viability was in direct relation to the appearance of cell clusters. It is proposed that cells in close 
contact at encapsulation are able to proliferate to form the cell clusters observed. Viability (live/ 
dead cell ratio) stabilized at 70% after a month and this was seen to continue, until no micro­
spheres remained (at three months post encapsulation).
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Similar results were observed for three of the four replicate encapsulated populations. By 
contrast, the fourth population exhibited markedly reduced viability 24 h post encapsulation. The 
cell viability continued to decrease, relative to the other three populations, until at 15 days after 
encapsulation, all encapsulated cells were dead. Cells encapsulated in this population were not 
observed to form cell clusters. We have not established a satisfactory explanation for the failure of 
this one batch, but it is noteworthy that the fate of each batch could be determined within 24 h of 
production, which will be an important factor in quality control for any therapeutic application.
In the context of cell encapsulation, the ingress of nutrients and oxygen toward the center of 
a sphere is extremely important. Hence, porosity and sphere size are factors in determining opti­
mum conditions for cells contained within a hydrogel matrix. Larger alginate microspheres 
(500-2000 fim) can easily be generated via standard droplet generation techniques such as air-jet 
break-up.20,21 However, in our experience it is significantly more difficult to produce spheres with 
a diameter of <400 yum using these conventional methods. By virtue of having decreased diffu­
sion paths, beads with smaller diameter are arguably more effective in averting cell hypoxia.10 
Using microfluidic devices with the shielded segmented flow junction described, we can now 
reliably synthesize monodisperse samples of alginate microspheres in the range 80-400 yum.
An important issue for the development of cell therapies toward clinical trial application, will 
be the need to develop GMP-compliant methods for the production, manipulation, and validation 
of encapsulated cells. Few existing droplet-generation protocols are sufficiently well developed to 
enable the reproducible production of cell capsules under GMP conditions. Microfluidic devices 
are intrinsically “sealed environments”; and this will likely prove to be a significant advantage in 
the attainment of GMP standards. Furthermore, the microfluidic device described here is entirely 
constructed from “generally regarded as safe” materials.
In the context of microsphere production, the output from a single-circuit microfluidic reactor 
is typically in the range of 1-20 ml/h (depending inter alia on reactive-fluid flow-rates and 
microsphere diameter). Pharmaceutical and life-science applications are likely to require tens or 
hundreds of liters of microsphere products for effective clinical trials. Clearly, it would be an 
extremely laborious task to produce these quantities of microspheres from such a single-circuit 
microreactor. Indeed, a single-circuit microfluidic device as described here is suitable primarily for 
the production of much smaller sample volumes for analysis and proof-of-principle studies. If 
microfluidic devices are to advance and add further value to the encapsulation of live cells, further 
work toward scaling-up and increasing production volumes must be performed. It is highly likely 
that this could be achieved via the development of GMP-compliant multicircuit-array devices.
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On-Chip Alginate Microencapsulation of 
Functional Cells
Victoria L. Workman, Stephen B. Dunnett, Peter Kille, Daniel D. Palmer*
*Communication S v i  Journals Rapid
We report the use of a PTFE-based microfluidic device for the encapsulation of living, 
therapeutically-active cells within monodisperse alginate microspheres. We present a novel 
microfluidic platform and a flexible experimental method for the production of alginate 
microspheres. Cell lines HEK293, U-2 OS and PC12 were 
separately encapsulated using this method, with mini­
mal loss of cell viability.
Introduction
Polymer encapsulation is now an accepted route into 
cellular therapies via implantation of therapeutically- 
active allogeneic and xenogeneic cells. Continual expres­
sion of functional molecules in vivo by an engineered cell 
line offers a particularly powerful and sustainable strategy 
for stable, long-term drug-delivery. The forty-year push[1’2] 
toward a stable, fully immuno-isolating, porous polymer 
membrane by academic and commercial research groups 
is indicative of the perceived therapeutic potential of this 
technology.[3,4] Numerous methods for generating poly­
mer microspheres have been used in the encapsulation of 
functional cells.ts~10] Among these, micro-electro-mechanical 
systems (MEMS) and microfluidic device technologies are 
perhaps the most promising for developing scaleable,
I
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GMP-compliant platforms for the production of mono­
disperse cell-containing microspheres.
The use of flow-focusing fluidic junctions for creating 
segmented flows of immiscible fluids is now well 
established.[11-15] Numerous organic liquids have been 
shown to be effective continuous phases for the produc­
tion of stable linear emulsions of aqueous solutions. A 
flow-focusing junction enables the droplet size of a 
dispersed phase to be precisely controlled, and is therefore 
highly suitable for the generation of droplets of alginate 
solutions.[16]
We have previously reported the difficulties in introdu­
cing divalent cations to a linear emulsion of alginate 
droplets in a cell-friendly manner.[17] We have also reported 
a novel feature of our microfluidic devices, termed "shielded 
flow" (Figure 1), that enables us successfully to produce 
such microspheres via an adaptation of Poncelet's internal 
gelation method.[17,18]
Two other groups have recently reported the synthesis 
of alginate microspheres via similar microfluidics-based 
droplet generation methods, utilising PDMA (Polydi- 
methylsiloxane) microfluidic devices containing flow- 
focussing fluidic junctions. Zhang et al.[19] have developed
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Figure i. A representation  of th e  shielded junction em ployed to  g e n e ra te  a lg in a te  m icro­
spheres. Aqueous sodium  alg inate mixed w ith CaC03 and cells is introduced in to  th e  central 
channel (A). Sunflower oil mixed w ith acetic acid is supplied to  th e  o u te rm o st channels 
(C). Sunflower oil is supplied to  th e  in term ediate channels (B) to  act as a shield p reven ting  
th e  alg inate solution from  com ing into contact w ith th e  acidified oil flow. B etw een channels 
B and A th e  tw o  oils flow in a lam inar fashion, w ith m inim al diffusion o f H+ in to  th e  
protective sunflow er oil. After droplet form ation a t th e  junction , H+ diffuses in to  th e  
alg inate  droplet, th u s  liberating Ca2+ from  CaC03, which causes gelation  o f  th e  a lg inate . 
Channels prior to  th e  junction are 500 jim 2, after th e  junction  channels are  1 0 0 0  p,m2.
a microfluidic m ethod for cross-linking alginate droplets 
on-chip by suspending calcium acetate in  the continuous 
phase. Calcium acetate dissolves upon contact w ith  the  
surface of the aqueous alginate-containing dispersed phase, 
inducing ionotropic cross-linking to produce externally 
gelled microspheres. Zhang and co-workers[19] report some 
difficulties in  adapting Poncelet’s m ethod for in ternal 
gelation emulsification, involving an aqueous suspension 
of calcium carbonate and an  acid-containing continuous 
phase, to their microfluidic platform. We have overcome 
these difficulties and in  this communication dem onstrate 
reproducible capsule synthesis using this method.
Huang et al. report a stable segm ented flow system  
comprising an alginate-calcium carbonate dispersed phase 
and an inert continuous phase.1201 This microfluidic device 
enabled the  generation of droplets, w hich were subse­
quently crosslinked off chip in  an acid-containing setting 
bath. Neither group have reported the  successful use of 
a microfluidic device for the encapsulation of living cells 
w ith in  product microspheres. Here w e present the  use of 
such a system  for the  encapsulation of three cell lines.
Experimental Part 
Materials
Cell culture media and supplements for 
HEK293 and PC12 cells were purchased 
from Invitrogen, Paisley, UK. Sera were 
purchased from Autogen Bioclear, UK. 
Media and supplements for U-2 OS cells 
were purchased from Sigma, UK. Nano­
crystalline precipitated CaC03 (average 
particle size 70 nm) was donated by 
Speciality Minerals, UK. Pronova UP 
MVM and MVG alginate was obtained 
from NovaMatrix™, Norway. All other 
chemicals were purchased from Sigma, 
UK and used as supplied.
Methods
Microfluidic Device
The microfluidic device consisted of a 
circular 316 stainless steel manifold 
in to  w hich HPLC fluid connectors 
w ere introduced equatorially. Verti­
cal th rough  holes were sealed w ith 
nitrile rubber O-rings, allowing fluid 
to  flow to th e  top surface of a virgin 
PTFE disc (50 m m  diam eter x3 mm; 
Polyflon, UK) located on the m ani­
fold. A circular PFA gasket was placed 
in  betw een  the  PTFE chip and a 
borosilicate glass disc (50 m m  dia­
m eter x5 m m ) cover. A 316 stainless steel clamping piece 
w as bolted to  th e  fluidic manifold, allowing the  entire 
lam inated  assem bly to  be compression sealed. A micro­
fluidic "chip" w as produced by m achining microfluidic 
channels in to  a PTFE disc using a Computer Numerical 
Controlled m illing m achine (Roland, UK). The fluidic input 
channels w ere of dim ension 500 p,m2, opening out to  1000 
p,m2 in  th e  sphere form ing channel.
Cell Culture
HEK293 cells (American Type Culture Collection, CRL-1573) 
w ere m ain ta ined  in  Dulbecco's modified Eagle m edium  
(DMEM) supplem ented w ith  10% fetal bovine serum  and 
penicillin-streptom ycin. G1S Cell Cycle Phase Marker cell 
line (U-2 OS cells exhibiting stable expression of a Green 
Fluorescent Protein sensor) w as m aintained in McCoy’s 5A 
m edium  containing 10% fetal calf serum, 2 x 10-3 m 
L-glutamine, 500 jig -m l-1 G418 and 100 units m l-1 
penicillin/100 p-g m l-1 streptomycin. PC12 cells (ATCC,
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CRL-1721, a gift from Dr. Jack Ham  at th e  Centre for 
Endocrine and Diabetes Sciences, Cardiff University, UK) 
w ere grown in DMEM supplem ented w ith  5% fetal calf 
serum, 10% heat-inactivated horse serum  and  penicillin- 
streptomycin.
Cell Encapsulation
All cell encapsulation experiments w ere carried ou t in  a 
Class II hood to  ensure sterility.
All cell types w ere dissociated using 0.02 wt.-% try p sin / 
0.05 wt.-% EDTA in PBS and resuspended at a concentration 
of 1 x  106 cells • m l-1 in  2.0 wt.-% MVM alginate containing 
0.5 wt.-% calcium carbonate (w/v) in  DMEM medium.
Fluids were introduced into the  microfluidic circuit 
using syringe drivers (KD Scientific, Linton Instrum enta­
tion, UK). The functional phase contained cells, alginate 
and  CaC03. The continuous phase w as a tw o-com ponent 
lam inar flow consisting of pure sunflower oil flowing 
alongside oil w ith  0.3 vol.-% acetic acid. Oil flow =  
10 ml • h “ \  acidified oil flow =  25 ml • h -1 and functional 
phase =  1 m l • h -1.
Viability Measurement
Direct cell counts of individual microspheres w ere carried 
out using an adapted trypan  blue exclusion method. 
Microspheres w ere placed on a haem ocytom eter and 
excess m edium  removed. Microspheres were dissolved by 
addition of 55 x 10-3 m sodium citrate. Cell viability (%) 
w as subsequently determ ined by trypan blue exclusion.
Confocal Microscopy
The viability of encapsulated cells w as determ ined using 
LIVE/DEAD viability/cytotoxicity kit for m am m alian cells 
(Invitrogen, UK), according to  the  m anufacturers’ instruc­
tions. Briefly, the microspheres w ere incubated in  1 m l of 
HBSS containing 2 x 10-6 m calcein stain  and 4 x 10~6 m of 
ethidium  homodimer-1 for 15 m in at room tem perature in  
the dark. Subsequently, the  distribution of red (dead) and 
green (live) cells w as visualized using a fluorescent 
microscope (Leica DM6000B upright microscope) a t x20 
magnification.
Results and Discussion
As stated by Zhang et al., rapid gelation occurred a t a 
microfluidic crossroad junction. To bypass this problem, 
calcium levels were reduced. This allowed droplet form a­
tion bu t cross-linker concentrations were insufficient for
Macromol. Rapid Commun. 2008, 2 9 ,1 6 5 -1 7 0
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solid gel microspheres to  be collected.1191 As w e have 
previously described, our novel shielded junction (Figure 1) 
allows alginate droplet form ation to  occur w ithout 
im m ediate gelation,1171 w hilst H+ diffusion and subse­
quent cross-linking occurs further down the channel. The 
alginate microspheres formed can be collected in oil or 
m edium  on exiting the  reactor.
Contact w ith  chemicals detrim ental to  cells should 
obviously be m inim ised during the  encapsulation process. 
For th e  m ethod presented here, calcium carbonate and 
glacial acetic acid are used to  crosslink alginate droplets 
w ith in  a sunflower oil continuous phase. Previous cyto­
toxicity testing  showed samples of alginate, calcium 
carbonate and  sunflower oil to  be non-toxic to the 
HEK293 cell-line after 4 h  incubation, w hilst 0.75 vol.-% 
acetic acid w as found to  kill 50% of HEK cells after 5 m in 
(unpublished data).
In contrast to  Zhang et al., a CaC03 concentration of 
0.5 wt.-% w as used, com pared to  0.1-0.25 wt.-%.[191 
Problems w ith  fluid flow or aggregation of solid CaC03, 
in  either th e  feed-tubing or the  microfluidic channels, were 
no t observed. A low er concentration of acetic acid was 
utilised: 0.3 vol.-% com pared w ith  5-25 wt.-%.[19] By 
reducing acetic acid levels and exposure tim e of cells to  
acid (from 5 m in  to  30 s) a 20% increase in  cell viability 
w as observed.
The aforem entioned experim ental conditions were 
applicable to  2.0 wt.-% solutions of MVM alginate. How­
ever, 2.0 wt.-% MVG alginate solutions (with higher 
guluronic acid content) could also be m anipulated w ithin 
th e  microfluidic device to  produce solid microspheres. At 
identical fluid flow  rates, an  increased concentration 
of CaC03 (1.0 wt.-%) w as required to  induce complete 
cross-linking. A com parison of the  effects of guluronic acid 
conten t on encapsulated  cell survival is currently under­
way.
The use of PDMS as a substrate for microfluidic devices 
is now  commonplace, due in  part to  its favourable 
hydrophobic properties, its relatively low  cost and stan­
dardisation of th e  soft-lithography technique. However, 
disadvantages of th is m aterial lead us to  propose PTFE 
(Teflon)-based microfluidic devices to  be more suitable for 
the fu ture developm ent of 3D hydrogel-cell capsules.
Synthesising a microfluidic device via the  multi-stage 
soft-lithography, PDMS casting, oven-curing and plasm a 
cleaning process has been reported to  take a m inim um  
of 8 h.[211 By using PTFE as a starting m aterial for our 
microfluidic chip synthesis, the  m ulti-step lithography 
process is avoided, and  substitu ted  by a single, autom ated 
m icro-m achining operation. This m ethod allows micro­
fluidic features consisting of microchannels w ith  dia­
m eters of 100 |rm  or greater to  be produced. Typically, a 
microfluidic device of th is kind, containing multiple 
parallel circuits m ay  be produced w ith in  sixty m inutes.
www.mrc-journal.de 167
Macromoiecular
Rapid Communications V. I~ Workman, S. B. Dunnett, P. Kille, D. D. Palmer
r>«» <minnw iniurr rrnnirnrr'-smmwiriTTti inn turn- • m-~i ■» - r i - n w .w . '- - - * - . <■,-■ &■ .... ■ . . ■■..
By avoiding a perm anently sealed cover, a compression- 
sealed PTFE device m ay be dismantled, cleaned and 
reassem bled as required. This is particularly useful in 
cases of accidental failure (e.g., channel blockage due to 
unw anted  gelation), allowing rapid recovery during te s t­
ing and optim isation of conditions.
Three cell lines have been encapsulated using the 
presented method: HEK293, U-2 OS and PC12. W hen grown 
as an adherent culture HEK293 cells exhibit epithelial 
qualities. In addition HEK293 cells have been successfully 
adapted for growth in  suspension.122,231 U-2 OS cells are 
derived from a bone carcinoma and also exhibit epithelial 
adherent morphology. The U-2 OS cell line used for this 
study stably expresses a  Green Fluorescent Protein sensor 
th a t is used to  indicate th e  cell cycle status of each 
individual cell. PC12 cells are derived from a rat pheo- 
chromocytoma.[24^  This cell-line secretes clinically useful 
catecholamines, including dopam ine and norepinephrine.
All three cell types w ere successfully encapsulated and 
m aintained initial viability over a t least 4 days (Figure 2), 
dem onstrating th a t this procedure is not acutely lethal to 
the  cell types tested. PC12 cells had lower viability after 
harvesting from tissue culture flasks, which w as not 
altered by the encapsulation process. In contrast, although 
U-2 OS and HEK293 cells had higher post harvest viability 
compared to  PC12, after encapsulation the num ber of 
viable cells decreased by approxim ately 20% for both cell 
lines. This m ay be due to  increased susceptibility of these 
cells types to  the  acidic conditions employed during 
encapsulation. During cytotoxicity testing PC12 cells
showed a 10% decrease in  viability after 5 m in  exposure 
to  0.3 vol.-% acetic acid, com pared to  a 50% reduction in 
viability for HEK293 cells (data no t shown).
After encapsulation, U-2 OS and HEK293 cells w ere 
random ly distributed th roughout the ir m icrospheres 
(Figure 3A,C). After 5 d these cells began to  form  clusters. 
Live/Dead staining w as em ployed and im ages w ere 
taken via confocal microscopy as illustrated after 21 d 
(Figure 3B,D).
HEK293 cells have previously been observed to  form  
clusters th a t eventually fill microspheres, causing th em  to 
disintegrated25’2^  Between one and  four cell clusters w ere 
seen to  form w ith in  any one m icrosphere (Figure 3D) 
varying in  size and shape. Some w ere spherical w ith  
a diam eter estim ated betw een 75 and  100 pm, m ore 
commonly; cigar-shaped clusters of length  100 to  350 pm  
were formed.
Although U-2 OS cells also form ed clusters, they  show ed 
different features to  those form ed by HEK293 cells. U-2 OS 
cell clusters w ere smaller th a n  HEK293 cell clusters, 
typically 75 pm  in  diam eter. These sm aller clusters took 
21 d to  form, slower th a n  the  7 d for HEK293 clusters. By 
day 21, only cells th a t had  form ed clusters near the  
periphery of a m icrosphere w ere observed to  be alive 
(Figure 3B). To our knowledge, th is cell type has not 
previously been encapsulated.
Unlike U-2 OS and HEK293 cells, PC12 cells grow  in  small 
clumps, w hich adhere poorly to  plastic substrates. Upon 
harvesting, cell clumps w ere tritu ra ted  as m uch as 
possible, bu t each microsphere contained a t least one
clum p of PC 12 cells upon 
synthesis (Figure 3E and  4). 
In contrast to  U-2 OS and 
HEK293 cells, PC12 cells did 
n o t increase in  num ber after 
encapsulation  (Figure 3F). 
PC12 cells encapsulated in  
hydroxyethyl m ethacrylate- 
m ethyl m ethacrylate copoly­
m er after an  in itial decrease 
exhibited a quiescent period 
from  day 7 to  day 21, follow­
ed by  an  increase in  viability 
of th e  surviving cells from 
day 21 to  day 28.f271
Conclusion
Previous examples of PDMS 
microfluidic devices have 
been show n to  be useful 
only in  the  production of 
inert alginate spheres. By
20% '
o% —.........   » ' ■ '. . . .' '. >
o OS 1 1.5 2 2.5 3 3.5 4
Time (days)
I Figure 2. Viability, estim ated  using trypan blue exclusion, of d ifferent cell ty p es encapsu la ted  w ithin alginate microspheres. Results are presen ted  as m ean values o f quadrup licate  beads ±  S tandard  Error. Although HEK293 (■ )  and U-2 OS ( o )  cells show  higher viability a fte r harvesting  th a n  PC12 (□ )  cells, no drop in viability is observed a fte r PC12 cells are encapsulated .
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 Figure 3. Im ages show ing distribution o f live and dead cells w ithin alg inate m icrocapsules 1 d (A, C, E) and 21 d (B, D, F) a fte r  encapsulation. 
A, B) U-2 OS cells encapsulated w ithin alginate microcapsules, show ing endogenous GFP expression. C-F) Confocal im ages of encapsulated  
cells sta ined  with Live/Dead dyes. Green fluorescence is em itted  from  th e  intracellular esterase-converted  calcein in live cells w hereas red 
fluorescence is em itted  from  ethidium  hom odim er present in dead cells. C, D) HEK293 cells and E, F) PC12 cells encapsulated  w ithin alg inate 
m icrospheres. Scale bar is 100 p,m.
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combining an adapted bulk emulsion process with a novel 
PTFE microfluidic production device, we have successfully 
encapsulated three different cell lines on-chip. Alginate 
samples consisting of both high and medium concentra­
tions of guluronic acid have been shown to be suitable 
for the micro-reaction process. Crucially, the present 
method has been shown to have minimal effect on the 
viability of encapsulated cells during and post processing. 
We are now seeking to optimise encapsulation of the 
PC12 cell-line to produce monodisperse stable samples of 
dopamine-producing cell-capsules for evaluation in neuro- 
degenerative disease models.
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Figure 4 . Light microscope im age o f encapsulated PC12 cells, 
show ing small cell clum ps presen t after encapsulation.
